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CHAPTER 1- INTRODUCTION
1.1 Introduction to Folate Biology
Folates are B9 vitamins required for cellular growth (Stokstad, 1990). Mammalian cells
cannot synthesize folates de novo, and must obtain these cofactors from exogenous sources.
Folates contribute to several one-carbon transfer reactions in the synthesis of serine, methionine,
thymidylate, and purine nucleotides. In its contribution to methionine synthesis, folates are
required for the synthesis of S-adenosyl methionine, which is necessary for DNA, histone, and
lipid methylation (Lu, 2000).
The major circulating form of folate is 5-methyl tetrahydrofolate (THF) (Figure 1.1),
which is converted to several other polyglutamylated forms (the preferred forms for metabolic
single-carbon transfer reactions) following uptake of the monoglutamyl forms into cells (Moran,
1999; Shane, 1989). Mammals must obtain folates through the diet. Dark green leafy vegetables
and liver are foods which are high in folate content, although several other foods including
bread, grains, and cereal have been fortified with folic acid, a synthetic form of folate not found
in tissues (Jacques et al., 1999).
At physiological pH, folates are hydrophilic anions and are unable to diffuse across
membranes. Over time, two major facilitative transporters have evolved in mammals in order to
facilitate transport of folates into cells, the reduced folate carrier (RFC; Solute Carrier (SLC)
19A1) and the proton-coupled folate transporter (PCFT; SLC46A1) (Goldman et al., 1968;
Matherly and Goldman, 2003; Qiu et al., 2006; Zhao et al., 2011a), as well as three isoforms of
folate receptors (FRs) (α, β, and γ) (Elwood, 1989; Lacey et al., 1989; Ratnam et al., 1989;
Sadasivan and Rothenberg, 1989; Shen et al., 1994; Shen et al., 1995).
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Figure 1.1 Structure of tetrahydrofolate. THF is the major form of dietary folate. The N5 and
N10 position can associate with several one-carbon moietys including methyl, formyl, methylene
and methenyl, which can be used in biosynthetic reactions. THF can have additional glutamate
groups added by FPGS, contributing to cellular retention.
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RFC is an anion exchange transporter and a member of the major facilitator superfamily
(MFS), which serves as the major folate uptake mechanism at neutral physiological pH and is
ubiquitously expressed in tissues and tumors. PCFT is a proton/folate symporter and also an
MFS protein, which serves as the primary mechanism of dietary folate uptake and with a
specificity for acidic pH folate uptake and distinct transport specificities from RFC. PCFT shows
substantial expression in the duodenum and jejunum, kidney, liver, and the choroid plexus (Inoue
et al., 2008; Qiu et al., 2006; Umapathy et al., 2007; Zhao et al., 2009a; Zhao et al., 2009b). FRα
and β are embedded in the plasma membrane by a glycosyl phosphatidylinositol (GPI) anchor in
certain cells including renal cells and macrophages, respectively (Elnakat and Ratnam, 2004;
Leamon and Low, 2001; Weitman et al., 1992b). FRs mediate uptake of folates into cells via
receptor-mediated endocytosis (Kamen et al., 1988; Leamon and Low, 1991; Turek et al., 1993;
Wu et al., 1997). FRα expression is found in the uterus, placenta, proximal renal tubules, and
choroid plexus, while FRβ shows expression in hematopoietic cells, activated macrophages, and
the placenta (Nakashima-Matsushita et al., 1999; Ratnam et al., 1989; Ross et al., 1994; Ross et
al., 1999; Weitman et al., 1992b). There is also FRγ, which is secreted and serves an unknown
purpose (Elnakat and Ratnam, 2004; Shen et al., 1995).
In addition to their role as facilitative transporters of folates, RFC and PCFT serve critical
roles in the transport of antifolates for used in cancer chemotherapy (Figure 1.2). Antifolates
including methotrexate (MTX), pemetrexed (PMX), raltitrexed (RTX) and pralatrexate (PDX)
are transported by both RFC and PCFT, although RFC transport dominates under neutral pH
conditions characterizing most tissues (Nakai et al., 2007; Sierra et al., 1997; Zhao and Goldman,
2007). Both RFC and PCFT were shown to be abundantly expressed in a wide variety of solid
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Figure 1.2 Structures of classical antifolate molecules. Structures for clinically relevant
antifolates: MTX, PMX, RTX, PDX, and AMT, as well as antifolates which had clinical trials:
LMX, ZD9331, GW1843U89, PT523, LY309887, AG2034. All drugs are described in Chapter
1.6.1-1.6.4.
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tumor cell lines, although gene expression data in primary tumors is still emerging (Desmoulin et
al., 2012b; Kugel Desmoulin et al., 2011) (also see Chapter 5). Notably, PCFT is characterized
by an acidic pH optimum and is well suited to transport in the acidic tumor microenvironment
(Nakai et al., 2007; Zhao and Goldman, 2007). Because of the ubiquitous expression of RFC in
normal tissues as well as tumors, there has been a recent interest in developing novel antifolate
molecules targeting the tumor microenvironment via PCFT over RFC (Cherian et al., 2013;
Desmoulin et al., 2012a; Golani et al., 2014; Wang et al., 2012; Wang et al., 2010; Wang et al.,
2011; Wang et al., 2015) (also see Chapters 5 and 6). While progress has been made in the
development of PCFT-specific antifolate compounds, these have been developed entirely
without PCFT structural modeling, due to the limited availability of PCFT structural data.
Molecular modeling using x-ray crystal structures from other MFS proteins has provided an
estimate of PCFT structure. Experimental manipulations of PCFT protein sequence have
contributed to our understanding of PCFT topology and key structural determinants of PCFT
function, in some cases validating and in other cases correcting the molecular models which have
been developed (Hou et al., 2012; Shin et al., 2011; Shin et al., 2010; Shin et al., 2013; Shin et
al., 2012; Subramanian et al., 2008; Unal et al., 2009a; Unal et al., 2009b; Unal et al., 2008;
Visentin et al., 2015; Zhao et al., 2007; Zhao et al., 2011b; Zhao et al., 2012; Zhao et al., 2010)
(also see Chapters 2, 3, and 4). A comprehensive understanding of PCFT structure is essential to
understanding the mechanism of transport and is complementary to the development of novel
cancer therapeutics targeting PCFT. This chapter serves as a review of the biology of folate
transport and metabolism, as well as to deseribe the history of antifolate drug development
leading to a novel series of PCFT-selective antifolate molecules as tumor-targeted drugs.

6
1.2 Reduced Folate Carrier
RFC has been well established as the main cellular and tissue folate uptake mechanism
(Matherly and Hou, 2008; Matherly et al., 2007). RFC is ubiquitously expressed, and serves as
the primary delivery system for both folates and antifolates throughout the body (Matherly et al.,
2007). RFC is a folate/anion antiporter in the MFS, and was first characterized in terms of its
kinetic and thermodynamic properties more than 40 years ago (Goldman, 1969; Goldman, 1971;
Goldman et al., 1968; Sirotnak et al., 1968). Murine RFC was first cloned in 1994 (Dixon et al.,
1994), while human RFC was cloned by multiple labs the following year (Moscow et al., 1995;
Prasad et al., 1995; Williams and Flintoff, 1995; Wong et al., 1995). Human RFC is located on
chromosome 21q22.3 (Moscow et al., 1995) and is regulated by multiple promotors spanning 35
kb upstream from the major AUG translation start point, as well as many noncoding exons
(Matherly et al., 2007). RFC is additionally regulated by promoter methylation and chromatin
structure (Liu et al., 2004; Payton et al., 2005a; Payton et al., 2005b; Whetstine et al., 2002b).
These mechanisms likely guarantee the ubiquitous expression of RFC. Measurements of RFC
transcriptional expression in various tissues and tumor cell lines revealed the highest RFC
expression in the placenta and liver, with additional high expression in kidney, lung, leukocytes,
bone marrow and small intestine, and low levels in heart and skeletal muscles (Whetstine et al.,
2002a). Although the function of RFC in the small intestine is unclear, as RFC function is
dramatically decreased in acidic pH, folate deficiency in rodents resulted in increased RFC
transcript and protein levels (Liu et al., 2005).
As an anion-folate antiporter, RFC functions optimally at neutral physiological pH, and
transport activity decreases dramatically at pHs below 7 (Sierra et al., 1997). While RFC has a
low affinity for folic acid, (6S)5-formyl THF and (6S)5-methyl THF are excellent RFC
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substrates (Goldman et al., 1968; Westerhof et al., 1995). Although transport of (6S)5-formyl
THF is favored over the (6R) stereoisomer (Sirotnak et al., 1979), RFC displays no
stereospecificity for 5-methyl THF (Chello et al., 1982; White et al., 1978). Additionally, many
clinically used antifolates have strong affinity for RFC transport, including MTX, PMX, PDX
and RTX (Jansen, 1999; Matherly and Hou, 2008; Matherly et al., 2007; Sirotnak et al., 1998;
Visentin et al., 2013). Novel antifolates PT523 (talotrexin) and GW1843U89 are among the best
RFC substrates yet described (Jansen, 1999; Rhee et al., 1994; Rosowsky et al., 1994; Wright et
al., 2000).
As with all MFS transport proteins (Abramson et al., 2003; Huang et al., 2003),
hydropathy plot analysis of RFC amino acid sequence (591 amino acids) predicted twelve
transmembrane domains (TMDs) with both carboxyl and amino termini located within the
cytosol (Figure 1.3) (Matherly and Hou, 2008; Matherly et al., 2007). Thease features have been
confirmed by scanning cysteine accessibility methods (SCAM), N-glycosylation mutagenesis
and hemagglutin epitope insertion (Cao and Matherly, 2004; Ferguson and Flintoff, 1999; Liu
and Matherly, 2002). RFC is glycosylated at Asn58 on the first extracellular loop connecting
TMDs 1 and 2, and mutation of this residue to Gln abolishes N-glycosylation without major
effects on membrane targeting or transport activity (Matherly et al., 1991; Wong et al., 1998). As
with many MFS proteins, RFC contains a long intracellular loop connecting the long distances
between TMDs 6 and 7 (Figure 1.3). For RFC, this TMD6-7 loop shows the lowest amount of
sequence conservation between species (human and rodents). Deletion of large segments of this
loop region (amino acid residues 215-263 or 204-263) abolished transport, while replacement of
this region with the MFS homolog SLC19A2 (thiamine transporter ThTr1) restored transport
(Liu et al., 2003). Removal of the C- and N- termini had minimal effects on trafficking and
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Figure 1.3 Membrane topology of the human reduced folate carrier. This figure shows the
predicted topology for RFC, much of which has been experimentally confirmed. EL,
extracellular loop; IL, intracellular loop.
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function of RFC (Liu et al., 2003). RFC was expressed as two distinct half-molecules (amino
acid residues 1-301 or 302-591) and while each half-molecule was non-functional, cotransfection of both half-molecules restored RFC function (Witt et al., 2004). These results
suggest that the TMD6-7 loop region of RFC plays a primarily structural role, connecting the
long gap between TMDs 6 and 7.
In order to perform SCAM to characterize the RFC protein structure, a “cys-less” RFC
was developed using mutagenesis to replace the 11 cysteine residues with serine (Cao and
Matherly, 2003). In total, 282 RFC cysteine mutants were developed from cys-less RFC and
used for 2-sulfonatoethyl methanethiosulfonate (MTSES) scanning via transfection into RFCnull Hela (R5) cells. Based on patterns of MTSES transport inhibition, it was determined that
TMDs 4, 5, 7, 8, 10 and 11 comprise the membrane translocation pathway for folate substrates
(Hou et al., 2005; Hou et al., 2006), confirming models predicted by hydropathy modeling and
MFS comparisons. Of the 282 cysteine mutants, only 10 were inactive for transport activity,
including residues on TMD4 (Arg133, Ile134, Ala135, Tyr136, Ser138), TMD7 (Tyr281),
TMD8 (Ser313) and TMD10 (Arg373). Arg133, Arg373 and Ser313 had been previously shown
to be functionally important (Liu and Matherly, 2001; Sadlish et al., 2002; Sharina et al., 2001;
Zhao et al., 1999).
RFC exists as a homo-oligomer (Hou and Matherly, 2009), although RFC monomers
function independently (Hou et al., 2010). Cofolding of RFC monomers is necessary for
intracellular trafficking and surface activity, such that RFC displays a dominant-negative effect
(Hou and Matherly, 2009). When wild-type RFC and inactive mutant S138C RFC were cotransfected into RFC-null (R5) HeLa cells, both RFC proteins displayed decreased cell surface
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expression due to impaired cellular trafficking, as observed by confocal microscopy and surface
biotinylation.
1.3 Folate Receptors
Folate receptors (FRs) are high affinity folate binding proteins, which bind folic acid,
reduced folates, and many antifolate molecules with low-nanomolar affinities, and bring them
into the cell using an endocytosis mechanism (Rijnboutt et al., 1996; Sabharanjak and Mayor,
2004). FRs exist in three isoforms; α, β, and γ (Elwood, 1989; Lacey et al., 1989; Ratnam et al.,
1989; Sadasivan and Rothenberg, 1989; Shen et al., 1994; Shen et al., 1995), which are each
encoded by unique genes located at chromosome 11q13.3-q13.5 (Elnakat and Ratnam, 2004).
Human FRs share 68-79% amino acid sequence identity. FRα contains three N-glycosylation
sites, while FRβ and FRγ have only two. While FRα and FRβ are GPI-anchored glycoproteins,
FRγ does not contain a signal for GPI-anchoring and is instead a secretory protein with an
unknown function (Elnakat and Ratnam, 2004).
Membrane-bound (α and β) FRs function to mediate cellular folate uptake via
endocytosis. Folates bind FRα/β at the plasma membrane, followed by invagination, formation,
and budding-off of an endosome (Rijnboutt et al., 1996; Sabharanjak and Mayor, 2004). Release
of folate ligand from FR ensues upon acidification of the endosome. Exit of the folate molecule
from the endosome involves either diffusion out of the intact vesicle or pH-dependent transport
processes (Kamen et al., 1988). PCFT has been implicated to play a role in the export of
endosomal folates (Zhao et al., 2009b).
FRα shows expression primarily in the choroid plexus, retinal pigment epithelium, and
proximal tubules in uterus, placenta, fallopian tubes, and kidney (Elnakat and Ratnam, 2004). In
these tissues, FRα is expressed on the apical (luminal) surface of polarized epithelial cells, and
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therefore does not come into contact with circulating folates (Chancy et al., 2000), a feature
which protects these tissues from circulating FRα-targeted antifolate molecules (Weitman et al.,
1992b). FRβ is expressed in the placenta and hematopoietic cells (Elnakat and Ratnam, 2004).
Expression of FRβ in normal bone marrow and peripheral blood cells is limited to the
myelomonocytic lineage, such as mature neutrophils, and is reported as non-functioning (Pan et
al., 2002; Reddy et al., 1999).
1.4 Proton-Coupled Folate Transporter
Although an additional transport mechanism other than RFC was previously recognized
as capable of intestinal folate uptake, it was not until 2006 that this transporter, PCFT, was
identified and cloned, providing the molecular basis for low pH folate transport activity (Assaraf
et al., 1998; Henderson and Strauss, 1990; Kuhnel et al., 2000; Sierra and Goldman, 1998; Zhao
et al., 2004a; Zhao and Goldman, 2007). PCFT plays a critical role in absorption of dietary
folates into the intestine, as demonstrated by hereditary folate malabsorption (HFM) patients
harboring loss-of-function mutations, as well as by PCFT knockout mice (Atabay et al., 2010;
Borzutzky et al., 2009; Diop-Bove et al., 2009; Lasry et al., 2008; Mahadeo et al., 2010;
Mahadeo et al., 2011; Meyer et al., 2010; Min et al., 2008; Qiu et al., 2006; Salojin et al., 2011;
Shin et al., 2011; Shin et al., 2010; Zhao and Goldman, 2007). PCFT knockout mice had
undetectable levels of serum folate (Salojin et al., 2011). PCFT plays a major role in intestinal
folate absorption, and has been shown to be expressed in certain other tissues (Desmoulin et al.,
2012a).
1.4.1 PCFT Tissue Expression
PCFT has been identified as a folate transporter which operates at an acidic pH optimum,
consistant with its main function of transporting dietary folates (Zhao and Goldman, 2007).
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PCFT levels are highest at the apical brush border membrane of the proximal jejunum and the
duodenum, but expression in other segments of the intestine and colon is dramatically decreased
(Inoue et al., 2008; Qiu et al., 2006; Qiu et al., 2007; Urquhart et al., 2010). PCFT is also
expressed in the choroid plexus and plays a role in folate transport into the central nervous
system, where it may function in conjunction with FRs to release folates from endosomes
(Wollack et al., 2008; Zhao et al., 2009b). While high levels of PCFT gene expression were
detected in other tissues, in particular liver and kidney, its role in these tissues has not been
explored (Desmoulin et al., 2012a).
1.4.2 Hereditary Folate Malabsorption
Mutations in PCFT can cause HFM, a rare autosomal-recessive disease which results in
loss of the low pH intestinal absorption of dietary folates by PCFT (Atabay et al., 2010;
Borzutzky et al., 2009; Geller et al., 2002; Lasry et al., 2008; Mahadeo et al., 2010; Meyer et al.,
2010; Min et al., 2008; Qiu et al., 2006; Shin et al., 2011; Shin et al., 2010; Unal et al., 2009b;
Zhao et al., 2007). HFM leads to systemic folate deficiency, and is associated with
developmental

delay,

peripheral

neuropathies,

seizures,

gait

disorders,

anemia,

hypoimmunoglobulinemia, and Pneumocyctis jiroveci pneumonia (Geller et al., 2002). Loss of
PCFT function in HFM also results in impaired transport of folates across the choroid plexus into
the central nervous system (Wollack et al., 2008; Zhao et al., 2009b). Infants who present HFM
display neurological defects, revealing the importance of PCFT function in the central nervous
system. The existence of HFM implies the importance of PCFT folate transport in both the
intestine and the nervous system.
1.4.3 PCFT Function
PCFT exhibits an acidic pH optimum, transporting folates most effectively at pH 5-5.5,
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with transport becoming less effective as pH increases (Inoue et al., 2008; Qiu et al., 2006; Zhao
and Goldman, 2007; Zhao et al., 2009a). Above pH 7, PCFT is nearly incapable of folate
transport, although specific transport efficiencies with increasing pH vary for particular
(anti)folate molecules, largely reflecting differences in substrate binding (Zhao and Goldman,
2007). Unlike RFC, PCFT shows similar binding affinities (Kt) for reduced folates (5-formyl and
5-methyl THF) as for folic acid, and is stereospecific for (6S)5-formyl THF. PCFT shows
stereospecificity for L- aminopterin over D-aminopterin, due to differences in binding affinity
(Kt) (Menter et al., 2012). PCFT is known to transport MTX, RTX, LMX and PDX (Deng et al.,
2009; Desmoulin et al., 2012a; Qiu et al., 2007; Zhao et al., 2008), while PMX is widely
considered to be the best PCFT substrate (Zhao and Goldman, 2007; Zhao et al., 2008). However,
a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine antifolates have been shown to have
similar or stronger affinities for PCFT as PMX (Cherian et al., 2013; Kugel Desmoulin et al.,
2011; Kugel Desmoulin et al., 2010; Wang et al., 2010; Wang et al., 2011; Wang et al., 2015)
(also see Chapters 5 and 6).
PCFT transport of folates is electrogenic, producing a net positive charge, indicating that
more than two protons are transported alongside bivalent folate anions (Qiu et al., 2006). PCFT
couples downhill proton influx with uphill anion influx, and PCFT transport results in
intracellular acidification (Zhao et al., 2009a). Under acidic conditions, PCFT displays channellike functions. Removal of Na+, K+, Ca2+, Mg2+, or Cl- does not effect PCFT transport, while
carbonylcyanide p-trifluoro-methoxyphenylhydrazone (a proton ionophore) or nigericin (a
K+/H+-exchanging ionophore) treatment does reduce PCFT transport activity (Inoue et al., 2008;
Qiu et al., 2006). PCFT is capable of functioning without a proton gradient, in which case
transport is dependent on membrane potentials (Qiu et al., 2006; Umapathy et al., 2007). An
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“alternate access model,” similar to other previously studied MFS proteins was described
(Abramson et al., 2003; Hou et al., 2012; Inoue et al., 2008; Qiu et al., 2006; Unal et al., 2009b).
According to this model, PCFT is predicted to exist in two distinct conformations, an inwardfacing and an outward-facing form. In the outward-facing (extracellular) form, PCFT binds a
proton first, followed by the folate molecule. The binding of folate causes a conformational
change in PCFT, resulting in the inward-facing (intracellular) form, in which the folate molecule
is released from PCFT first, followed by the release of the proton (the rate-limiting step) and
then another conformational change back into the outward-facing form. In the absence of protons,
the transformation from inward-facing to outward-facing conformation is the rate limiting step
(Unal et al., 2009b). In the inward-facing conformation, TMDs 1, 2, 7 and 11 form an
extracellular gate (Zhao et al., 2016).
Additionally, PCFT exists as an oligomer (Hou et al., 2012). PCFT dimers are the most
common form, although higher-order oligomers have been identified. PCFT dimers are capable
of restoring folate transport activity to inactive variants of PCFT, such that wild-type PCFT is
capable of restoring activity to inactive PCFT mutants (such as the P425R mutation) via
oligomerization (possibly explaining the recessive nature of HFM) (Geller et al., 2002; Hou et al.,
2012).
1.4.4 PCFT Structure
The human PCFT protein is made up of 459 amino acid residues, with a predicted
molecular mass of 49.8 kDa (Figure 1.4). By molecular modeling with MFS proteins, including
the glycerol-3-phosphate transporter and lactose permease (Abramson et al., 2003; Huang et al.,
2003), hPCFT is predicted to have twelve transmembrane domains (TMDs), with both the Nand C- termini located in the cytosol. This basic structure has been verified experimentally by
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Figure 1.4 Membrane topology of the human proton-coupled folate transporter. This figure
shows the predicted topology for PCFT, much of which has been experimentally confirmed.
Domains of interest in this dissertation have been highlighted. The 7 cys residues of PCFT are
highlighted in red. TMD2 is highlighted in blue, while the TMD2-3 connecting loop is
highlighted in green. TMDs 3 and 6 are highlighted in purple. The TMD6-7 connecting loop is
highlighted in orange. EL, extracellular loop; IL, intracellular loop.

16
SCAM using MTSEA (2-aminoethyl methanethiosulfonate)-biotin in order to identify intra- and
extracellular TMD-connecting loop regions (Unal et al., 2008; Zhao et al., 2010). On the first
extracellular loop region (connecting TMDs 1 and 2), PCFT contains two N-glycosylation sites
at Asn58 and Asn68, and loss of both of these residues by mutation to glutamine did not impact
protein expression or transport function (Unal et al., 2008). Two cysteine residues, Cys66 (first
extracellular loop) and Cys298 (fourth extracellular loop), form a disulfide bond which is not
essential to transport function (Zhao et al., 2010). The first predicted intracellular loop region
(connecting TMDs 2 and 3) is thought to contain a functionally important β-turn structure,
although this has not been experimentally determined (Lasry et al., 2009; Lasry et al., 2008;
Subramanian et al., 2008) (see Chapter 2). The third predicted intracellular loop, which connects
TMDs 6 and 7, contains a long sequence of 30 amino acid residues, necessary to span the long
gap between these two domains (see Chapter 4). The ten residues found on the C-terminus of
PCFT (450 to 459) seem to play no obvious role, as experimental removal of these residues from
PCFT sequence had no effect on transport function or membrane expression (Subramanian et al.,
2008).
Much work has been done to identify key amino acid residues of PCFT protein sequence.
Often, these residues are characterized by expression of DNA vectors containing PCFT mutant
coding sequence via transfection into PCFT-null cell lines, epitomized by the R1-11 HeLa cell
line which lacks both PCFT and RFC expression (Diop-Bove et al., 2009). Transfected cells can
be used to measure uptake of tritiated folates (folic acid, MTX, PMX) at pH 5.5 and 37oC in
order to determine the functional impact of mutagenesis of the PCFT residue of interest. Via this
method, experimental characterization of PCFT mutants identified in HFM patients has revealed
several key residues in PCFT function (Zhao et al., 2007). One such residue, His281 (TMD7)
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(Figure 1.4), faces the extracellular region of TMD7 and plays an important role in PCFT
protonation, a feature which contributes to folate substrate binding (the H281A mutant PCFT
displayed a 11.3-fold increase in Kt for [3H]folic acid compared to wild-type) (Unal et al., 2009a).
Residue Glu185 (TMD5) plays a role in proton coupling, and mutations in Glu185 (including
Ala, Leu, Cys, Asp, His, Gln) drastically decreased PCFT transport activity at acidic pH, while
the E185A mutant showed no significant decrease in transport activity at pH 7.4 compared to
wild-type PCFT and was capable of trans-stimulation (increased transport activity when preincubated with substrate) (Unal et al., 2009b). Arg376 (TMD10) contributes to both proton
coupling and substrate binding, as mutation to glutamine resulted in an increased Km (14-fold
increase over wild-type) for PMX as well as a “proton slippage” effect, observed via
electrophysiological analysis (Xenopus oocytes were used to measure currents associated with
folate transport) (Mahadeo et al., 2010). Mutation of Pro425 (TMD12) to arginine had an impact
on transport efficiency, although this effect was variable between different substrates (Shin et al.,
2012). In a kinetic comparison between MTX and PMX, P425R displayed decreased Vmax for
both substrates, while the Kt value for MTX increased and the PMX Kt decreased (4.98-fold and
0.68-fold relative to wild-type, respectively) (Shin et al., 2012). The dietary folate 5-methylTHF
had the most notable loss in uptake of any substrate, suggesting a role for P425R in HFM (Shin
et al., 2012). Asp156 (TMD4) mutation to tyrosine was discovered in an HFM patient, and sidedirected mutagenesis of Asp156 to several other residues (including Asn, Lys, Trp, Phe, Val)
resulted in dramatic losses in cell surface protein expression, revealing the critical role of
Asp156 in PCFT protein stability (Shin et al., 2010).
Mutation of Arg113 (Figure 1.4) was also identified in multiple HFM patients. The
R113C mutant protein cannot transport folate molecules due to protein misfolding, with a lack of
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protein translocation to the apical membrane (Shin et al., 2011). One group predicted that
Arg113 could protrude into the membrane cavity formed by TMDs 1, 3, 4, and 6, as shown by
molecular modeling, due to a β-turn structure formed by residues 109-114 (DSVGRR sequence)
in the TMD 2-3 connecting loop region, similar to other DXXGRR structures found within other
MFS proteins (Lasry et al., 2008). However, this was not experimentally tested (see Chapter 2).
Complete replacement of residues 109-114 with alanine resulted in endoplasmic reticulum
retention and a loss of transport activity (Subramanian et al., 2008). Additionally, a study of
aspartic acid residues in PCFT found that Asp109 is essential for transport function, and cannot
be replaced with other residues (Shin et al., 2010).
Other functionally important residues have been identified by random mutagenesis (via
manipulation of both manganese and dGTP concentrations in PCR reactions) (Zhao et al.,
2011b). One study found that only 4.5% of all mutations had a direct impact on PCFT function,
which is plausible given the rarity of HFM (Zhao et al., 2011b). In total, 26 independent loss-offunction mutations were isolated. This study identified M222R (TMD6), V134E (TMD3) and
L31P (TMD1) as mutations which dramatically decreased PCFT protein expression by ectopic
expression and western blotting (Zhao et al., 2011b). The E232G (TMD6) mutatant protein was
unable to form a structural conformation to facilitate folate transport, while the L161R (TMD4)
mutation resulted in a reduced Vmax and I304F (TMD8) showed a decreased binding affinity
(increased Kt) (Zhao et al., 2011b). While neither F426V (TMD12) nor L432H (TMD12)
mutations showed any effect on transport activity, these mutations completely inhibited transport
activity in combination, likely due to an instability of the protein structure rather than an
interaction between the two residues (Zhao et al., 2011b).
A systematic study of all tyrosine residues of PCFT identified several residues in TMDs
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which face the substrate translocation pathway [Tyr291 (EL4), Tyr315 (TMD7), and Tyr362
(TMD10)], as shown by cysteine mutant accessibility to MTSEA-biotin (Visentin et al., 2015).
Interestingly, the mutant Y414C (EL6) showed transport which could be inhibited by MTSET
(2-(Trimethylammonium)ethyl methanethiosulfonate, bromide), despite its extracellular position
(Visentin et al., 2015). Tyr291 (EL4), Tyr362 (TMD10), and Tyr414 (EL6) all displayed
enhanced transport compared to wild-type PCFT for 50 µM MTX (but not 0.5 µM MTX) when
mutated to alanine, cysteine, or phenylalanine, while Tyr315 (TMD7) displayed this
phenomenon only when alanine mutation was introduced (Visentin et al., 2015). Conversely,
Tyr315 mutants for alanine, cysteine, and phenylalanine all displayed enhanced transport for 50
µM PMX, a phenomenon explained by an increased Vmax, accompanied by a decreased Kt
compared to wild-type PCFT.
In another study, Zhao et. al. identified point mutation c.575G>A, an inactivating PCFT
mutation of G192V, which led to the evaluation of the evolutionally conserved G189XXG192
domain of TMD5, as “GXXG” domains have been shown to serve as RNA binding domains
without a known function in membrane transporters (Zhao et al., 2012). Inactivating mutations in
both glycine residues (G189A, G192V) were identified, while additional residues lining the
substrate binding domain were also identified (Zhao et al., 2012). When mutated to cysteine,
both Ile188 and Met193 interacted with MTSET (as indicated by loss of transport activity),
indicating their aqueous accessibilities (Zhao et al., 2012). I188C MTSET transport inhibition
was abolished by PMX co-incubation at 0°C, suggesting its direct role in substrate binding.
M193C did not display this phenomenon, indicating its position in the substrate binding cavity
without a direct role in substrate binding.
As with all MFS proteins, PCFT forms two distinct halves composed of TMDs 1-6 on
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one side, and TMDs 7-12 on the other. These two halves are linked by a TMD6-7 connecting
loop (residues 236 to 265), the longest of PCFT’s transmembrane loop domains, containing 30
amino acids (see Chapter 4). This region contains the functionally important residue His247,
which has been suggested to interact with Ser172, another intracellular residue, and serve as a
functional gatekeeper for transport substrate access to the substrate binding site (Unal et al.,
2009a). Mutation of His247 to alanine resulted in increased binding affinities (decreased Kt, Ki)
for several substrates, while influx (Vmax) was decreased, and transport of folate and protons also
became uncoupled (Unal et al., 2009a).
A recent study characterized an extracellular “gate” in PCFT. While in the inward-facing
conformation, TMDs 1, 2, 7, 11 come within close proximity to one another toward the
extracellular ends of each TMD (Zhao et al., 2016). This was confirmed via crosslinking
experiments using single- and double-cysteine mutants of Q45C, N90C, L290C, S407C and
N411C (Zhao et al., 2016). In many combination double-cysteine mutants, disulfide bonds
formed between cysteine residues, preventing the labeling with MTSEA-biotin which was
observed in single-cysteine mutants (Zhao et al., 2016). Treatment of these mutants with
dithiothreiotol (DTT) to break disulfide bonds enhanced transport, while chemical crosslinking
using CuPh or CdCl2 inhibited transport. Chemical crosslinking could be blocked by incubation
of PCFT with folic acid, restoring transport activity (Zhao et al., 2016).
1.4.5 PCFT Oligomerization
Several studies have identified PCFT homo-oligomers (Hou et al., 2012; Zhao et al.,
2012). One study demonstrated oligomerization by protein crosslinking using 1,1- methanediyl
bismethanethiosulfonate (MTS-1-MTS, a chemical which crosslinks nearby cysteine residues
together) (Zhao et al., 2012) (also see Chapter 3), while another showed fluorescence resonance
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energy transfer (FRET) between co-expressed YPet- and ECFP*-tagged PCFT monomers and
co-binding of HA- and His10-tagged PCFT monomers to nickel-affinity columns (Hou et al.,
2012). As previously mentioned, PCFT dimers displayed a dominant-positive functional
phenotype. Wild-type PCFT can restore activity to the inactive PCFT mutant P425R, such that
when wild-type PCFT was cotransfected with P425R in equal amounts, the transport of [3H]
MTX was greater than that of wild-type alone, and equal to that of two wild-type PCFT
transfectants (Hou et al., 2012). Confocal microscopy also revealed that cotransfection with
wild-type PCFT increased trafficking of P425R PCFT to the surface membrane (Hou et al.,
2012).
Studies have attempted to identify the dimerization interface for PCFT. The human PCFT
sequence contains two “GXXXG” motifs, which are analogous to previously described
dimerization motifs found in other proteins, and which form a flat surface and allow for a tight
interaction between two transmembrane α-helicies (Duan et al., 2011; Gerber and Shai, 2001;
Lebovka et al., 2014; McClain et al., 2003; Melnyk et al., 2002; Mendrola et al., 2002; Mueller
et al., 2014; Overton et al., 2003; Polgar et al., 2004; Russ and Engelman, 2000; Whittington et
al., 2001; Wilson et al., 2015; Zhao et al., 2012). For human PCFT, these groups are found from
Gly93 to Gly97 (TMD2), which is highly conserved, and from Gly155 to Gly159 (TMD4) which is
not conserved (Figure 1.4). An initial study of this region found that mutations G93A and G97A
did not inhibit protein crosslinking by MTS-1-MTS (a measure of PCFT oligomerization),
although this study did not include the TMD4 GXXXG motif (Zhao et al., 2012). Further
investigation of this region by Gly-to-Leu mutations revealed that disruptions of either or both of
the GXXXG motifs had no effect on PCFT oligomerization, reflected in protein crosslinking,
and rather decreased protein stability and intramolecular packing (Wilson et al., 2015).
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Other studies have utilized cysteine-less PCFT to crosslinking of PCFT monomers. By
replacing each individual cysteine residues with serine (Figure 1.4), and examining cysteinecrosslinking via MTS-1-MTS treatment, localization of a putative dimerization domain of PCFT
could be determined (Zhao et al., 2012). Of the seven cysteine residues of PCFT, only Cys229
was implicated as important for MTS-1-MTS crosslinking (thus, in forming an oligomer
interface), suggesting a possible role for TMD6 in PCFT oligomerization (Zhao et al., 2012) (see
Chapter 3).
1.5 The Metabolic Role of Folates
The biological significance of folates relates to their participation in one-carbon transfer
reactions which are critical to the de novo synthesis of thymidylate and purine nucleotides, the
catabolism of formic acid and histidine, the conversion of homocysteine to methionine and
interconversions between glycine and serine (Stokstad, 1990; Tibbetts and Appling, 2010). Via
synthesis of methionine, a precursor of S-adenosyl methionine, folates contribute to the
methylation of DNA, histones, lipids, and neurotransmitters (Lu, 2000). Folate molecules consist
of three structural components: the pteridine ring, the p-aminobenzoic acid, and the L-glutamine
(Assaraf, 2007; Zhao et al., 2009a) (Figure 1.1). Folic acid is the synthetic form of metabolically
important folates, which vary in the level of oxidation of the pteridine ring, the single-carbon
moieties (formyl, methyl, methylene, methenyl) bound to the N5 and/or N10 positions, and the
level of polyglutamylation (Stokstad, 1990). 5-Methyl THF is the major circulating folate form.
Following cellular uptake 5-methyl THF is polyglutamylated by folylpoly-γ-glutamate synthase
(FPGS), a process by which between 2 and 8 glutamyl residues are linked to the γ-carboxyl of
the p-aminobenzoic acid of THF, which contributes to the cellular retention of THF (Shane,
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1989) (Figure 1.1). Then, THF can be converted to various forms bound to single-carbon units to
contribute to metabolic reactions (Stokstad, 1990).
1.5.1 One-Carbon Metabolism
The main source of single-carbon units comes from the conversion of serine to formate in
the mitochondria (Barlowe and Appling, 1988; Barlowe and Appling, 1990; Davis et al., 2004;
Garcia-Martinez and Appling, 1993; Gregory et al., 2000; Herbig et al., 2002; Kastanos et al.,
1997; Pasternack et al., 1994; Pasternack et al., 1996; Patel et al., 2003; Quinlivan et al., 2005;
Tibbetts and Appling, 2010). In the mitochondria, carbon 3 of serine is transferred to THF in a
relation catalyzed by serine hydromethyltransferase (SHMT), which produces 5,10methyleneTHF and glycine (Figure 1.3) (Tibbetts and Appling, 2010). 5,10-MethyleneTHF is
converted to 10-formylTHF by either methylenetetrahydrofolate dehydrogenase (MTHFD) 2
(MTHFD2) (embryonic tissues) (Mejia and MacKenzie, 1985) or MTHFD2-like (MTHFD2L)
(adult tissues) (Bolusani et al., 2011) (Figure 1.5). 10-FormylTHF can be reduced to formate and
THF by MTHFD 1-like (MTHFD1L) 10-formyl THF synthase (Prasannan et al., 2003), after
which formate can be exported to the cytoplasm and react with unsubstituted THF via MTHFD1
to form 10-formylTHF (cytosolic) (Figure 1.5) (Hum et al., 1988; Paukert et al., 1977; Schirch,
1978; Smith et al., 1980).
MTHFD1 can also convert 10-formyl THF to 5,10-methenyl THF or, subsequently, 5,10methylene THF (Hum et al., 1988; Paukert et al., 1977; Schirch, 1978; Smith et al., 1980;
Thigpen et al., 1990). 5,10-MethyleneTHF donates its methylene group to deoxyuriine
monophosphate (dUMP) to synthesize thymidylate (dTMP) in a reaction catylized by
thymidylate synthase (TS) (Figure 1.5) (Friedkin and Roberts, 1956; Phear and Greenberg, 1957).
In this reaction, 5,10-methylene THF is converted to dihydrofolate (DHF), which can be
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Figure 1.5 Folate metabolic pathways. The schematic shows metabolic steps which are
metabolized by folates, resulting in the synthesis of purines, thymidine, methionine, serine and
glycine.
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converted to unsubstituted THF by DHF reductase (DHFR) (Figure 1.5) (Humphreys and
Greenberg, 1958; McDougall and Blakley, 1960). An alternate route for 5,10-methyleneTHF is
to be reduced to 5-methylTHF by 5,10-MethyleneTHF reductase (MTHFR) (Figure 1.5), which
can donate its methyl group to homocysteine, synthesizing methionine via methionine synthase
and regenerating unsubstituted THF (Hatch et al., 1961).
1.5.2 Purine Biosynthesis
Purines are an essential component of both DNA and RNA, while also regulating
enzymatic activity and serving to mediate energy transfer in the cell as components of ATP,
cyclic AMP, NADH and coenzyme A (King et al., 1983). Differentiated adult cells can usually
satisfy purine requirements through purine salvage mechanisms, while proliferating cells usually
rely on de novo purine biosynthesis in order to meet the demands of DNA and RNA synthesis
(Denkert et al., 2008; Fairbanks et al., 1995; Howell et al., 1981; Jackson and Harkrader, 1981;
King et al., 1983; Kondo et al., 2000; LeLeiko et al., 1983; Mackinnon and Deller, 1973) De
novo purine biosynthesis inhibitors prevent lymphocyte and tumor cell growth, suggesting that
purine salvage pathways are insufficient in these rapidly-dividing cell types (Christopherson et
al., 2002; Hovi et al., 1976).
10-FormylTHF can be used in the de novo synthesis of purine nucleotides (Figure 1.6).
The formate group of 10-formylTHF can be dontated to β-glycinamide ribonucleotide (GAR)
formyltransferase (GARFTase) and 5-aminoimidazole-4-carboxamide (AICA) ribonucleotide
formyltransferase (AICARFTase), catalyzing the third and ninth, respectively, of the ten steps in
de novo purine biosynthesis from phosphoribosyl pyrophosphate (PRPP) to inosine
monophosphate (Figure 1.6). This leads to a net transfer of two one-carbon units transferred from
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Figure 1.6 De novo purine biosynthesis. The 10 steps from PRPP to inosine monophosphate
are detailed. Two steps are catalyzed by 10-formylTHF, step 3 (catalyzed by GARFTase) and
step 9 (catalyzed by AICARFTase). The AGF series of compounds discussed in this dissertation
inhibit GARFTase.
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10-formylTHF and to the C-2 and C-8 of the purine ring and the regeneration of two molecules
of unsubstituted THFs (Hartman and Buchanan, 1959b; Smith et al., 1981; Smith et al., 1980).
Hypoxanthine PRPP is also required in purine salvage. Hypoxanthine phosphoribosyl
transferase converts guanine and hypoxanthine into GMP and IMP (inosine monophosphate),
respectively, while adenine is converted to AMP by adenosine phosphorribosyl transferase; both
reactions require PRPP (Murray, 1971). This pathway was characterized in avian models, and
has since been shown to be conserved across all nearly all species (Hartman and Buchanan,
1959a).
1.5.3 Polyglutamylation of Folates
In the blood, folates exist primarily in the monoglutamate form (Assaraf, 2007; Stokstad,
1990). However, upon transport into the cell, folates are polyglutamylated by FPGS. FPGS can
be located in both the cytosol and the mitochondria (McGuire et al., 2000), and catalyzes an
ATP-dependent reaction to add glutamic acid groups to the γ-carboxyl group of folates. This
reaction can occur multiple times, sequentially, such that multiple glutamates can be bonded to a
single folate molecule (Figure 1.1). The primary purpose of polyglutamylation is to contribute to
the cellular retention of folate molecules (Baugh et al., 1973; McBurney and Whitmore, 1974;
Moran, 1999; Moran et al., 1976). Following polyglutamylation, folates become better substrates
for folate-dependent enzymes, including TS, GARFTase and AICARFTase (Allegra et al., 1985;
Allegra et al., 1987; Baggott et al., 1986; Jackman et al., 1991b; Schirch and Strong, 1989; Shih
et al., 1997). Additionally, long chain (n>3) polyglutamate folates are no longer substrates for
RFC or several efflux proteins including multidrug resistance proteins (MRPs) and breast cancer
resistance protein, which contributes to their cellular retention (Assaraf, 2006; Matherly and
Goldman, 2003; Volk and Schneider, 2003; Wielinga et al., 2005; Zeng et al., 2001).
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1.6 Antifolate Treatment of Cancer
Rapidly proliferating tumor cells have specific metabolic requirements, as excessive
nutrient quantities are needed to support synthesis of macromolecules required for cell division.
Folates are required to contribute to the de novo synthesis of purine nucleotides and thymidylate
necessary for DNA replication (Scotti et al., 2013) (Figure 1.5). In order to keep up with the
folate requirements, tumors have been shown to express folate transporters and receptors (Kugel
Desmoulin et al., 2011). Membrane transport of circulating folates is essential, as folates exist as
anions at physiological pH. Both PCFT and RFC have been shown to be expressed in a wide
variety of human tumor cell lines (Gonen et al., 2008; Kugel Desmoulin et al., 2011; Matherly et
al., 2007; Zhao et al., 2004a). For 29 of 32 human tumor cell lines including cell lines from the
National Cancer Institute 60 cell line panel, [3H]MTX uptake was shown to be increased at pH
5.5 compared to pH 7.4, suggesting PCFT-mediated uptake (Zhao et al., 2004a). FRα
overexpression has been shown in several cancer types including ependymal brain tumors and
non-mucinous adenocarcinomas of ovary, cervix, and uterus (Bueno et al., 2001; Buist et al.,
1995; Campbell et al., 1991; Elnakat and Ratnam, 2004; Evans et al., 2001; Garin-Chesa et al.,
1993; Ross et al., 1994; Veggian et al., 1989; Weitman et al., 1994; Weitman et al., 1992a; Wu et
al., 1999). FRα expression increases with tumor stage in ovarian cancer (Buist et al., 1995;
Garin-Chesa et al., 1993; Veggian et al., 1989). FRα is expressed in some non-small cell lung
cancer patients (NSCLC), although expression levels are highly variable (Christoph et al., 2013;
Nunez et al., 2012; O'Shannessy et al., 2012) (also see Chapter 5). FRβ expression was found in
chronic myelogenous leukemia and acute myelogenous leukemia, but not in acute lymphoblastic
leukemia (ALL) (Pan et al., 2002; Ross et al., 1999).
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1.6.1 DHFR Inhibitors
Based on observations which established the importance of folates in cancer progression,
Sidney Farber and colleagues at Harvard hypothesized in 1947 that cancer cell proliferation
could be inhibited via folate antagonists, based on the observation that folic acid stimulated
leukemic cell growth (Farber et al., 1947). Aminopterin (AMT) (Figure 1.2), an antifolate
synthesized by Yellapragada Subbarow, was the first ever chemotherapeutic compound shown to
cause remission of ALL (Farber and Diamond, 1948). AMT was later improved through the
synthesis of MTX (Figure 1.2), which could be used to treat ALL with fewer side effects and less
toxicity (Farber, 1949). MTX remains relevant today as a treatment for ALL, lymphomas, and
several solid tumors (Jolivet et al., 1983; Monahan, 2001; Pui and Evans, 2006), as well as nonmalignant diseases such as rheumatoid arthritis, psoriasis and Crohn’s disease (Chladek et al.,
1998; Feagan et al., 1995; Wessels et al., 2008). AMT, too, has found new interest in therapy of
cancer and inflammatory diseases (Cole et al., 2008; Menter et al., 2012). As such, antifolate
compounds have remained an essential class of cancer chemotherapeutic for nearly 70 years.
However, the therapeutic utility of MTX is limited by its lack of tumor specificity and the
existence of both de novo and acquired resistance (Matherly et al., 2007; Zhao and Goldman,
2003).
Both MTX and AMT are highly potent inhibitors of DHFR (Gonen and Assaraf, 2012;
Zhao and Goldman, 2003). DHFR inhibition causes accumulation of DHF, generated by TS.
DHF is reduced to THF by DHFR, and the buildup of DHF as a result of DHFR inhibition causes
net depletion of unsubstituted THF and termination of THF-dependent carbon transfer reactions
in the biosynthesis of thymidylate, purine nucleotides, methionine and serine (Matherly et al.,
1987; Seither et al., 1989). AMT has a much stronger affinity than MTX for both RFC and FPGS,
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which adds additional glutamates to folate molecules and contributes to cellular retention
(Matherly et al., 1985). Thus, AMT enters the cell and is polyglutamylated much more quickly
than MTX, resulting in much higher levels of AMT polyglutamates (Matherly et al., 1985), and
displays far more potent antitumor activity than MTX (Goldin et al., 1955; Sirotnak et al., 1984).
However, this may also be the reason for the increased toxicity of AMT in patients, reflecting the
ubiquitous expression of RFC.
PDX (10-propargyl-10-deaza-AMT) (Figure 1.2) was the product of a collaboration
between F. M. Sirotnak of Memorial Sloan-Kettering Cancer Center and J. I. Degraw of
Southern Research Institute to improve cellular pharmacology of antifolate compounds. PDX
precursors 10-deaza-AMT and 10-ethyl-10-deaza-AMT were more potent than MTX (Schmid et
al., 1985; Sirotnak et al., 1984; Sirotnak et al., 1993). PDX, the third generation in this series of
compounds, was found to be 3-fold less potent at DHFR inhibition than MTX, but displayed 10fold higher transport rates by RFC and higher polyglutamylation by FPGS, ultimately resulting
in increased drug efficacy toward breast cancer, NSCLC and leukemia cell lines both in vitro and
in vivo (DeGraw et al., 1993; Sirotnak et al., 1998; Visentin et al., 2013). In phase I and II trials,
which included non–small-cell lung cancer and peripheral T-cell lymphoma patients, PDX
showed both efficacy and safety, leading to the Food and Drug Administration (FDA) approval
for the treatment of relapsed, refractory peripheral T-cell lymphoma in 2009 (Krug et al., 2003;
Marchi et al., 2013; O'Connor et al., 2009; Thompson, 2009). Since 2009, PDX has been tested
in combination with other therapies in several different cancer types with promising results
(Azzoli et al., 2007; Marchi et al., 2010; Toner et al., 2006; Zain and O'Connor, 2010a; Zain and
O'Connor, 2010b).
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PT523 (Figure 1.2) is a hemiphthaloylornithine antifolate synthesized by A. Rosowsky
and colleagues at Dana-Farber Cancer Institute (Rosowsky et al., 1988). PT523 is a strong
inhibitor of DHFR with a submicromolar Kt for RFC, while also being a very poor substrate for
PCFT (Kugel Desmoulin et al., 2010; Rhee et al., 1994; Rosowsky et al., 1988; Wang et al.,
2010; Wright et al., 2000; Zhao and Goldman, 2007). PT523 lacks a terminal glutamate, and is
not a substrate for polyglutamylation, which decreases the impact of intracellular THF levels on
PT523 compared to MTX. In a phase I study including 18 patients with relapsed or refractory
NSCLC, PT523 displayed acceptable toxicity and efficacy (2 partial responses, 9 stable disease)
after multiple chemotherapy cycles (Lima et al., 2006).
1.6.2 TS Inhibitors
RTX (Tomudex; ZD1694; (S)-2-(5-methyl((2-methyl-4-oxo-1,4-dihydroquinazolin-6yl)methyl)amino)thiophene-2-carboxamido)pentanedioic acid) (Figure 1.2) is a quinazoline
antifolate and an inhibitor of TS. RTX was designed by scientists at the Institute for Cancer
Research and Astra Zeneca (Hughes et al., 1999; Jackman and Calvert, 1995). Earlier attempts to
develop a TS-targeted antifolate resulted in CB3717 (N10-propargyl-5,8-dideazafolic acid; N-[4[N-[(2-amino-4-hydroxy-6-quinazo-linyl)methyl]prop-2-ynylamino] benzoyl]-L-glutamic acid),
which showed efficacy against ovarian, liver and breast cancers in phase I/II clinical trials but
also resulted in hepatic toxicity and dose-limiting nephrotoxicity in 70% of patients given doses
above 450 mg/m2 (Jackman and Calvert, 1995). In order to reduce toxicity and increase
solubility, CB3717 was modified by substitution of the 2-amino group with 2-desamino-2methyl, replacement of benzoyl ring with thiophene ring, and replacement of N10-propargyl with
a methyl (Jackman et al., 1996; Jackman et al., 1991a; Jackman et al., 1991b). These
modifications resulted in RTX, which is a poorer TS inhibitor than CB3717. RTX is a greater
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RFC and FPGS substrate than CB3717, resulting in enhanced antitumor efficacy in vivo and in
vitro as well as increased water solubility (Hughes et al., 1999; Jackman et al., 1991b). RTX has
been approved for use in the treatment of advanced colorectal cancer in Australia, Canada, and
Europe, and for treatment of malignant pleural mesothelioma in combination with cisplatin in
several European countries (Chu et al., 2003; Surmont and van Meerbeeck, 2011). RTX
represents the success of developing structure activity relationships (SAR) through careful
testing of chemical modifications made to antifolate compounds.
ZD9331 (Plvitrexed, BGC9331) (Figure 1.2) is a quinazoline antifolate with a γ tetrazole.
ZD9331 lacks FPGS activity but remains an excellent RFC substrate and inhibitor of TS
(Jackman and Calvert, 1995; Jackman et al., 1997). While RFC is the primary mechanism of
transport, ZD9331 is also a substrate for FRs and PCFT (Jansen, 1999; Matherly and Gangjee,
2011). ZD9331 was developed with the intention of circumventing polyglutamylation-based
resistances tumors can develop during antifolate treatment, associated with low FPGS or high γglutamyl hydrolase activity (Zhao and Goldman, 2003), and ZD9331 activity was preserved in
RTX-resistant L1210 murine leukemia cells with low FPGS activity (Jackman et al., 1997).
Phase II clinical trials of ZD9331 showed some efficacy in patients with metastatic colorectal,
ovarian, and pancreatic cancers with a manageable toxicity profile (Hainsworth et al., 2003;
Louvet et al., 2004; Rader et al., 2003; Schulz et al., 2004; Smith and Gallagher, 2003).
GW1843U89 (Figure 1.2) was discovered at the Burroughs Wellcome Company in an
attempt to identify antifolates which might be useful as antimicrobial agents (Smith et al., 1999).
GW1843U89 is an extremely potent TS inhibitor, with a Ki of 0.09 nM, while also being an
excellent RFC substrate (Duch et al., 1993). GW1843U89 is a good FPGS substrate, but the
diglutamyl GW1843U89 is a poor FPGS substrate, leading to diglutamyl GW1843U89 being the
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major cellular form (Duch et al., 1993; Hanlon and Ferone, 1996). Polyglutamylation status of
GW1843U89 seemed to have no effect on TS inhibition (Hanlon and Ferone, 1996).
GW1843U89 was later encapsulated in liposomes, forming the new drug OSI-7904L, which was
shown to be well tolerated in patients and effective in patients with advanced gastric cancer or
gastroesophageal cancers (Falk et al., 2006) but not patients with advanced biliary cancer
(Ciuleanu et al., 2007).
In the case of antifolates that target either TS or DHFR, cell death occurs due to a lack of
thymidylate and accumulation of dUMP (Matsui et al., 1996; Yin et al., 1997). The net effect is a
decrease in the level of deoxythymidine triphosphate (dTTP), which results in the
misincorporation of deoxyuridine triphosphate (dUTP) into DNA synthesis. This causes DNA
strand breaks, as dUTP incorporation into DNA is recognized as incorrect and cycles of
unsuccessful excision-repair occur, leading to cell death (Bronder and Moran, 2003)
1.6.3 Inhibitors of De Novo Purine Biosynthesis
Lometrexol (LMX) (Figure 1.2) is a (6R) diastereomer of 5,10-dideaza THF which was
developed by E.C. Taylor of Princeton University and Chuan (Joe) Shih of Eli Lilly in an attempt
to develop antifolates which have enzyme targets other than DHFR (Mendelsohn et al., 1999b;
Moran et al., 1989; Taylor et al., 1985). LMX is structurally identical to THF, with the exception
that carbons 5 and 10, which participate in carbon transfer reactions and have been replaced with
nitrogens. LMX is an RFC substrate, although it can also be transported by PCFT and FRs
(Desmoulin et al., 2012a; Jansen, 1999; Matherly et al., 1993; Westerhof et al., 1995). LMX is
polyglutamylated by FPGS (Baldwin et al., 1991; Matherly et al., 1993; Moran et al., 1989), and
polyglutamyl forms of LMX are potent GARFTase inhibitors, depleting cells of ATP and GTP
(Beardsley et al., 1989; Mendelsohn et al., 1999b; Moran et al., 1989). Because loss of ATP
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renders p53 transcriptionally inert, LMX displayed cytotoxicity in a p53-independent manner
(Bronder and Moran, 2003). Based on in vivo and in vitro models, LMX was considered a
promising anticancer agent (Beardsley et al., 1989; Mendelsohn et al., 1999b; Moran et al., 1989).
However, in Phase I clinical trials, LMX treatment resulted in severe toxicity, with dose-limiting
myelosuppression and mucositis (Ray et al., 1993). Clinical toxicity can be reduced by the coadministration of folic acid with LMX, allowing for a ten times greater dose than LMX treatment
without folic acid (Roberts et al., 2000a). It was hypothesized that the high toxicity may be
caused by a gradual release of LMX metabolites from the liver (Taber et al., 1991), that folate
depletion increased liver FR expression, contributing to increased uptake (Mendelsohn et al.,
1996; Pohland et al., 1994) and that polyglutamate forms of LMX are essentially impossible to
eliminate from circulation (Jackman, 1999).
In an attempt to reduce the toxicities of LMX, LY309887 [(2S)-2-[[5-[2-[(6R)-2-amino4-oxo-5, 6, 7, 8-tetrahydro-1H-pyrido [2,3-d] pyrimidin-6-yl] ethyl] thiophene- 2-carbonyl]
amino] pentanedioic acid] (Figure 1.2) was synthesized. LY309887 was designed to have lower
FR affinity, lower polyglutamylation, and increased affinity for GARFTase compared to LMX
(Budman et al., 2001; Mendelsohn et al., 1996; Mendelsohn et al., 1999b; Wang et al., 1992).
Another

compound,

AG2034

[N-[(5-(2-[(6S)-2-amino-4-oxo-4,6,7,8-tetrahydro-1H-

pyrimido[5,4-b][1,4]thiazin-6-yl]ethyl)thiophen-2-yl)carbonyl]-L-glutamic acid] (Figure 1.2)
was designed based on the X-ray crystal structure of GARFTase, and AG2034 was shown to be a
potent GARFTase inhibitor (Almassy et al., 1992; Boritzki et al., 1996) and exhibited reduced
FR affinity (Boritzki et al., 1996). However, in phase I clinical trials, both LY309887 and
AG2034 showed similar cumulative toxicities to those observed in LMX-treated patients (Bissett
et al., 2001; Boritzki et al., 1996; Budman et al., 2001; Kisliuk, 2003; Roberts et al., 2000b).
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1.6.4 Multitargeted Antifolate
PMX

(LY231514;Alimta;N-[4-[2-(2-amino-4,7-dihydro-4-oxo1H-pyrrolo[2,3d]

pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid) (Figure 1.2) was synthesized by Eli Lilly in an
attempt to meet FDA requirements of purity and to eliminate chirality at the 6 position of the 5deazapteridine ring of LMX by replacement with a pyrrolo[2,3-d]pyrimidine ring (Taylor, 1993;
Taylor et al., 1992). In vitro experiments revealed that PMX was a potent TS inhibitor, and
additionally was a weak inhibitor of DHFR, GARFTase and AICARFTase (Shih et al., 1997;
Taylor et al., 1992). PMX is also an excellent substrate for both PCFT and RFC, being among
the best substrates for PCFT (Wang et al., 2004; Westerhof et al., 1995; Zhao et al., 2008).
Unlike MTX or RTX, the antitumor efficacy of PMX is maintained or even enhanced in cells
with low RFC expression, so long as PCFT is expressed (Zhao et al., 2008). PMX is highly
polyglutamylated and is among the best known FPGS substrates, although polyglutamylation is
negatively affected by intracellular folate status (Desmoulin et al., 2012b; Shih et al., 1997; Zhao
et al., 2001; Zhao et al., 2004b). PMX polyglutamylation enhanced TS inhibition, as PMX
pentaglutamate showed a TS Ki value of 1.3 nM compared to 109 nM for parent PMX. Ki values
for GARFTase and AICARFTase were much higher, suggesting decreased inhibition potency of
these enzymes, although polyglutamates were still more potent inhibitors than non-polyglutamyl
drug (Shih et al., 1997; Taylor et al., 1992). Additionally, PMX has a very low affinity for DHFR.
Potent TS inhibiton by PMX would obviate any effect on DHFR, as dihydrofolate would not be
generated once TS is inhibited.
Recently, it has been suggested that AICARFTase may be a more important secondary
target for PMX than originally realized (Racanelli et al., 2009; Rothbart et al., 2010). Treatment
with PMX results in an accumulation of the purine synthesis intermediate 5-aminoimidazole-4-
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carboamide ribotide (ZMP), the AICARFTase substrate (Racanelli et al., 2009). ZMP is an AMP
mimetic and can activate AMP-activated protein kinase (AMPK), which phosphorylates proteins
involved in initiation of energy metabolism, cap-dependent translation, and lipid synthesis
(Mihaylova and Shaw, 2011). AMPK phosphorylation due to PMX treatment results in inhibition
of mTOR signaling in lung and colon cancer cells (Gwinn et al., 2008; Inoki et al., 2003;
Racanelli et al., 2009; Rothbart et al., 2010). However, in the absence of direct TS inhibition,
AMPK activation by PMX or by direct AMPK activators (metformin) did not produce an
antiproliferatve effect in KB tumor cells (Mitchell-Ryan et al., 2013). PMX was found to act
synergistically with the multi-kinase inhibitor sorafenib by promoting autophagy which led to
activation of apoptosis pathways, thereby enhancing antitumor effects (Bareford et al., 2011).
PMX was approved by the FDA in 2004 for treatment of malignant pleural mesothelioma
in combination with cisplatin (Hazarika et al., 2005). In 2008, PMX was approved as a primary
treatment for non-squamous NSCLC (NS-NSCLC) coadminstered with cisplatin (Cohen et al.,
2009) and in 2009 for maintenance therapy in patients with local advanced or metastatic NSNSCLC (Cohen et al., 2010). Randomized clinical trials have revealed that PMX is superior to
other chemotherapy agents in the treatment of NS-NSCLC, while being inferior to other drugs in
squamous cell lung cancer either as monotherapy or in combination with platinum-based
chemotherapies (Ciuleanu et al., 2009; Hanna et al., 2004; Scagliotti et al., 2009; Scagliotti et al.,
2008).
Despite widespread use in the treatment of NS-NSCLC, the utility of PMX in the
treatment of these patients is modest, as the median progression free survival of these patients is
only 3.5 months when treated with PMX and carboplatin in combination and 3.6 months when
treated with PMX monotherapy (Ardizzoni et al., 2012). This suggests that there is a high
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amount of variability in the efficacy of PMX between patients. As a standard practice, patients
who will be treated with PMX are given dexamethasone (Dex) in order to reduce the possibility
of a severe skin rash caused by PMX treatment. Patients are given 4 mg Dex twice the day
before treatment, once the day of and once the day after. The effects of Dex are mediated by the
glucocorticoid receptor (GR), a transcription factor which can regulate cell proliferation,
apoptosis, immune response, inflammation, and cellular senescence (Ge et al., 2012;
Mangelsdorf et al., 1995; Vilasco et al., 2011). An immunohistochemical analysis of GR
expression in NSCLC showed heterogeneity of GR expression, with approximately half of the
tumors showing a relatively high GR expression (Lu et al., 2006). In vitro studies of NS-NSCLC
cell lines revealed that Dex treatment suppresses cell progression into S-phase, causes downregulation of TS, DHFR, RFC and PCFT and reduces the efficacy of PMX in cells with high
GRα expression (Patki et al., 2014). These effects were p53-independent and could be restored
within 24 hours, suggesting that Dex treatment before, during, and after PMX treatment can
drastically reduce the efficacy of PMX in patients with high tumor GR expression (Patki et al.,
2014).
1.6.5 Antifolate Resistance
Resistance to MTX via impaired RFC function has been identified in vitro (Hill et al.,
1979; Niethammer and Jackson, 1975; Sirotnak et al., 1968; Sirotnak et al., 1981) and in many
disease types, including ALL, osteosarcoma, colorectal cancer and primary central nervous
system lymphoma (Belkov et al., 1999; Ferreri et al., 2004; Gorlick et al., 1997; Guo et al., 1999;
Ifergan et al., 2003; Levy et al., 2003; Wettergren et al., 2005; Yang et al., 2003). This impaired
RFC function can be the result of either decreased RFC expression or reduced RFC function
(Assaraf, 2007; Matherly and Goldman, 2003; Matherly et al., 2007), results which can be
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produced by a variety of mutations including promoter methylation, point mutations, frameshift
mutations, genomic deletions and loss of RFC alleles (Chattopadhyay et al., 2006; Ding et al.,
2001; Rothem et al., 2002; Worm et al., 2001; Zhao et al., 2004b; Zhao et al., 1999).
Reduced polyglutamylation can also result in antifolate resistance (Drake et al., 1996; Li
et al., 1992; Liani et al., 2003; Mauritz et al., 2002; McCloskey et al., 1991; McGuire et al.,
2000; Pizzorno et al., 1989; Pizzorno et al., 1988; Pizzorno et al., 1995). Folate-dependent
enzymes, such as TS and DHFR, can aquire mutations which reduce the impact of antifolates,
either via enzyme mutations resulting decreased drug affinities or increased enzyme expression
(Albrecht et al., 1972; Alt et al., 1978; Dolnick et al., 1979; Drake et al., 1996; Flintoff and
Essani, 1980; Freemantle et al., 1995; Goldie et al., 1980; Haber et al., 1981; Horns et al., 1984;
Jackman and Calvert, 1995; Jackson and Harrap, 1973; Jackson et al., 1976; Kitchens et al.,
1999; McIvor and Simonsen, 1990; Melera et al., 1984; Melera et al., 1988; Mini et al., 1985;
Miyachi et al., 1995; Nunberg et al., 1978; O'Connor et al., 1992; Sigmond et al., 2003;
Srimatkandada et al., 1989; Tong et al., 1998; Trent et al., 1984; Wang et al., 2001; White and
Goldman, 1981). MTX resistance can be acquired through DHFR gene amplification (Alt et al.,
1978) which has been observed clinically in various cancers following treatment with MTX
(Horns et al., 1984; Trent et al., 1984). Additionally, overexpression of MRPs may also
contribute to antifolate resistance (Assaraf, 2006; Assaraf, 2007). MRP1, MRP2 and MRP3 have
been shown to be methotrexate transporters (Assaraf, 2006)
1.6.6 Utility of FRα Overexpression in Cancer for Therapy and Imaging
Because of the ubiquitous expression of RFC, which causes the non-specific action of
classical antifolates toward normal tissues as well as tumors, there has been an increased interest
in utilizing FRα overexpression in cancer (and limited normal tissue expression) for a variety of
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purposes, including both therapeutics and imaging. This concept has been demonstrated by the
development of ONX0801 (previously BGC 945), a FRα-specific TS inhibitor with a low
affinity for RFC (Gibbs et al., 2005; Theti et al., 2003). This compound displays a 70% binding
affinity compared to folic acid, and a Ki of 1.2 nM for TS (Gibbs et al., 2005) and an IC50 of 3.6
nM in KB cells (Theti et al., 2003). This compound was licensed by Onyx Pharmacuticals for a
Phase I study, laying the groundwork for numerous FRα-targeted molecules.
In addition to therapeutics, FRα-targeted imaging agents are also being developed. A
radiolabeled derivitave of folic acid, 111In-DPTA-folate, was shown to detect new ovarian cancer
in mice as well as patients in a phase I/II clinical study (Siegel et al., 2003). A version of folic
acid conjugated with 99mTechneitum, called EC20, uses a more cost effective label with a shorter
half-life, and has demonstrated higher specificity to FRα and a higher clearance rate from the
blood and kidneys (Leamon et al., 2002). EC20 has been used to image over 200 ovarian cancer
patients (Sega and Low, 2008).
Recently, there has been an interest in utilizing FR overexpression in various cancer types
to deliver cytotoxic drugs via conjugation with folic acid. The first of these to be evaluated in
tumor therapy was EC131, a folate-maytansinoid conjugate (Reddy et al., 2007). Maytansinoid, a
microtubule-inhibiting agent, was shown to be tumor-targeted to FR-positive M109 tumors in
BALB/c mice and tumor growth was inhibited.
A conjugate of folate and desacetylvin-blastinemonohydrazide (a derivative of
microtubule destabilizing agent vinblastine), Vintafolide (or EC145), has been shown to be safe
in a phase I clinical study (Lorusso et al., 2012; Vlahov et al., 2006). Multiple phase II and III
clinical trials have been performed in lung and ovarian cancer (Edelman et al., 2012; Lorusso et
al., 2012). One phase II clinical study showed that ovarian cancer patients with higher FRα
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expression displayed longer progression free survival when treated with vintafolide compared to
patients treated with PEGylated liposomal doxorubicin (Naumann et al., 2013). However, the
subsequent phase III clinical trial failed because the vintafolide-treated patients did not meet the
preliminary outcome for progression free survival (Merck, 2014). An additional phase II clinical
study in lung adenocarcinoma patients failed to demonstrate a firm conclusion on efficacy of
vintafolide due to non-random study design (Hanna et al., 2014).
Another folate conjugate, EC0225, is a folate linked to both a vinca alkaloid and
mitomycin, has had a phase I clinical trial to determine the maximum tolerated dose (Sharma et
al., 2010). Additional folate conjugates including Epofolate [a folate and epothilone A
(microtubule stabilizing agent) conjugate], EC0489 (a vintafolide analogue), and EC1456 (a folic
acid-tubulysin small-molecule drug conjugate) all had a phase I clinical trials (Gokhale et al.,
2013; Leamon et al., 2011; Lee et al., 2002; Peethambaram et al., 2015; Reddy et al., 2009).
1.6.7 Tumor Targeted Antifolates with PCFT and FR Selectivity
Cancer cells have an increased need for energy and biosynthesis of nucleotides due to
enhanced rates of growth and proliferation. In order to meet this demand, cancer cells become
reliant on the altered metabolism known as the “Warburg effect,” or aerobic glycolysis, in which
cells become highly glycolytic despite the presence of normal oxygen levels (Lunt and Vander
Heiden, 2011). In order to maintain a normal intracellular pH, glycolytically-produced acids
must be flushed out of the cell, which cells achieve by increasing expression and/or activity of
plasma membrane ion pumps and transporters. Examples include H+-ATPases and vacuolar
ATPases (Hinton et al., 2009; Martinez-Zaguilan et al., 1993; Sennoune et al., 2004), the Na+/K+
exchanger (Chiang et al., 2008; Kumar et al., 2009; McLean et al., 2000; Miraglia et al., 2005),
and the monocarboxylate H+ efflux symporter (Chiche et al., 2012; Kennedy and Dewhirst, 2010;
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Pinheiro et al., 2008a; Pinheiro et al., 2008b; Pinheiro et al., 2010). Increased activity of these
transporters allows cells to maintain an intracellular pH of ≥7.4, while creating a tumor
microenvironment of extracellular pH ranging from ~6.7-7.1. This is opposed to normal
differentiated adult cells, which have an intracellular pH of ~7.2 and an extracellular pH of ~7.4
(Busco et al., 2010; Gallagher et al., 2008; Gillies et al., 2002; Stuwe et al., 2007; Webb et al.,
2011). This acidic tumor microenvironment creates an H+-electrochemical gradient which acts as
a driving force for proton-coupled solute transporters at the cell membrane, while also increasing
substrate affinity and broadening substrate specificity for these transporters (Leuthold et al.,
2009; Nozawa et al., 2004; Qiu et al., 2006; Rubio-Aliaga et al., 2003).
There is a precedent for tumor targeting using chemotherapeutics which are specifically
transported by proton-coupled transporters (Anderson and Thwaites, 2010). Proton-coupled
di/tripeptide transporters PepT1 and PepT2 have shown increased tumor expression and activity
and provide utility in transporting cancer therapies, including prodrugs floxuridine and
cytarabine (Sun et al., 2009), photodynamic therapy and the imaging agent 5-aminolevulinic acid
(Anderson et al., 2010), and bestatin, an aminopeptidase inhibitor (Nakanishi et al., 2000; RubioAliaga and Daniel, 2002). A proton-coupled amino acid transporter, PAT1, has also been shown
to mediate uptake of 5-aminolevulinic acid and L-cycloserine in low pH conditions (Anderson et
al., 2004; Anderson et al., 2010). Several members of the organic anion transporter (OAT)
family displayed low pH polypeptide transport (Leuthold et al., 2009). OATP1A2 has been
shown to transport MTX at low pH (Badagnani et al., 2006), while OATP2B1 has also
demonstrated low pH antifolate transport (Visentin et al., 2012).
PMX is a 5-substituted 2-amino-4-oxo-pyrrolo[2,3-d]pyrimidine antifolate with a pamino-benzoyl glutamate attached by a 2-carbon bridge region. The 6-substituted regioisomer of
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PMX has no activity against tumor cells (Shih, 1993), but 6-substituted regioisomers with an
elongated carbon bridge region connecting the heterocycle and the p-aminobenzoate including
three (AGF17) or four (AGF23) (Figure 1.7) carbons were cabable of inhibiting proliferation of
KB and IGROV1 cells at nanomolar drug concentrations (Deng et al., 2008). These compounds
were later characterized in Chinese hamster ovary (CHO) (Flintoff et al., 1976) cells engineered
to express either human RFC (PC43-10) (Wong et al., 1995) or human PCFT (R2/PCFT4) (Deng
et al., 2009), and it was reported that AGF17 and AGF23 were selective for PCFT over RFC and
were active at nanomolar concentrations (Kugel Desmoulin et al., 2010), while also being
inhibitors for FRα- and β-expressing CHO cells (RT16 and D4, respectively) (Deng et al., 2008).
Following AGF17 and AGF23, 6-substituted pyrrolo[2,3-d]pyrimidine with thienoyl-forbenzoyl substitutions were synthesized, designated AGF94 (three carbon bridge) and AGF71
(four carbon bridge) (Figure 1.7). This thienoyl replacement of the side-chain phenyl moiety was
inspired by the same substitution used in the creation of LY309887 (Mendelsohn et al., 1999b)
and AG2034 (Boritzki et al., 1996). AGF94 and AGF71 are PCFT-selective antifolates (Kugel
Desmoulin et al., 2011; Wang et al., 2010; Wang et al., 2011) with IC50 values for R2/PCFT4
CHO cells of 3.34 nM and 43 nM, respectively (Wang et al., 2010; Wang et al., 2011). Both
AGF94 and AGF71 showed significant inhibition of tumor growth in vivo in IGROV1
xenografts (Wang et al., 2011). AGF94 additionally inhibited growth of H2452 (malignant
mesothelioma) cells in vitro and in vivo as tumor xenografts in severe-combined
immunodeficient (SCID) mice (Cherian et al., 2013). Both drugs displayed potent GARFTase
inhibition in R2/PCFT4 CHO cells (IC50s of 0.69 nM for AGF94, 1.96 nM for AGF71) (Wang et
al., 2011), as measured with an in situ metabolic assay which measured incorporation of
[14C]glycine into the GARFTase product formyl GAR. AGF71 and AGF94 displayed inhibition
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Figure 1.7 Structures of novel antifolates. Structures of novel tumor-targeted pyrollo[2,3d]pyrimidines with specificity for PCFT over RFC. All compounds were synthesized by Dr.
Aleem Gangjee of Duquesne University in collaboration with Dr. Larry Matherly. All drugs are
discussed in Chapter 1.6.7.
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of colony formation in PCFT-expressing CHO cells (derived from R2, CHO cells which lack
RFC and PCFT expression) establishing cell killing, and both showed dose and time dependent
killing (Wang et al., 2011). In HeLa cells, AGF94 and AGF71 were shown to be
polyglutamylated at pH 6.8, while AGF94 revealed ~6 times greater polyglutamate accumulation
compared to AGF71 (Desmoulin et al., 2012b). Compounds with longer carbon bridge regions
displayed far less efficacy in vitro toward PCFT-expressing tumor cells (Wang et al., 2010;
Wang et al., 2011).
A series of thieonyl regioisomers of AGF71 were synthesized, in which the position of
the sulfur atom varies within the thiophene ring between molecules. Two of these novel
compounds, AGF117 (thienoyl substitutions 3’,5’) and AGF118 (2’,4’) (Figure 1.7), were
inactive towards RFC-expressing PC43-10 CHO cells but were very active towards PCFTexpressing R2/PCFT4 CHO cells (IC50s of 63.82 for AGF117, 41.54 for AGF118) (Wang et al.,
2012). AGF117 and AGF118 also displayed potent GARFTase inhibition in IGROV1 ovarian
cancer cells (IC50s of 2.03 nM for AGF117, 1.79 nM for AGF118). As with AGF17 and AGF23,
AGF94, AGF71, AGF117 and AGF118 exhibited activity towards FR-expressing CHO cell lines
(Wang et al., 2012; Wang et al., 2010; Wang et al., 2011).
A series of thieonyl regioisomers was also developed for AGF94. These include two
potent PCFT-targeted compounds, AGF150 (thieonyl substitutions 2’,4’) and AGF154 (3’,5’)
(Figure 1.7) (Wang et al., 2015) (also see Chapter 5). These drugs have very low IC50 values in
R2/PCFT4 cells (5.39 nM for AGF150 and 6.51 nM for AGF154) (Wang et al., 2015). AGF150
and AGF154 were shown to be potent GARFTase inhibitors via a spectrophotometric assay with
recombinant human GARFTase (formyltransferase domain) (Ki values of 13 nM for AGF150,
9.1 nM for AGF154 and 68 nM for AGF94), as well as parallel in situ GARFTase assays in KB
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cells (IC50 values of 2.4 nM for AGF150, 2.6 nM for AGF154, and 3.5 nM for AGF94) (Wang et
al., 2015). AGF150 and AGF154 also exhibited significant FR-binding affinities and in vitro
efficacies in inhibiting proliferation of FR-expressing CHO cell lines (Wang et al., 2015). This
characteristic of PCFT and FR dual-targeting may be a feature which could benefit the therapy of
tumors that express FRs along with PCFT such as epithelial ovarian cancer (George and
Matherly, unpublished) and a subset of NS-NSCLC (Wang et al., 2015) (also see Chapter 5). In
vivo, AGF154 inhibited tumor growth of SKOV3 xenografts in SCID mice in a similar manner to
AGF94, albeit at a lower dose (28 mg/kg for AGF94, 16 mg/kg for AGF154) (Wang et al., 2015).
The development and characterization of tumor-targeted antifolates with PCFT selectivity and
potent inhibition of de novo purine biosynthesis, typified by AGF17, 23, 71, 94, 117, 118, 150
and 154, provides a definitive proof-of-concept for tumor targeting via PCFT (with or without
FR).
This dissertation will focus on both the characterization of important PCFT
functional/structural determinants of drug transport, as well as the continued development and
application of novel tumor targeted PCFT-selective antifolate compounds.
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CHAPTER 2- PROTON-COUPLED FOLATE TRANSPORTER TRANSMEMBRANE
DOMAIN 2-3 CONNECTING REGION FORMS REENTRANT LOOP
STRUCTURE
2.1 Introduction
PCFT is predicted to have 12 TMDs with cytosolic N and C termini (Figure 1.4) (Unal et
al., 2008; Zhao et al., 2010). This has been experimentally validated by indirect
immunofluorescence staining of N- and C-terminal hemagglutinin (HA)-tagged human (h)PCFT
and by SCAM involving Cys insertions into the TMD loop domains and reaction with MTSEAbiotin (Zhao et al., 2010). The extracellular location of the loop connecting TMDs 1 and 2 was
further evidenced by the fact that two predicted N-linked glycosylation sites in that loop (Asn-58
and Asn-68) are glycosylated in human PCFT (Unal et al., 2008). Other aspects of hPCFT
structure

have

been

validated,

including

reactivity

of

membrane-impermeable

methanethiosulfonate reagents with Phe157, Gly158, and Leu161 in TMD4 and with Ile188 in
TMD5. Because methanethiosulfonate reactivity was protected by the hPCFT antifolate substrate
PMX, these residues likely lie within or near the aqueous accessible substrate binding site (Shin
et al., 2013; Zhao et al., 2012). Most recently, TMDs 1, 2, 7, and 11 have been shown to form an
extracellular “gate” when PCFT is in the cytosol-facing conformation (Zhao et al., 2016).
However, the contributions of other TMDs to the three-dimensional hPCFT structure have not
been determined.
A number of specific amino acid residues were implicated as functionally important in
hPCFT including Glu185 (TMD5; involved in proton coupling), His281 (TMD7; involved in
substrate binding), and Arg376 (TMD10; impacts proton and substrate binding) (Figure 1.4)
(Mahadeo et al., 2010; Unal et al., 2009a; Unal et al., 2009b). His247, localized to the loop
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domain between TMDs 6 and 7, is predicted to interact with Ser172 at the cytoplasmic opening
to control substrate access to the aqueous binding site (Unal et al., 2009a) (see Chapter 4).
The conserved loop domain linking TMD2 and TMD3 (residues 109–114) is of particular
interest. This stretch is predicted to have a cytoplasmic orientation (Figure 1.4) and includes
Asp109 and Arg113, both of which cannot be replaced by other amino acids regardless of charge
or polarity (Lasry et al., 2008; Shin et al., 2010; Zhao et al., 2007). It was predicted that the loop
region connecting TMD2 and TMD3 including Asp109 and Arg113 forms a β-turn structure
involving the DSVG tetrapeptide and may be functionally important (Lasry et al., 2008;
Subramanian et al., 2008). By homology modeling based on the GlpT template, Arg113 was
predicted to protrude into a hydrophobic cavity composed of TMDs 1, 3, 4, and 6 (Lasry et al.,
2008). However, experimental confirmation was not provided.
In this chapter we use SCAM with a cys-less (clhPCFTHA) hPCFT that exhibits
functional characteristics virtually identical to wild-type (wthPCFTHA) hPCFT and MTSEAbiotin, combined with systematic site-directed mutagenesis, to directly explore the structural and
functional significance of the TMD2-3 loop domain and TMD2 in hPCFT. Our results establish
that the TMD2-3 domain forms a novel “reentrant loop” structure and suggest that amino acids at
positions 93 and 94 in TMD2 may comprise part of a critical substrate binding domain with
aqueous accessibilities (Yan and Luo, 2010). Our results are unprecedented and provide
important new insights into key structural and functional determinants of hPCFT uptake. The
work described in this chapter was previously published in the Journal of Biological Chemistry
(Wilson et al., 2014).
2.2 Materials and Methods
2.2.1 Reagents
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[3’,5’,7-3H]MTX (20 Ci/mmol) was purchased from Moravek Biochemicals (Brea, CA).
Unlabeled MTX was provided by the Drug Development Branch, NCI, National Institutes of
Health (Bethesda, MD). Folic acid was purchased from Sigma. PMX (Alimta) was purchased
from LC Laboratories (Woburn, MA). Tissue culture reagents and supplies were purchased from
assorted vendors with the exception of fetal bovine serum (FBS), which was purchased from
Hyclone Technologies (Logan, UT).
2.2.2 Generation of Cys-less hPCFT and Single-substitution Mutants
clhPCFTHA, including a HA epitope at the C terminus in pCDNA3, was prepared by PCR
from the C-terminal HA-tagged wthPCFTHA (Hou et al., 2012) construct by mutagenizing
individual Cys residues (Cys21, -66, -151, -229, -298, -328, and -397) to serine using the
QuikChangeTM Multi Site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA) as
described by the manufacturer. Single amino acid substitutions were generated using either wt or
clhPCFTHA as a template and the QuikChangeTM site-directed mutagenesis kit (Agilent). Primers
were developed using the QuikChangeTM Primer Design program (Agilent) and are available
upon request. PCR conditions were 95 °C for 30s, 55°C for 1 min, and 68°C for 8 min for 16
cycles. All mutations were confirmed by DNA sequencing by Genewiz, Inc. (South Plainfield,
NJ).
2.2.3 Cell Culture
The hPCFT-null R1-11 HeLa cell line was a gift of Dr. I. David Goldman (Bronx, NY)
(Diop-Bove et al., 2009). Cells were grown in RPMI 1640 media supplemented with 10% FBS,
1% penicillin/streptomycin, and 2 mM L-glutamine. For transfections with hPCFT constructs,
R1-11 cells were seeded in 60-mm culture dishes at a density of 0.8 million cells per plate in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS and antibiotics.
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After 24 h, the cells were transfected with hPCFT expression constructs (above) in pCDNA3 (1
µg/plate) using Lipofectamine 2000 (Invitrogen) (10 µl/plate) in Opti-MEM as described by the
manufacturer (Invitrogen). After 4 h the transfection medium was replaced with DMEM
containing 10% FBS.
2.2.4 Membrane Transport
Forty-eight hours post-transfection, cellular uptake of [3H]MTX (0.5 µM) was measured
over 2 min at 37 °C in 60-mm dishes in 2-(N-morpholino)ethanesulfonic acid (MES)-buffered
saline (20 mM MES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, and 5 mM glucose; pH 5.5), as
previously described (Kugel Desmoulin et al., 2010). Cells were washed 3x with Dulbecco’s
phosphate-buffered saline (PBS), and the cells were solubilized in 0.5 N NaOH. Levels of
intracellular radioactivity were calculated as pmol/mg of protein based on measurements of
radioactivity and protein concentrations of the alkaline cell homogenates (Laemmli, 1970) (34).
In some experiments cells were pretreated for 15 min at 37 °C with MTSEA-biotin (see below)
before the transport assays with [3H]MTX treatments. To measure MTX transport kinetics, cells
were treated with concentrations of [3H]MTX between 0.33 and 5 µM with results analyzed
using Lineweaver-Burke plots for determinations of Kt and Vmax values. For determining Ki
values for nonradioactive substrates including folic acid and PMX, cells were treated with 0.5
µM [3H]MTX and inhibitors at concentrations from 0.3 to 1.5 µM. Results were analyzed by
Dixon plots to calculate Ki values. To compare the optimal pH for transport by wt and
clhPCFTHA, transport assays were performed at pH values from 5.5 and 7.2. MES-buffered
saline was used for pHs 5.5, 6.0 and 6.5, whereas HEPES-buffered saline (20 mM HEPES, 140
mM NaCl, 5 mM KCl, 2 mM MgCl2, and 5 mM glucose) was used for pH values 6.8 and 7.2.
2.2.5 Surface Biotinylation with MTSEA-biotin
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Forty-eight hours post-transfection (above), cell surface proteins were surfacebiotinylated with MTSEA-biotin (Biotium, Hayward, CA). MTSEA-biotin was freshly dissolved
in DMSO at 2 mg/100 µl and then diluted 1:100 in PBS. Cells were washed with PBS twice and
treated with MTSEA-biotin solution for 30 min at room temperature. The MTSEA-biotin was
aspirated, and cells were treated with 14 mM β-mercaptoethanol in PBS for 5 min to quench the
reactions, then washed twice with PBS. To collect crude membrane proteins, plates were placed
in 4 °C and treated with 1.4 ml of hypotonic buffer (0.5 mM Na2 HPO4 , 0.1 mM EDTA, pH
7.0) containing a protease inhibitor mixture (Roche Applied Science). The cells were removed
from the plates with a rubber policeman, followed by centrifugation at 16,000 rpm for 10 min at
4 °C. The supernatants were removed, and cell pellets were resuspended in 0.4 ml of lysis buffer
(50 mM Tris base, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, pH 7.4) by
vortexing, then mixed on a rotisserie shaker for 1 h at 4°C. The samples were centrifuged at
16,000 x g for 15 min at 4 °C, leaving the detergent-solubilized membrane proteins in the
supernatant. An aliquot (25 µl) of this fraction was used as a loading control, and the remaining
375 µl were added to 50 µl of streptavidin-agarose resin (Thermo Scientific, Waltham, MA)
(prewashed 3x with lysis buffer). This mixture was mixed overnight at 4 °C in a rotisserie shaker.
The following day the mixture was centrifuged at 16,000 x g for 1 min, and the supernatant was
aspirated. The resin was washed 3 times with lysis buffer, followed by a wash with lysis buffer
supplemented with 2% SDS. Bound proteins were released from the streptavidin resin by heating
to 95 °C for 5 min in 2x Laemmli loading buffer that contained dithiothreitol (Laemmli, 1970).
For some experiments protection from MTSEA-biotin biotinylation by the PCFT substrate, PMX,
was tested. For these experiments, plates were treated with 2 ml of PBS containing 250 µM PMX
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for 15 min immediately before MTSEA-biotin treatment. Results were compared with those for
untreated controls, incubated in parallel.
2.2.6 Western Blotting
Procedures for SDS-polyacrylamide gel electrophoresis, and electrotransfer to
polyvinylidene difluoride membranes (Pierce) were identical to previously reported methods
(Hou et al., 2012). For standard Western blotting, membrane proteins were electrophoresed on
7.5% polyacrylamide gels in the presence of SDS (Laemmli, 1970) and electroblotted onto
polyvinylidene difluoride membranes (Pierce) (Matsudaira, 1987). Blots were probed with antiHA antibody (Covance, Princeton, NJ) and IRDye800-conjugated secondary antibody. Anti-βactin antibody (Sigma) was used to probe for loading controls. Imaging and densitometry were
performed with an Odyssey Infrared Imaging System (LI-COR, Lincoln, NE).
2.2.7 Statistical Analysis
Unpaired t tests were conducted using GraphPad 6.0 software.
2.3 Results
2.3.1 Alanine-scanning Mutagenesis of TMD2 and the TMD2-3 Loop Region of hPCFT
A previous study used progressive alanine substitution mutagenesis with stretches of
alanines to disrupt the predicted TMD2-3 β-turn in hPCFT and found that transport activity was
abolished due to impaired intracellular trafficking to the plasma membrane (Subramanian et al.,
2008). As an extension of this work, we used a targeted alanine-scanning mutagenesis strategy
with individual alanine substitutions across this stretch (including flanking regions) with
wthPCFTHA as a template and extended this to include the entire TMD2 for a total of 33 mutants
spanning positions 85–118 (Figure 1.4). Mutant hPCFT constructs were transfected into hPCFTnull R1-11 HeLa cells. Membrane transport of [3H]MTX was measured at pH 5.5, the pH
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Figure 2.1 Impact of scanning alanine mutagenesis on hPCFT expression and transport.
Panel A, wthPCFTHA and alanine mutants in TMD2 and the TMD2-3 loop domain were
transiently transfected into R1-11 cells, and hPCFT activity was determined after 48 h by
[3H]MTX uptake assay at pH 5.5 over 2 min at 37 °C. Results are expressed as relative to
wthPCFTHA and are reported as the mean values ± S.E. (error bars) from triplicate experiments.
Results for D109A, G112A, and R113A were not significantly increased over those for R1-11
cells (p < 0.05, noted by asterisks). wthPCFTHA is indicated by the gray bar. TMD2 mutants are
shown in black, and the TMD2-3 loop mutants are shown in white. Panels B and C, Western
blots are shown for membrane proteins (10 g) from HA-tagged TMD2 (Panel B) and TMD2-3
loop (Panel C) alanine mutants isolated 48 h after transient transfections of R1-11 cells. Results
are shown for membrane proteins probed with HA-specific antibody with equal loading
confirmed with β-actin. Results are representative of at least two blots from independent
experiments. Figure previously published in Wilson et. al. J Biol Chem. 2014.
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optimum for PCFT, and HA-tagged hPCFT proteins in crude plasma membranes were assayed
by Western blotting with HA-specific antibody. We found that all 33 hPCFT alanine mutants
were expressed in crude membranes (Figure 2.1B) and that 30 of these were active for transport
(25–115% of wthPCFTHA), including all of the mutants in TMD2 (Figure 2.1A). Conversely, for
residues located in the TMD2-3 loop domain (i.e., positions 109, 112, and 113), Ala
replacements abolished uptake ([3H]MTX uptake values were not significantly different from
those with R1-11 cells (p < 0.05)). Although most of the TMD2-3 loop mutants were detected at
substantial levels on Western blots, for the Gly-112 and Arg-113 mutants, loss of transport
activity was associated with substantially reduced hPCFT membrane expression (Figure 2.1C).
These results with Asp109 and Arg113 are consistent with previous reports that any
amino acid replacement (including even conservative substitutions) at these positions was
inactive (Lasry et al., 2008; Shin et al., 2010; Subramanian et al., 2008; Zhao et al., 2007) (9, 11,
17, 30). For Asp109, mutation disrupts the DSVG tetrad (109-112) and β-turn in the TMD2-3
loop domain. Similarly, mutation of Gly112 to Pro significantly reduced hPCFT expression on
Western blots (Figure 2.2B) and caused a complete loss of transport activity (Figure 2.2A),
further implying that disruption of the β-turn structure results in protein misfolding and protein
degradation. By contrast, with Arg114, we found that mutation to increasingly non-conservative
residues, including Lys, His, and Asp, preserved expression on Western blots (Figure 2.2B)
while progressively decreasing transport without abolishing it altogether (Figure 2.2A).
2.3.2 Cys-scanning Mutagenesis and Cys Accessibilities to Biotinylation with MTSEAbiotin for TMD2 and the TMD2-3 Loop Region of hPCFT
Our goal was to further determine the structural and functional significance of TMD2 and
the TMD2-3 loop domain in hPCFT using Cys-scanning mutagenesis and SCAM. hPCFT
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Figure 2.2 Characterization of hPCFT mutants. Panel A, TMD2 and TMD2-3 loop mutants
were transiently transfected into R1-11 cells, and PCFT activity was determined 48 h later by
[3H]MTX uptake assay at 37 °C at pH 5.5 over 2 min. Results are expressed as relative to
wthPCFTHA and are reported as the mean values S.E. (error bars) from triplicate experiments.
Results for the F94R and G112P mutants were not significantly increased over the level in R1-11
cells (noted by the asterisks; p > 0.05). TMD2 mutants are shown in black, and TMD2-3 loop
mutants are shown in white. wthPCFTHA is indicated by a gray bar. Panel B, Western blots of
membrane proteins (10 µg) from HA-tagged TMD2 and TMD2-3 loop mutants 48 h after
transient transfections of R1-11 cells. Results are representative of at least two independent
experiments. Figure previously published in Wilson et. al. J Biol Chem. 2014.
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includes 7 Cys residues (Figure 1.4), two (Cys66 and Cys298) of which form a disulfide linkage
(Zhao et al., 2010). Because Cys residues in wthPCFTHA reacted with thiol-reactive MTSEAbiotin in pilot studies (not shown), we generated a “Cys-less” hPCFT construct (with a Cterminal HA epitope) by mutating the seven Cys residues to serine. When transiently expressed
in hPCFT-null R1-11 HeLa cells, clhPCFTHA retained 77.5% (± 2.8%) of the transport activity of
wthPCFTHA. The addition of 10 µM PMX completely blocked MTX transport levels for both wt
and clhPCFTHA (Figure 2.3B). clhPCFTHA displayed a similar decrease in the level of membrane
hPCFT protein on Western blots (70 ± 10%) of the wthPCFTHA level (Figure 2.3A). clhPCFTHA
and wthPCFTHA showed nearly identical transport characteristics including Kt and Vmax values
for [3H]MTX and Ki values for folic acid and PMX (Table 2.1). Furthermore, for both
clhPCFTHA and wthPCFTHA, pH-dependent transport of [3H]MTX was essentially identical with
decreasing activity from the high level measured at pH 5.5 and the very low levels above pH 7
(Figure 2.3C). Collectively, these results establish that wt and clhPCFTHA are functionally
equivalent.
To study the roles of the TMD2 and TMD2-3 loop regions in hPCFT structure and
transport function, we used site-directed mutagenesis with clhPCFTHA as a template to introduce
single Cys residues from positions 85 to 118 (Figure 1.4). The 33 individual Cys constructs were
transiently transfected into R1-11 HeLa cells, followed by assays of [3H]MTX uptake at pH 5.5
and of hPCFT protein levels on Western blots (Figure 2.4A-C). Cys substitutions at a number of
positions were less tolerated than were the Ala substitutions (compare Figures 2.1A and 2.4A).
Twenty-eight of the 33 Cys mutants were considered “active” based on statistically significant
increases in [3H]MTX uptake (2-fold; p < 0.05) over the very low residual level in R1-11 cells.
These include Cys mutants of several residues (Asn90, Leu104, Gly105, Pro115) with modest
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Figure 2.3 Characterization of Cys-less hPCFT. Panel A, wthPCFTHA and CL- PCFT were
transiently transfected into R1-11 cells. A Western blot of membrane proteins (10 µg) prepared
48 h post-transfection for HA-tagged wthPCFTHA and clhPCFTHA is shown. β-Actin was used to
confirm equal loading. Results are representative of three independent experiments. By
densitometry, the hPCFT/ β-actin ratios of clhPCFTHA were 70% (± 10%) of the wthPCFTHA
level. Panel B, hPCFT transport was measured 48 h later by [3H]MTX uptake assay at pH 5.5
over 2 min, with (black) or without (gray) the addition of unlabeled 10 µM PMX. Data are
presented as the mean values S.E. from three to seven independent experiments. For clhPCFTHA,
transport was 77.5% (± 2.8%) that for wthPCFTHA. Transport was inhibited in the presence of 10
µM nonradioactive PMX. Panel C, the pH dependence for [3H]MTX uptake over 2 min from pH
5.5 to 7.2 for transiently expressed wthPCFTHA and clhPCFTHA in R1-11 cells is shown. Results
are presented as the mean values ± S.E. from triplicate experiments. Figure previously published
in Wilson et. al. J Biol Chem. 2014.
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TABLE 2.1
Kinetic Analysis of WT- and CL-PCFT.
Constant
Kt (µM)
Vmax (pmol/mg/min)
Ki (µM)
Ki (µM)

Compounds
MTX
MTX
Folic Acid
PMX

hPCFT Variants
WT-PCFT
CL-PCFT
0.44 ± 0.06
0.51 ± 0.03
276.8 ± 59.7
236.2 ± 27.5
1.51 ± 0.18
1.49 ± 0.45
0.13 ± 0.04
0.13 ± 0.05

WT-PCFT and CL-PCFT were transiently transfected into R1-11 cells, and PCFT transport was
measured 48 h later by [3H]MTX uptake assay at pH 5.5 over 2 min. To determine Kt and Vmax
values, cells were treated with [3H]MTX with concentrations between 0.33 µM and 5 µM, with
results analyzed by Lineweaver-Burke plots. To determine Ki values, cells were incubated with
0.5 µM [3H]MTX with folic acid or PMX as competitors from 0.3 µM to 1.5 µM, and results were
analyzed by Dixon plots. Data are presented as mean values +/- standard errors from three
independent experiments.
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Figure 2.4 Characterization of hPCFT single-Cys mutants. Panel A, TMD2 and TMD2-3
loop single-Cys hPCFT mutants were transiently transfected into R1-11 cells, and PCFT activity
was measured after 48 h by [3H]MTX uptake assay at pH 5.5 over 2 min. Results are expressed
as relative to those for clhPCFTHA and are reported as mean values ± S.E. (error bars) from
triplicate experiments. Transport levels for W107C, D109C, G112C, R113C, and R114C mutants
(noted with asterisks) were not significantly increased over the low level in R1-11 cells (p >
0.05), whereas transport for the other 28 samples was significantly increased over the transport
level in R1-11 cells (p < 0.05). clhPCFTHA is indicated by the gray bar. The TMD2 mutants are
shown in black, and the TMD2-3 loop mutants are shown in white. Panels B and C, Western blot
analysis was performed on membrane proteins (10 µg) prepared from HA-tagged TMD2 (Panel
B) and the TMD2-3 loop (Panel C) Cys mutants 48 h post-transfection. Results are shown for
hPCFT proteins probed with HA-specific antibody, with equal loading confirmed with β-actin.
Results are representative of at least two blots from independent experiments. Figure previously
published in Wilson et. al. J Biol. Chem 2014.
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levels of transport. Analogous to their Ala mutant counterparts, Cys replacements at Asp109,
Gly112, and Arg113 were completely inert (Figure 2.4A). Whereas Ala replacements of Trp107
and Arg114 preserved substantial transport activity (Figure 2.1A), transport was abolished for
Cys replacements at these positions (Figure 2.4A). For many of the Cys mutants, transport
activity paralleled levels of hPCFT protein on Western blots (Figure 2.4B-C), suggesting that the
substantial losses of transport for the inactive hPCFT Cys mutants were likely the result of
mutant protein misfolding, resulting in impaired intracellular trafficking and protein degradation.
However, for a few of the Cys mutants in the TMD2-3 loop domain (i.e. Cys105 and Cys108),
transport was disproportionately low relative to the levels of PCFT protein (Figure 2.4A-C),
suggesting functionally inactive protein.
For the 28 active Cys mutants spanning TMD2 and the TMD2-3 loop region, we used
MTSEA-biotin to establish their aqueous accessibilities in forming an aqueous transmembrane
pathway for anionic (anti)folate substrates. MTSEA-biotin is a membrane-impermeable,
bifunctional reagent that includes thiol-reactive MTS and biotin moieties, thus permitting
isolation of biotinylated hPCFT protein by precipitation with streptavidin beads for analysis on
Western blots. R1-11 cells were transiently transfected with the active Cys hPCFT mutants, then
treated with MTSEA-biotin, followed by pull-down with streptavidin beads. The biotinylated
proteins were eluted and analyzed on Western blots with HA-specific antibody, and the results
were compared with those for total hPCFT proteins in membrane fractions sampled before
MTSEA-biotin treatments. The G207C hPCFT mutant mapping to the extracellular loop 3
domain (Figure 1.4) was used as a positive control for the pulldown experiments.
Cys mutants at positions 85-89 mapping to the exofacial segment of TMD2 (Figure 1.4)
were extensively biotinylated, likely reflecting their extracellular accessibilities to the
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Figure 2.5 Biotinylation of single-Cys mutants in TMD2 and the TMD2-3 loop with
MTSEA-biotin. Panels A and B, TMD2 (Panel A) and TMD2-3 loop (Panel B) single-Cys
mutants were transiently transfected into R1-11 cells, and 48 h later cells were treated with
MTSEA-biotin. Cells were harvested, and membranes prepared, solubilized, and incubated with
streptavidin beads to pull down biotinylated proteins. The G207C mutant located in the
extracellular loop 3 domain (Figure 1.4) was used as a positive control for the pulldown assays.
Biotinylated proteins were eluted and analyzed by Western blotting using an anti-HA antibody
(Pull down). An aliquot (25 µl) of the crude membrane fraction before MTSEA-biotin treatment
was also analyzed by Western blotting as a control (Membrane). Panels C and D, transiently
transfected R1-11 cells were treated with or without 250 µM PMX before treatment with
MTSEA-biotin, streptavidin precipitation, and Western blotting as described for Panels A and B.
Panel E, TMD2 and TMD2-3 loop single-Cys mutants were transiently transfected into R1-11
cells. After 48 h, cells were incubated with or without MTSEA-biotin followed by assay of
PCFT transport with [3H]MTX at pH 5.5 over 2 min. Results are expressed relative to the nontreated sample and are reported as the mean values ± S.E. for two (positions 104 –111) or three
(R1-11, clhPCFTHA, and positions 207, 158, 93, and 94) independent experiments. For positions
158, 93, and 94, losses of transport activity by MTSEA-biotin treatment compared with untreated
samples were statistically significant (p < 0.05; noted by asterisk). In the transport experiments,
clhPCFTHA and G207C were negative controls, whereas MTSEA-biotin-reactive G158C was
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used as a positive control (all shown in gray) (Shin et al., 2013). Results for the TMD2 mutants
are shown in black, and TMD2-3 loop mutants are shown in white. Panel F, diagram of the
TMD2-3 reentrant loop structure. Figure previously published in Wilson et. al. J Biol Chem.
2014.
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hydrophilic MTSEA-biotin reagent (Figure 2.5A, upper panel). However, other positions in
TMD2 also reacted with MTSEA-biotin, especially positions 93 and 94, predicted to lie in the
mid-TMD2 region, although flanking positions were poorly or completely unreactive. For the
G93C mutant, reaction with MTSEA-biotin is particularly notable given its modest levels in the
total membrane fraction (Figure 2.5A, lower panel). For the TMD2-3 loop (positions 107-114)
and flanking regions (104-106, 115-118), predicted to have a cytosolic orientation, we found that
the G105C, A106C, S108C, S110C, and V111C clhPCFTHA mutants were uniquely reactive with
MTSEA-biotin in comparison with other mutants (e.g. L104C and P115C) (Figure 2.5B). Thus,
positions 93 and 94 in TMD2 and positions 105, 106, 108, 110, and 111 in the TMD2-3 loop
region seem to be aqueous accessible despite their predicted membrane topologies.
2.3.3 Impact of hPCFT Substrate on Biotinylation and Transport Inhibition by
Biotinylation
To examine whether the MTSEA-biotin-reactive positions in the TMD2 and the TMD2-3
loop regions (positions 93, 94, 105, 106, 108, 110, and 111) contribute to an aqueous binding
domain for hydrophilic (anti)folate substrates, we preincubated transiently transfected R1-11
cells expressing the G93C, F94C, L104C, G105C, A106C, S108C, S110C, and V111C mutants
with the PCFT substrate PMX (250 µM) before treatment with MTSEA-biotin. Controls were
incubated in parallel without PMX. Biotinylated proteins were precipitated with streptavidin
beads and analyzed on Western blots. PMX substantially decreased MTSEA-biotin reactivity
with Cys residues at positions 93 and 94 (Figure 2.5C). However, the biotinylated TMD2-3 loop
residues were unaffected by PMX treatment (Figure 2.5D). To determine whether biotinylation
of these residues also inhibited transport activity, we incubated transiently transfected R1-11
cells expressing G93C, F94C, L104C, G105C, A106C, S108C, S110C, and V111C hPCFT
mutants with [3H]MTX (0.5 µM) for 15 min at 37 °C with or without a 15 min MTSEA-biotin
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pretreatment. In this series of experiments, clhPCFTHA and G207C were negative controls,
whereas MTSEA-biotin-reactive G158C was used as a positive control (Shin et al., 2013).
We found that of these residues, only for the G93C and F94C mutants was transport
significantly inhibited by biotinylation (Figure 2.5E, 63.5 and 18.2%, respectively; p < 0.05).
Collectively, these results are consistent with the notion of a direct interaction between positions
93 and 94 and substrate, although an indirect effect mediated by conformational changes
resulting from more distal substrate binding cannot be excluded.
2.4 Discussion
In this chapter we studied the structural and mechanistic roles of TMD2 and the TMD2-3
loop region in hPCFT. Our results establish aqueous accessibilities of residues located in the
TMD2-3 loop despite their predicted membrane topologies. These results are best interpreted as
a reentrant loop structure (Figure 2.5F), similar to those reported for other MFS transporters (e.g.
EAAT1) (Seal and Amara, 1998; Yan and Luo, 2010). These results support those of
Subramanian et al., which establish that disruption of the TMD2-3 loop results in hPCFT protein
misfolding and loss of surface expression and transport activity (Subramanian et al., 2008). In
previous studies it was reported that Asp109 and Arg113 in this stretch cannot be replaced with
even conservative substitutions (Lasry et al., 2009; Zhao et al., 2007). Our results show that this
now extends to the G112P mutant as well, although substitutions (Lys, His, Asp) at Arg114 were
tolerated. Finally, our results suggest that positions 93 and 94 in TMD2 may directly participate
in forming the hPCFT substrate binding pocket/membrane translocation pathway. Determining
the structural determinants of hPCFT membrane transport is requisite to understanding the
molecular mechanisms of transport, including critical determinants of (anti)folate binding.
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CHAPTER 3- TRANSMEMBRANE DOMAINS 3 AND 6 OF THE PROTON-COUPLED
FOLATE TRANSPORTER FORM OLIGOMERIZATION INTERFACE
3.1 Introduction
Reflecting its biological and therapeutic importance, studies have begun to explore key
structural determinants of hPCFT function (Hou et al., 2012; Hou and Matherly, 2014; Matherly
et al., 2014). Thus, structurally and/or functionally important residues in hPCFT were identified,
including Asp109, Arg113 , Asp156 , Gly158 , Leu161 , Ser172 , Glu185 , Ile188 , Gly189 ,
Gly192 , Glu232 , His247 , His281 , Ile304 , Arg376 and Pro425 (Lasry et al., 2008; Mahadeo et
al., 2010; Matherly et al., 2014; Shin et al., 2011; Shin et al., 2010; Shin et al., 2013; Unal et al.,
2009a; Unal et al., 2009b; Zhao and Goldman, 2007; Zhao et al., 2011b; Zhao et al., 2012), and
stretches including TMDs 2, 4 and 5 were identified by SCAM as forming substratebinding/membrane-translocation domains (Shin et al., 2013; Zhao et al., 2012) (also see Chapter
2). hPCFT is N-glycosylated at Asn58 and Asn68 (Unal et al., 2008). A unique β-turn structure
in the TMD 2–3 loop region forms a novel reentrant loop structure and is essential for
intracellular trafficking and high level transport (Lasry et al., 2008; Subramanian et al., 2008;
Unal et al., 2008) (also see Chapter 2).
hPCFT forms homo-oligomers both in detergent solution and in situ with the hPCFT
dimer as the dominant form (Hou et al., 2012). With ectopically expressed hPCFT,
oligomerization was established by cross-linking with MTS-1-MTS, blue native gel
electrophoresis, binding of co-expressed haemagglutinin (HA) and His10-tagged hPCFT
monomers to nickel affinity columns and FRET between co-expressed YFP (YPet)- and
enhanced cyan fluorescent protein (with K26R/N164H mutation; ECFP*)-tagged hPCFT
monomers (Hou et al., 2012). Combined wt and inactive mutant P425R hPCFTs exhibited a
distinctive ‘dominant-positive’ transport phenotype, implying positive co-operativity between
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hPCFT monomers and functional ‘rescue’ of mutant hPCFT by wthPCFT (Hou et al., 2012).
hPCFT oligomers were also identified by Zhao et al. by homobifunctional cross-linking with
MTS-1-MTS and a putative TMD6 interface between hPCFT monomers was implied from the
finding that MTS-1-MTS treatment generated cross-links between Cys229 (located in TMD6) in
individual PCFT monomers, but not when Cys229 was mutated to serine (Zhao et al., 2012).
Based on these results, the experiments described in this chapter explore the roles of residues
localized to TMDs 3 and 6 in forming critical structural interfaces between hPCFT monomers.
The work described in this chapter was previously published in Biochemical Journal (Wilson et
al., 2015)
3.2 Materials and Methods
3.2.1 Reagents
[3’ ,5’ ,7-3H]MTX (20 Ci/mmol) was purchased from Moravek Biochemicals. Unlabelled
Mtx was provided by the Drug Development Branch, National Cancer Institute, National
Institutes of Health. Synthetic oligonucleotides were obtained from Invitrogen. Tissue culture
reagents and supplies were purchased from assorted vendors with the exception of FBS, which
was purchased from Hyclone Technologies. The cross-linking reagent 1,6-hexanediyl
bismethanethiosulfonate (MTS-6-MTS) was purchased from Toronto Research Chemicals.
3.2.2 Cell Culture
The RFC- and hPCFT-null HeLa cell line, designated R1-11 (Diop-Bove et al., 2009),
was a gift of Dr I. David Goldman (Bronx, NY). R1-11 cells were maintained in complete RPMI
(Roswell Park Memorial Institute) 1640 medium containing 10% FBS, 2 mM L-glutamine, 100
units/ml penicillin and 100 µg/ml streptomycin (Hou et al., 2012).
3.2.3 hPCFT Plasmid Constructs and Transient Transfections

66
Cysteine-less (cl) hPCFT (see Chapter 2), including a HA epitope at the C-terminus
(clhPCFTHA) in pCDNA3 was prepared by PCR from the hPCFTHA construct (Diop-Bove et al.,
2009), by mutagenizing Cys21 , Cys66 , Cys151 , Cys229 , Cys298 , Cys328 and Cys397 to
serine, using the QuikChangeTM Multi Site-Directed Mutagenesis Kit (Agilent) (see Chapter 2) .
Single cysteine replacements were generated using clhPCFTHA as template and the
QuikChangeTM Site-Directed Mutagenesis Kit (Agilent). Primers were designed using the
QuikChangeTM Primer Design program (Agilent) and are available upon request. All mutations
were confirmed by DNA sequencing by Genewiz, Inc.
wthPCFTHA and mutant hPCFT constructs (see below) were transiently transfected into
R1-11 HeLa cells with Lipofectamine-Plus reagent (Invitrogen), as previously described (Hou et
al., 2005) (also see Chapter 2). With all transfections, cells were harvested after 48 h for
transport and for preparing plasma membranes and Western blotting (see below). For
experiments in which results for transfections with two plasmid constructs were directly
compared with results for cells transfected with a single plasmid construct, constant DNA
amounts were maintained by adding empty pCDNA3 (Invitrogen) to the single transfections.
3.2.4 Membrane Transport Experiments
Cellular uptake of [3H]MTX (0.5 µM) was measured over 2 min at 37° C in 60-mm
dishes in MES-buffered saline (20 mM MES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2 and 5
mM glucose) at pH 5.5 (Kugel Desmoulin et al., 2010) (see Chapter 2). Levels of intracellular
radioactivity were expressed as pmol/mg protein, calculated from direct measurements of
radioactivity and protein contents (Lowry et al., 1951) of the cell homogenates.
3.2.5 Membrane Preparations and Western Blot Analysis of Plasma Membrane hPCFT
Proteins
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Plasma membrane preparations, SDS/PAGE and electrotransfer to polyvinylene
difluoride membranes (Pierce) were as reported previously (Hou et al., 2005) (see Chapter 2).
Detection and quantification of immunoreactive proteins used anti-HA (Covance) or and
IRDye800-conjugated secondary antibody with an Odyssey® infrared imaging system (LI-COR).
β-Actin was used as a loading control (Sigma).
3.2.6 Cross-linking of Cysteine-substituted Mutants of hPCFT
Forty-eight hours post-transfection with hPCFT mutants, R1-11 cells (in 60-mm dishes)
were washed twice with Dulbecco’s PBS and then treated with MTS-6-MTS [freshly dissolved
in DMSO at 7.2 mg/ml (30 mM) and then diluted in PBS 1:100 (0.072 mg/ml or 0.3 mM)] on ice
for 1 h. The cells were washed twice with PBS, then treated with 1.4 ml of hypotonic buffer (0.5
mM Na2 HPO4 , 0.1 mM EDTA, pH 7.0) which contained a protease inhibitor cocktail (Roche)
on ice for 30 min. The cells were scraped from the dishes with rubber policemen and then
centrifuged at 16,000 x g at 4° C for 10 min. The cell pellets were solubilized in 0.4 ml of lysis
buffer (50 mM Tris-base, 150 mM NaCl, 1% NP40 and 0.5% sodium deoxycholate, pH 7.4),
then centrifuged (16,000 x g, 4° C) for 15 min to remove cell debris. The supernatant was frozen,
protein contents determined [Bradford assay (BioRad)] and constant protein amounts were
analysed by Western blotting using DTT-free 2× SDS/PAGE loading buffer.
3.2.7 Molecular Modeling
Using the crystal structure of GlpT (1PW4) as template (Huang et al., 2003), we did
homology modelling of the hPCFT monomer with Robetta Server (http://robetta.bakerlab.org).
The top five hPCFT homology models retrieved through Robetta were evaluated by
superimposing them over crystal structures of LacY, obtained at various states (1PV6, 1PV7,
2CFP, 2CFQ, 2V8N and 2Y5Y) and of GlpT (1PW4), by Chimera MatchMaker
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(http://www.cgl.ucsf.edu/chimera) with parameters optimized by superimposing GlpT (1PW4)
over LacY (1PV6) that gave the lowest RMSD values over the longest Cα atoms. This was based
on the notion that all crystal structures from three members (LacY, GlpT and EmrD) of the MFS
of transporters have preserved both secondary and tertiary structure elements during evolution
(Abramson et al., 2004). The hPCFT model (hPCFT_R5) showing the lowest RMSD values
(above) was manually adjusted with COOT (http://lmb.bioch.ox.ac.uk/coot/) to reflect the
TMD2-3 re-entrant loop (see Chapter 2), resulting in hPCFT_R5_2-3RL. The hPCFT_R5_2-3RL
model was further validated by assigning known residues that line the potential substrate binding
pocket of hPCFT. The validated hPCFT_R5_2-3RL homology model was used to build an
hPCFT dimeric model using MDOCK server (Pierce et al., 2014), based on the notion that
hPCFT forms oligomers with the dimer as dominant species (Hou et al., 2012). This modeling
was performed by Zhanjun Hou (Karmanos Cancer Institute) and Jun Ye (Chinese Academy of
Sciences).
3.2.8 Statistical Analysis
Statistical analyses were performed using GraphPad 6.0 software.
3.3 Results
3.3.1 TMDs 3 and 6 Form a Boundary Between Monomeric hPCFT
A role for Cys229 (in TMD6) in hPCFT oligomerization was previously implied from the
finding that mutation of Cys229 to serine abolished cross-linking with MTS-1-MTS (Zhao et al.,
2012). Using GlpT as a template (Huang et al., 2003) and based on published studies for hPCFT
(Lasry et al., 2009; Lasry et al., 2008; Mahadeo et al., 2010; Shin et al., 2010; Shin et al., 2013;
Unal et al., 2009a; Unal et al., 2009b; Zhao et al., 2011b; Zhao et al., 2012), we generated a 3D
homology model for monomeric hPCFT in which TMDs 1, 2, 4, 5, 7, 8, 10 and 11 comprise an
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aqueous transmembrane pathway, flanked by TMDs 3, 6, 9 and 12 (Figures 3.1A and B). With
MDOCK modelling (Pierce et al., 2014) of this hPCFT monomer structure, a dimeric hPCFT
structure was predicted (Figure 3.1C) with juxtaposed TMDs 2, 3, 4 and 6 as structural interfaces
between hPCFT monomers, analogous to other oligomeric MFS proteins (Korkhov et al., 2004;
Scholze et al., 2002; Sitte et al., 2004).
To begin to test this model and to extend the published results of Zhao et al. (Zhao et al.,
2012), we inserted cysteine residues into a clhPCFTHA background (see Chapter 2) from
positions 115–137 spanning TMD3 and from positions 213–236 spanning TMD6. Individual
cysteine mutant constructs were transfected into R1-11 cells and after 48 h, transfected cells
were assayed for hPCFT protein levels in crude membranes by SDS/PAGE and Western blotting
(Figure 3.2A and B, lower panels) and for transport at pH 5.5 with [3H]MTX (0.5µM) (Figure
3.2A and B, upper panels). Most of the cysteine-insertion mutants preserved substantial transport
activity and only G123C, V130C, E232C and T233C were functionally inert (<2- fold increased
over R1-11 cells; noted with asterisks in Figures 3.2A-B) (p < 0.05).
The active cysteine mutants in TMDs 3 and 6 were cross-linked with MTS-6-MTS crosslinker and analysed on Western blots. Cys229-hPCFT formed cross-links, as reflected in slowly
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Figure 3.1 3D homology models for hPCFT. Panels A and B, Using Robetta as a modelling
platform with GlpT as template (Huang et al., 2003) and based on experimental results and
bibliographic data mining, we generated a 3D homology model for monomeric hPCFT in which
TMDs 1, 2, 4, 5, 7, 8, 10 and 11 comprise an aqueous transmembrane pathway, flanked by
TMDs 3, 6, 9 and 12. Panel C, A molecular model for dimeric hPCFT, predicted with MDOCK
(Pierce et al., 2014) and based on experimental data in the present study, as described in the text.
The model predicts that TMDs 2, 3, 4 and 6 in hPCFT form critical structural interfaces between
hPCFT monomers. Modeling peroformed by Zhanjun Hou and Jun Ye. Figure previously
published in Wilson et. al. Biochem J. 2015.
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Figure 3.2 Cysteine scanning of TMD3 and TMD6 mutants in cysteine-less hPCFTHA.
Panels A and B, To characterize the transport function and protein expression of single-cysteine
mutants of hPCFT, single-cysteine mutants of TMD3 (Panel A) and TMD6 (Panel B) were
transiently transfected into hPCFT-null R1-11 cells. Transfected cells were assayed for transport
at pH 5.5 with [3H]MTX (0.5 µM) for 2 min at 37° C. hPCFT protein expression was measured
in crude membranes by SDS/PAGE and Western blotting with HA-specific antibodies. β-Actin
was used as a loading control. The molecular mass markers for SDS/PAGE are noted. Transport
results are expressed relative to those for clhPCFTHA and are reported as mean values ±
standard errors from two independent experiments. Figure previously published in Wilson et. al.
Biochem J. 2015.
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Figure 3.3 MTS-6-MTS cross-linking of TMD3 and TMD6 cysteine-insertion mutants in
cysteine-less hPCFTHA. Single cysteine mutants (HA-tagged) of TMD6 (from positions 213–
236) and TMD3 (from positions 115–137) in a clhPCFTHA background were transiently
transfected into R1-11 cells and 48 h later cells were treated with the MTS-6-MTS cross-linker
(0.3 mM for 1 h on ice). clhPCFTHA and S229C hPCFTHA with and without cross-linker
treatment were included as controls. Cells were harvested and membrane proteins were analysed
on Westerns with anti-HA antibody. The hPCFT monomer migrates at ~45 kDa and cross-linked
hPCFT migrates at ~90 kDa. The molecular mass markers for SDS/PAGE are noted. Figure
previously published in Wilson et. al. Biochem J. 2015.
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migrating high molecular mass (~90 kDa) hPCFT species not seen with clhPCFTHA or noncross-linked S229C (Figure 3.3, upper panel). Distinct cross-linked species were also formed for
the Q136C and L137C mutants in TMD3 (Figure 3.3, middle panel) and for the W213C, L214C,
L224C, A227C, F228C, F230C and G231C hPCFT mutants in TMD6 (Figure 3.3, lower panel).
Again, no similar higher molecular mass species were detected in the absence of cross-linker
(Figures 3.2A-B, lower panels).
These results establish the proximities between vicinal residues localized in the exofacial
end of TMD3 and in the exofacial and cytosolic ends of TMD6, consistent with the notion that
these stretches of amino acids form structural interfaces between hPCFT monomers, as
suggested by the molecular model in Figure 3.1C.
3.4 Discussion
hPCFT forms homo-oligomers that are functionally important (Hou et al., 2012). In this
chapter, we systematically interrogated potential structural determinants of hPCFT monomer
associations in the formation of hPCFT oligomers. Previously published cross-linking results
implied an important role for TMD6 in forming a critical interface between hPCFT monomers
(Zhao et al., 2012).
Our cross-linking results implicated TMDs 3 and 6 as forming critical monomer
interfaces in homo-oligomeric hPCFT since homobifunctional cross-linking of cysteine-insertion
mutants across these stretches established the proximities between these individual TMDs. These
results directly support molecular modelling results which predict that TMDs 2, 3, 4 and 6 form
critical interfaces between hPCFT monomers. Based on these results, additional experiments are
warranted to further define the minimal determinants for hPCFT oligomerization.
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CHAPTER 4- FUNCTIONAL AND MECHANISTIC ROLES OF THE PROTONCOUPLED FOLATE TRANSPORTER TRANSMEMBRANE DOMAIN
6-7 LINKER
4.1 Introduction
PCFT contains a large loop domain connecting TMDs 6 and 7 (see Figure 1.4), which
includes a stretch of 30 mostly non-conserved amino acids (positions 236-265) with the
exception of a conserved stretch of amino acids (RLFXXRH) from positions 241-247, Leu254
and Arg264 (Figure 4.1). His247 was previously implicated as functionally important, as amino
acid substitutions (Ala, Arg, Gln, or Glu) at this position were associated with decreased
transport rates (decreased Vmax) and increased substrate binding affinities (decreased Kt)
compared to wild-type hPCFT (Unal et al., 2009a). By molecular modeling, His247 was
predicted to reside at the cytoplasmic end of a solute pathway with hydrogen bonding to Ser172
where it restricts substrate access to the folate binding pocket (Unal et al., 2009a).
In this chapter, we systematically explore the functional and mechanistic importance of
the hPCFT TMD6-7 connecting loop by site-directed, deletion, and insertion mutagenesis. Our
findings suggest that the PCFT TMD6-7 connecting loop may serve a unique functional role by
potentially restricting substrate access to the folate translocation pathway in a manner that
depends principally on secondary structure rather than individual sequence elements. The work
described in this chapter was previously published in Biochemical Journal (Wilson et al., 2016a).
4.2 Materials and Methods
4.2.1 Reagents
[3’,5’,7-3H]MTX (20 Ci/mmol) was purchased from Moravek Biochemicals (Brea, CA).
Unlabeled MTX was obtained from the Drug Development Branch, NCI, National Institutes of
Health (Bethesda, MD). Folic acid, leucovorin (LCV) [(6R,S)5-formyl tetrahydrofolate] and FBS
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were purchased from Sigma Chemical Co. (St. Louis, MO). Other tissue culture supplies were
purchased from various vendors.
4.2.2 hPCFT Mutagenesis.
Wild-type hPCFT constructs with various epitope tags, including wthPCFTHA and
wtFLAGhPCFTMyc-His10, and clhPCFTHA were previously described and used as templates for sitedirected, deletion, and insertion mutagenesis (Hou et al., 2012) (see Chapter 2). Mutations were
generated with the QuikChangeTM Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA). (i)
Twenty-nine individual alanine insertions from positions 236 to 266 were introduced using
wthPCFTHA in the pCDNA3 vector as a template. (ii) Eleven Cys residues were introduced from
positions 241-251 using clhPCFTHA in pCDNA3 as a template. (iii) Additional mutants of
His247 and His248, including amino acid replacements (Ala, Arg, Gln, Glu) or deletions [ΔH247
(deletion of His247), ΔH247/ΔH248 (deletions of both His247 and His248), and ΔH247/H248A
(His247 deletion, Ala248 replacement)], were generated using wthPCFTHA as a template. (iv)
wthPCFTHA was used as a template for PCR to remove the TMD6-7 loop including amino acids
236 to 265, generating dlhPCFTHA. With dlhPCFTHA as a template, we reintroduced 30 amino
acids (positions 236 to 265) from hPCFT (designated pphPCFTHA; as a control) or from
SLC19A2 (ThTr1; positions 250 to 279) (designated tthPCFTHA), or we replaced hPCFT
sequence in 15 amino acid segments (positions 236 to 250 or positions 251 to 265) with ThTr1
sequence (positions 250 to 264 or positions 265 to 279, respectively, from ThTr1), generating
tphPCFTHA and pthPCFTHA, respectively. (v) Additional mutagenesis generated several new
replacements at position 247 (Glu, Arg, Ala, His) or position 247 deletions, using tphPCFTHA,
pthPCFTHA, and tthPCFTHA as templates.
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To generate the hPCFT-TMD1-6HA half-molecule construct, we used PCR to introduce a
HA tag, followed by a stop codon after amino acid 251 of wthPCFTHA in pcDNA3. To create
FLAG

hPCFT-TMD7-12Myc-His10, we introduced EcoR1 cleavage sites following amino acids 24

and 249 in full length wtFLAGhPCFTMyc-His10 by PCR. The mutant construct was digested with
EcoR1 (New England Biolabs; Ipswich, MA) and the linearized fragment was gel-purified from
a 1% agarose gel with a QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). The fragment
was religated (Promega, Fitchburg, WI) to reassemble

FLAG

hPCFT-TMD7-12Myc-His10 in

pCDNA3, which contained a FLAG epitope following Met1, followed by amino acids 2-24 and
252-459 from wild-type hPCFT sequence. We used additional mutagenesis to remove the
TMD6-7 loop residues from the PCFT half-molecules, generating hPCFT-TMD1-6HA236-251Δ
(residues 1-235) and FLAGhPCFT-TMD7-12Myc-His10252-265Δ (residues 1-24 and 266-459).
In all cases, mutagenesis primers were designed with the QuikChangeTM Primer Design
program and are available upon request. PCR conditions were 95° C for 30 s, 55° C for 1 min,
and 68° C for 8 min for 16 cycles. All hPCFT mutant constructs were confirmed by DNA
sequencing (Genewiz, Inc., South Plainfield, NJ).
4.2.3 Cell Culture
The human RFC and hPCFT-null R1-11 HeLa cell line was a gift from Dr. I. David
Goldman (Bronx, NY) (Zhao et al., 2008). R1-11 cells were grown in RPMI 1640 media
supplemented with 10% FBS, 2 mM L-glutamine, 100 units/ml penicillin/100 µg/ml
streptomycin, and 600 µg/ml G418 and 500 nM MTX. For transfections with the hPCFT
constructs, R1-11 cells were seeded in DMEM) supplemented with 10% FBS in 60 mm culture
dishes at a density of 0.8 million cells per dish. After 24 hours, R1-11 cells were transiently
transfected with hPCFT constructs (in pCDNA3) (above) at 1 µg DNA/plate using
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Lipofectamine 2000 (10 µL/plate) in Opti-MEM, per the manufacturer’s instructions (Life
Technologies, Carlsbad, CA). The transfection medium was replaced with DMEM, containing
10% FBS, 4 hours after transfection.
4.2.4 Membrane Transport
Forty-eight hours after transfection of R1-11 cells, cellular uptake of [3H]MTX (0.5 µM)
was measured at 37° C over 2 min. Uptake assays were performed in 60 mm dishes using MESbuffered saline (20 mM MES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, and 5 mM glucose; pH
5.5), as previously described (Hou et al., 2012). Dishes were washed three times with PBS and
cells were solubilized in 0.5 N NaOH. Intracellular radioactivity was calculated in units of
pmol/mg protein, based on measurements of radioactivity and protein concentrations of the
alkaline cell homogenates (Lowry et al., 1951). To measure MTX transport kinetics for R1-11
cells transfected with wthPCFTHA and hPCFT mutant constructs, [3H]MTX uptake was measured
over 2 min at 37° C from 0.33 µM to 5 µM [3H]MTX, and results were analyzed using
Lineweaver-Burke plots to calculate Kt and Vmax values. To determine Ki values for nonradioactive substrates (folic acid, LCV), transfected cells were incubated with 0.5 µM [3H]MTX
and unlabeled inhibitors from 0.3 µM to 1.5 µM, with results compared to those without
inhibitors. Ki values were calculated from Dixon plots. To compare transport pH dependences
for wthPCFTHA and hPCFT mutants, transport assays were conducted at pHs from 7.2 to 5.5.
HEPES-buffered saline (20 mM HEPES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, and 5 mM
glucose) was used for pHs 7.2 and 6.8, and MES-buffered saline (20 mM MES, 140 mM NaCl, 5
mM KCl, 2 mM MgCl2, and 5 mM glucose) was used for pHs 6.5, 6.0, 5.8 and 5.5.
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4.2.5 Surface Biotinylation with MTSEA-Biotin
Forty-eight hours after transfection of R1-11 cells with hPCFT Cys mutants in
clhPCFTHA (above), cells were treated with MTSEA-biotin (Biotium, Hayward, CA) to
biotinylate aqueous accessible Cys residues exactly as previously described (see Chapter 2).
4.2.6 Surface Protein Biotinylation with Sulfo-NHS (N-hydroxysuccinimide)-SS-Biotin
We used the Cell Surface Labeling Accessory Pack (Thermo Scientific) to biotinylate and
isolate surface membrane proteins. Forty-eight hours after transfection of R1-11 cells with the
hPCFT constructs, the cells were treated with 0.25 mg/ml sulfo-NHS-SS-biotin in PBS at 4° C
for 30 min. The cells were treated with lysis buffer, followed by sonication and centrifugation to
remove the insoluble fraction. The supernatants were incubated with immobilized
NeutrAvidinTM gel slurry for 1 h at room temperature, and the beads were washed five times
with wash buffer. Proteins were eluted with 1× Laemmli sample buffer (Lowry et al., 1951)
containing 50 mM dithiotheitol and analyzed by SDS/polyacrylamide gel electrophoresis
(PAGE)/Western blotting (see below). All buffers (i.e., lysis, washing, elution) were
supplemented with a protease inhibitor mixture (Roche Applied Science).
4.2.7 Western Blotting
Protocols for plasma membrane preparation, SDS-PAGE, and electrotransfer to
polyvinylidene difluoride membranes (Pierce; Rockford, IL) were identical to those previously
described (Hou et al., 2012; Matherly et al., 1991). For fractionation of crude membrane
fractions, 10% SDS/PAGE gels were used. For fractionation of biotinylated surface membrane
proteins, NovexTM 4-20% Tris-Glycine mini protein gels were used. Anti-HA antibody
(Covance; Princeton, NJ), anti-Myc antibody (Covance) and IRDye800-conjugated secondary
antibody were used with an Odyssey Infrared Imaging System (LI-COR, Lincoln, NE) to
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identify HA- and Myc-tagged hPCFT proteins. Anti-β-actin (Sigma) or anti-Na+/K+ ATPase
(Novus Biologicals, Littleton, CO) antibodies were used to establish equal protein loading.
Densitometry values were calculated using the Odyssey Infrared Imaging System and software
package.
4.2.8 Confocal Microscopy
R1-11 cells were seeded in Lab-Tek II Chamber Slides (Nalge Nunc International,
Naperville, IL) at a density of 6.9×104 cells/well. After 24 hours, cells were transfected with
hPCFT constructs in pCDNA3, as described above, using 88.7 ng of DNA and 0.86 µl of
Lipofectamine 2000 per sample. Forty eight hours post-transfection, cells were fixed with 3.3%
paraformaldehyde (in PBS) and permeabilized with 0.1% Triton X-100 (in PBS). Chamber slides
were stained with primary antibodies, followed by incubation with secondary antibodies. The
primary antibodies used were goat anti-HA polyclonal antibodies (Abcam, Cambridge, MA) and
mouse anti-FLAG antibody (Sigma). Fluorescent secondary antibodies included Alexa Fluor®
568 donkey anti-goat IgG (H+L) and Alexa Fluor® 488 donkey anti-mouse IgG (H+L) (Life
Technologies). Slides were viewed with a Zeiss LSM-510 META NLO microscope, using a 63×
water immersion lens and the same parameters for all samples. Confocal microscopy was
performed in the Microscopy, Imaging, and Cytometry Resources Core at Wayne State
University School of Medicine.
4.2.9 Molecular Modeling
We used the crystal structures of members of MFS transporters GlpT (1PW4; for
pphPCFT) (Huang et al., 2003) and YajR (3WDO; for pt, tp and tthPCFT) (Jiang et al., 2013) as
templates for homology modeling of hPCFT monomers containing varied 6-7 loop sequence
replacements with Robetta Server (http://robetta.bakerlab.org). Modeling was based on the
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notion that all crystal structures from members of MFS members have preserved tertiary
structural elements during evolution, thus enabling published structures to extrapolate to other
MFS members (Abramson et al., 2004; Lemieux, 2007; Vardy et al., 2004). The top hPCFT
homology model retrieved through Robetta for each hPCFT form was superimposed by the
SALIGN server (http://modbase.compbio.ucsf.edu/salign/). Structures were visualized with
PyMol. The secondary structure of the 6-7 loop from each form was predicted with GOR4
(Garnier et al., 1996). This modeling was performed by Zhanjun Hou (Karmanos Cancer
Institute) and Jun Ye (Chinese Academy of Sciences).
4.2.10 Statistical Analysis
GraphPad v.6.0 software was used for plotting and data analysis including descriptive
statistics.
4.3 Results
4.3.1 Homology Analysis and Cysteine Accessibilities of Positions 241-251 in the hPCFT
TMD6-7 Loop Region
Based on computer-predicted hydropathy models (Matherly et al., 2014; Zhao et al.,
2010), hPCFT contains twelve TMDs with cytosolic-oriented C- and N- termini and segments
comprised of TMDs 1-6 and TMDs 7-12, connected by a long cytosolic-facing loop domain (30
amino acids) between TMDs 6 and 7 (positions 236-265) (Figure 1.4). Portions of this topology
structure have been confirmed experimentally (Zhao et al., 2010) (also see Chapter 2). We
compared the amino acid sequences across the TMD6-7 loop in PCFTs from five species from
Xenopus to humans. Of the 30 amino acids, seven residues were completely conserved among all
five species, including Arg241, Leu242, Phe243, Arg246, His247, Leu254, and Arg264
(numbering corresponds to hPCFT; Figure 4.1). His247 was previously implicated from site-

81

Zebrafish
Xenopus
Cattle
Mouse
Human

256
240
236
236
236

PDPQARLFSTRHHQAVCRLYSSDAPPGRRS
DKKPARLFTHRHYQSFFRLFTVQGENNRRR
ERTPTRLFTLRHHRSVIQLYVTQAPEKSRK
EPKSTRLFTLRHHRSIARLYVVPAPEKSRM
EPKSTRLFTFRHHRSIVQLYVAPAPEKSRK

285
269
265
265
265

Figure 4.1 Sequence alignment of the PCFT TMD6-7 connecting loop across five species
including zebrafish, xenopus, cattle, mouse, and human. The color codes are as follows: red,
residues are conserved across all species; green, residues are conserved across three or four
species; blue, residues are similar across species; and black, residues are not similar. Figure
previously published in Wilson et. al. Biochem J. 2016.
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directed mutagenesis and molecular homology modeling to be important in hPCFT transport by
virtue of its location at the putative cytoplasmic opening to the membrane translocation pathway
(Unal et al., 2009a).
Previous studies used SCAM and MTSEA-biotin reactivity with Cys insertions at Thr240
and Glu261 in the TMD6-7 loop of clhPCFTHA to establish the likely cytosolic orientations at
these positions (Zhao et al., 2010). To further establish the aqueous accessibilities (i.e.,
membrane topology) of amino acids comprising the TMD6-7 loop, particularly the conserved
stretch from positions 241 to 247, we generated 11 Cys replacements from positions 241-251,
using clhPCFTHA as a template for site-directed mutagenesis. As we previously reported,
clhPCFTHA exhibits functional characteristics virtually identical to those for wthPCFTHA (see
Chapter 2). The Cys mutant constructs were transfected into hPCFT-null R1-11 cells and were
assayed for [3H]MTX transport at pH 5.5 and 37oC (Figure 4.2A) and for hPCFT protein
expression on Western blots (Figures 4.2B-C). Results were compared to those for clhPCFTHA
transfected cells and for untransfected R1-11 cells. We found that all hPCFT Cys mutants were
expressed in crude membrane fractions (as broadly banding glycosylated proteins on 10% gels)
(~21% to ~54% of clhPCFTHA levels by densitometry; Figure 4.2B) and that most mutants were
active for [3H]MTX transport [~55%-100% of clhPCFTHA transport (Figure 4.2A); all uptakes
were significantly greater than for R1-11 cells], although activities for two Cys mutants, L242C
and H247C, were notably decreased (18.3% and 12.4%, respectively, of clhPCFTHA uptake; p <
0.0002). These decreases were accompanied by reduced surface protein expression relative to
clhPCFT (28% for L242C, 29% for H247C) (Figure 4.2C).
To establish aqueous accessibilities, we treated the 11 Cys mutants with membrane
impermeable MTSEA-biotin, using G207C in the TMD5-6 external loop and S110C in the
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Figure 4.2 Scanning Cys-insertion mutagenesis for positions 241-251 in the TMD6-7
connecting loop. Panel A, hPCFT single-Cys mutants from positions 241-251 in a clhPCFTHA
background were transiently transfected into hPCFT-null R1-11 cells. Transport activity was
measured after 48 h with [3H]MTX (0.5 µM) over 2 min at pH 5.5 and at 37oC. Results
expressed as a percentage of clhPCFTHA activity and reported as mean values ± S.E. (error bars)
from triplicate experiments. All single-Cys mutants were significantly more active than the nontransfected R1-11 control (p<0.05). Panel B, Western blots are shown for membrane proteins (10
µg) from HA-tagged hPCFT Cys mutants, compared clhPCFTHA transfected and untransfected
R1-11 cells. Densitometry (as relative percentages, noted below each lane) is representative of
duplicate experiments and was normalized to β-actin expression. Migrations of molecular mass
standard proteins (in kDa) are shown. Panel C, HA-tagged hPCFT surface membrane proteins
(40 µg) were labeled with sulfo-NHS-SS-biotin (0.25 mg/ml) and isolated on immobilized
NeutrAvidinTM gel. Biotinylated proteins were analyzed by SDS/PAGE and Western blotting.
Relative densitometry is representative of duplicate experiments and is normalized to Na+/K+
ATPase expression. Migrations of molecular mass standard proteins (in kDa) are shown. Panel
D, Substituted Cys accessibility analysis for positions 241-251 in the TMD6-7 connecting loop.
TMD6-7 loop single-Cys mutants were transiently transfected into R1-11 cells. Cells were
treated with MTSEA-biotin (0.2 mg/mL) 48 h later. After 30 min, cells were harvested, and
membranes prepared, solubilized and incubated with streptavidin beads in order to pull-down
biotinylated proteins. Biotinylated proteins were eluted and analyzed by Western blotting using
an anti-HA antibody (labeled “Pull-down”). A 25 µl aliquot of the crude membrane fraction prior
to exposure to streptavidin beads was also analyzed by Western blotting as a control (labeled
“Membrane”). The S110C and G207C mutants (located in the 1st intracellular (reentrant) loop
and 3rd extracellular loop, respectively) were used as positive controls and clhPCFTHA was a
negative control. Figure previously published in Wilson et. al. Biochem J. 2016.
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TMD2-3 reentrant loop as positive controls (see Chapter 2). Following MTSEA-biotin
treatments, biotinylated proteins were “pulled down” with streptavidin beads and analyzed on
Western blots with HA-specific antibody. Whereas G207C and S110C were biotinylated, none of
the 11 Cys mutants from positions 241-251 were biotinylated (Figure 4.2D). These results
suggest that residues in the TMD6-7 loop are not accessible to the extracellular aqueous milieu,
and that the TMD6-7 loop does indeed have a cytosolic orientation, as predicted by the hPCFT
hydropathy model (Matherly et al., 2014), analogous to other MFS proteins such as RFC (Liu
and Matherly, 2002).
4.3.2 Scanning Alanine Mutagenesis Across the hPCFT TMD6-7 Loop Region
To explore the functional importance of the TMD6-7 loop region in hPCFT membrane
transport, we used scanning alanine mutagenesis with wthPCFTHA in pCDNA3 to generate
alanine replacement mutants from positions 236 to 266 (positions 257 and 259 are already
alanines). Each of the 29 alanine mutant constructs was transfected into R1-11 Hela cells, and
after 48 hours the transfectants were assayed for [3H]MTX transport (Figure 4.3A), and for
hPCFT membrane protein expression (Figure 4.3B), compared to wthPCFTHA. All of the hPCFT
mutants were expressed, although there were some variations (measured by densitometry),
ranging from ~28% (for S250A) to ~128% (for P260A) of the wthPCFTHA level. Twenty-six of
the alanine mutants showed high levels of transport (~60-110% of wthPCFTHA). Although three
mutants (H247A, S250A, I251A) were notably less active (13%, 15%, and 13%, respectively, of
wthPCFTHA; p < 0.0001), they were nonetheless significantly more active than the nontransfected negative control (R1-11; p < 0.01) (Figure 4.3A). In each case, loss of transport
activity and hPCFT expression in crude membranes was related to loss in surface membrane
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Figure 4.3 Alanine-scanning mutagenesis of residues 236-266 in the TMD6-7connecting
loop. Panel A, Alanine mutants were generated in wthPCFTHA from positions 236-266 spanning
the TMD6-7 connecting loop and transfected into hPCFT-null R1-11 cells. Transport activity
was measured after 48 h with [3H]MTX over 2 min at pH 5.5 and at 37oC. Results are expressed
as a percentage of wthPCFTHA activity and are reported as mean values ± standard errors (error
bars) from triplicate experiments. All the alanine mutants were significantly more active than the
non-transfected control, R1-11 (p<0.05). Panel B, Western blots are shown for membrane
proteins (10 µg) from HA-tagged hPCFT alanine mutants. Densitometry (as relative percentages,
noted below each lane) is representative of duplicate experiments and was normalized to β-actin
expression. Migrations of molecular mass standard proteins (in kDa) are shown. Panel C, HAtagged hPCFT surface membrane proteins (40 µg) were labeled with sulfo-NHS-SS-biotin (0.25
mg/ml) and isolated on immobilized NeutrAvidinTM gel. Biotinylated proteins were analyzed by
SDS/PAGE and Western blotting. Relative densitometry is representative of duplicate
experiments and is normalized to Na+/K+ ATPase expression. Migrations of molecular mass
standard proteins (in kDa) are shown. Figure previously published in Wilson et. al. Biochem J.
2016.
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expression (Figure 4.3C; relative surface expression by densitometry of 51% for H247A, 11%
for S250A, and 63% for I251A, compared to the wthPCFT level).
Taken with the results of the Cys-scanning mutagenesis (Figure 4.2), these results imply
that most of the residues comprising the hPCFT TMD6-7 loop region are not essential for
transport. When comparing results for Cys and alanine substitutions across the TMD6-7 loop,
His247 in the conserved RLFXXRH motif (positions 241-247; Figure 4.1) was the only amino
acid for which its replacement consistently caused a significant loss of transport activity.
4.3.3 Co-expression of hPCFT TMD1-6 and TMD7-12 Half-Molecules
To further investigate the functional and structural roles of the hPCFT TMD6-7
connecting loop, we generated hPCFT “half-molecule” constructs. These include hPCFT-TMD16HA, comprised of amino acids 1-251 (TMDs 1-6) with a C-terminal HA epitope, and
FLAG

hPCFT-TMD7-12Myc-His10, comprised of amino acids 252-459 (TMDs 7-12) and an N-

terminal FLAG epitope just after Met1, followed by 23 N-terminal amino acids (residues 2-24)
and a C-terminal Myc-His10 (see schematic in Figure 4.4A).
The hPCFT half-molecule constructs were expressed in R1-11 HeLa cells both
individually and together, which were then assayed for restoration of [3H]MTX transport and
protein expression. Results were compared to those for wthPCFTHA and wtFLAGhPCFTMyc-His10
transfectants, and for untransfected R1-11 cells. When transfected separately, individual halfmolecules were detected on Westerns (Figure 4.4D) but were unable to restore transport activity
above the low residual level in R1-11 cells (Figure 4.4B). The HA signal on the Westerns for
hPCFT-TMD1-6HA was notably decreased (48%) compared to that for wthPCFTHA (Figure 4.4D,
left panel); the Myc signal for

FLAG

hPCFT-TMD7-12Myc-His10 was ~12% compared to

wtFLAGhPCFTMyc-His10 (Figure 4.4D, right panel). Cotransfection of hPCFT-TMD1-6HA with
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Figure 4.4 Expression of TMD1-6 and TMD7-12 hPCFT half-molecules. Panel A, A
schematic is shown of all half-molecule constructs/proteins. Panel B, Half-molecule constructs
were transiently transfected into R1-11 cells both individually and together. Transport activity
was measured after 48 h by [3H]MTX uptake assays over 2 min at pH 5.5 and at 37oC. Results
are expressed as a percentage of wthPCFTHA activity and are reported as mean values ± standard
errors (error bars) from triplicate experiments. Transport by the individual hPCFT-TMD1-6HA
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and FLAGhPCFT-TMD7-12Myc-His10 transfectants was not significantly greater than for negative
control R1-11 cells (p > 0.05). However, when transfected together, hPCFT-TMD1-6HA and
FLAG
hPCFT-TMD7-12Myc-His10 showed significantly increased transport activity, exceeding that
for R1-11 cells. hPCFT-TMD1-6HA/ FLAGhPCFT-TMD7-12Myc-His10Δ252-265 cotransfection also
restored transport activity over R1-11 cells (p < 0.05) which was not statistically different from
that for the hPCFT-TMD1-6HA/FLAGhPCFT-TMD7-12Myc-His10 cotransfected cells (p > 0.05) (*
indicates an increased level of transport over R1-11; p < 0.05). Panel C, [3H]MTX transport
activity of wthPCFTHA and hPCFT-TMD1-6HA/FLAGhPCFT-TMD7-12Myc-His10 transfectants at
pHs from 5.5 to 7.2 is shown. Uptake for each transfectant (wthPCFTHA and hPCFT-TMD1-6HA/
FLAG
hPCFT-TMD7-12Myc-His10) was normalized to its own uptake at pH 5.5. Panel D, Western
blots are shown for membrane proteins (10 µg) from HA-tagged or Myc-tagged hPCFT halfmolecules. Densitometry (as relative percentages, noted below each lane) is representative of
duplicate experiments and was normalized to β-actin. Migrations of molecular mass standard
proteins (in kDa) are shown. Panel E, HA- and Myc-tagged hPCFT surface membrane proteins
(40 µg) were labeled with sulfo-NHS-SS-biotin (0.25 mg/ml) and isolated on immobilized
NeutrAvidinTM gel. Proteins were analyzed by SDS/PAGE and Western blotting. Relative
densitometry (as relative percentages, noted below each lane) is representative of duplicate
experiments and was normalized to Na+/K+ ATPase expression. Migrations of molecular mass
standard proteins (in kDa) are shown. Panel F, Confocal microscopy of hPCFT TMD1-6 and
TMD7-12 half-molecules. Results are shown for HeLa R1-11 cells transfected with wthPCFTHA
or co-transfected with hPCFT-TMD1-6HA and FLAGhPCFT-TMD7-12Myc-His10 constructs.
Transfected cells were fixed with 3.3% paraformaldehyde, permeabilized with 0.1% Triton X100, and stained with Alexa Fluor® 488-conjugated (for FLAG-tagged PCFT; green) or Alexa
Fluor® 568-conjugated (for HA-tagged hPCFT; red) secondary antibodies. Images were
obtained using a Zeiss LSM-510 META NLO using a 63x water immersion lens. Staining is
shown for the individual fluors and as a merged image. Figure previously published in Wilson et.
al. Biochem J. 2016.
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FLAG

hPCFT-TMD7-12Myc-His10 resulted in an increased level of

FLAG

hPCFT-TMD7-12Myc-His10

over the individual transfectant, accompanying a modest restoration of transport activity (5.3%
of wthPCFTHA) that was significantly higher than for the non-transfected R1-11 cells (p < 0.05)
(Figure 4.4B). By confocal microscopy, hPCFT-TMD1-6HA and

FLAG

hPCFT-TMD7-12Myc-His10

were co-expressed and at least a portion co-localized to the cell surface, although significant
intracellular fluorescence for both hPCFT-TMD1-6HA and

FLAG

hPCFT-TMD7-12Myc-His10 was

detected (Figure 4.4F). Surface expression of co-expressed hPCFT-TMD1-6HA and

FLAG

hPCFT-

TMD7-12Myc-His10 was confirmed by surface biotinylation (Figure 4.4E). Transport activity for
the hPCFT-TMD1-6HA and

FLAG

hPCFT-TMD7-12Myc-His10 co-transfected cells showed the

characteristic pH dependence for PCFT transport that was essentially identical to that for
wthPCFTHA (Figure 4.4C).
Since hPCFT-TMD1-6HA and

FLAG

hPCFT-TMD7-12Myc-His10 included TMD6-7 loop

sequence (residues 236-251 and 252-265, respectively), we created and expressed two variant
half-molecule constructs in which segments of the TMD6-7 loop were deleted. These constructs
are hPCFT-TMD1-6Δ236-251HA (TMD1-6Δ), comprised of PCFT amino acids 1-235, and
FLAG

hPCFT-TMD7-12Δ252-265Myc-His10 (TMD7-12Δ), comprised of PCFT amino acids 1-24 and

266-459 (Figure 4.4A). Low levels of hPCFT-TMD1-6Δ236-251HA and

FLAG

hPCFT-TMD7-

12Δ252-265Myc-His10 were detected on Westerns when transfected both singly and in combination
(Figure 4.4D). Surface biotinylation confirmed surface expression of the co-expressed halfmolecules (Figure 4.4E), paralleling patterns seen in crude membrane fractions (Figure 4.4D).
Deletion of the residual loop sequence from both half-molecule constructs (hPCFT-TMD16Δ236-251HA and

FLAG

hPCFT-TMD7-12Δ252-265Myc-His10) abolished the modest transport

activity recorded for combined hPCFT-TMD1-6Δ236-251HA with

FLAG

hPCFT-TMD7-12Myc-His10
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(Figure 4.4B). Whereas hPCFT-TMD1-6HA (including amino acids 236-251) combined with
FLAG

hPCFT-TMD7-12Δ252-265Myc-His10 failed to restore transport above that for R1-11 cells, co-

transfection of hPCFT-TMD1-6Δ236-251HA with

FLAG

hPCFT-TMD7-12Myc-His10 (including

amino acids 252-265) restored low level transport activity (4.2% of wthPCFTHA), greater than for
R1-11 cells (p < 0.05) and equivalent to that for combined hPCFT-TMD1-6HA and

FLAG

hPCFT-

TMD7-12Myc-His10.
Collectively, these results demonstrate that transport function can be partly restored by
expressing hPCFT as separate TMD1-6 and TMD7-12 half-molecules and suggest that the 252265 loop segment (but not amino acids 236-251) is essential for this restored transport activity.
4.3.4 Expression of hPCFT-ThTr1 TMD6-7 Loop Chimeric Transporters
The thiamine transporter ThTr1 (SLC19A2) is less than 20% homologous to hPCFT at
the amino acid level and there is an almost complete loss of amino acid identity across the
TMD6-7 loop domains for hPCFT and ThTr1 (Figure 4.5A). To further examine the primary
sequence requirement for the hPCFT TMD6-7 loop (amino acids 236-265), we replaced this
stretch in hPCFT with structurally analogous but non-homologous sequence from the TMD6-7
loop of ThTr1 (amino acids 250-279) (Figure 4.5A).
To achieve this, we first removed the nucleotide sequence encoding amino acids 236-265
from wthPCFTHA by PCR, generating dlhPCFTHA (Figure 4.5A). Using dlhPCFTHA as a
template, we then reintroduced hPCFT 236-265 sequence (designated pphPCFTHA; as a control)
or ThTr1 250-279 sequence (tthPCFTHA). Two additional mutant constructs were generated with
partial (15 amino acids) TMD6-7 loop replacements. These include pthPCFTHA, with amino
acids 236-250 from hPCFT, followed by amino acids 265-279 from ThTr1, and tphPCFTHA,
with amino acids 250-264 from ThTr1, followed by amino acids 251-265 from hPCFT (Figure
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Figure 4.5 Expression of hPCFT-ThTr1 chimeric transporters with replacement of the
hPCFT TMD6-7 loop with ThTr1 sequence. Panel A, A schematic is shown of the ThTr1
sequence replacements for pphPCFTHA, pthPCFTHA, tphPCFTHA, and tthPCFTHA. Mutants were
generated first by removing amino acid residues 236-265 through PCR mutagenesis
(dlhPCFTHA) and then inserting new sequence. pphPCFTHA serves as a positive control and
contains an exact replacement of the hPCFT residues 236-265. tthPCFTHA contains ThTr1
residues 250-279 in place of hPCFT residues 236-265. The TMD6-7 loop of pthPCFTHA
contains hPCFT residues 236-250, followed by ThTr1 residues 265-279. The TMD6-7 loop of
tphPCFTHA contains ThTr1 residues 250-264, followed by hPCFT residues 251-265. Panels B,
hPCFT/ThTr1 chimera mutants were transiently transfected into R1-11 cells. Transport activity
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was measured after 48 h by [3H]MTX uptake assays over 2 min at pH 5.5 and at 37o C. Results
are expressed as a percentage of wthPCFTHA activity and are reported as mean values ± standard
errors (error bars) from triplicate experiments. All hPCFT-ThTr1 chimera proteins were
significantly more active than for the non-transfected control, R1-11. Transport for dlhPCFTHA
and tthPCFTHA-E247H was insignificantly different from that for R1-11 cells (* indicates that
transport activity is not significantly different than R1-11; p > 0.05). Panel C, Western blots are
shown for membrane proteins (10 µg) from HA-tagged hPCFT chimera mutants. Densitometry
(as relative percentages, noted below each lane) is representative of duplicate experiments and
was normalized to β-actin levels. Migrations of molecular mass standard proteins (in kDa) are
shown. Panel D, HA-tagged hPCFT surface membrane proteins (40 µg) were labeled with sulfoNHS-SS-biotin (0.25 mg/ml) and isolated on immobilized NeutrAvidinTM gel. Biotinylated
proteins were analyzed by SDS/PAGE and Western blotting. Relative densitometry (as relative
percentages, noted below each lane) is representative of duplicate experiments and was
normalized to Na+/K+ ATPase expression. Migrations of molecular mass standard proteins (in
kDa) are shown. Panel E, R1-11 cells expressing hPCFT/ThTr1 chimera mutant proteins were
tested for [3H]MTX transport activity as in panel B, using MES- and HEPES-buffered saline, as
appropriate, at different pHs. Uptake for each mutant at the individual pHs was normalized to
uptake at pH 5.5 (* indicates that mutant PCFT transport showed a greater decrease from pH 5.5
to pH 6.0 than wthPCFT; p < 0.05). Figure previously published in Wilson et. al. Biochem J.
2016.
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4.5A). All hPCFT mutant constructs were transiently expressed in R1-11 HeLa cells and were
assayed for hPCFT levels on Westerns and for [3H]MTX uptake compared to wthPCFTHA
(Figures 4.5B and C).
The re-engineered full-length hPCFT (pphPCFTHA) showed a modest decrease in
transport activity (~85% of wthPCFTHA; Figure 4.5B), accompanying slightly decreased hPCFT
protein expression (Figures 4.5C), including surface hPCFT (Figure 4.5D). Complete removal of
the hPCFT TMD6-7 loop sequence (residues 236-265) in dlhPCFTHA abolished [3H]MTX
transport (< 2% of wthPCFTHA), reflecting a significant loss of membrane (Figure 4.5C) and
surface (Figure 4.5D) hPCFT protein. Complete replacement of the 236-265 hPCFT sequence
with amino acids 265-279 from ThTr1 (tthPCFTHA) likewise resulted in low expression and
activity (~2% of wthPCFTHA, although this was significantly higher than R1-11 transport; p <
0.0001) (Figures 4.5B-D). Replacement of either the C-terminal TMD6-7 loop fragment (amino
acids 251-265) in pthPCFTHA or the N-terminal fragment (amino acids 236-250) in tphPCFTHA
with ThTr1 sequence preserved significant transport (23% and 11%, respectively; Figure 4.5B).
Compared to wthPCFTHA, pthPCFTHA and tphPCFTHA showed insignificant differences in
binding affinities for assorted transport substrates (as reflected in Kt and Ki values; Table 4.1)
and only minor differences in pH dependence for transport (Figure 4.5E). The reduced transport
activity relative to wthPCFTHA appeared to be entirely due to decreased Vmax values (measured
with [3H]MTX; Table 4.1) and was reflected in levels of membrane (Figure 4.5C) and surface
(Figure 4.5D) hPCFTHA proteins on Western blots.
To better understand functional differences between wild-type hPCFT and the hPCFTThTr1 chimeric transporters with various TMD6-7 loop sequence replacements in relation to
structure, we used molecular homology modeling. Superimposition of structural models for the
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Table 4.1
Kinetic Analysis of wthPCFTHA, His247 hPCFT Substitution and Deletion Mutants, and
hPCFT/ThTr1 Chimera Proteins.
Constant

Kt (µM)

hPCFT variant
wthPCFTHA
wt-H247A
wt-ΔH247
wt-ΔH247/ΔH248
tphPCFT
tp-E247H
tp-E247R
pthPCFT

0.75 ± 0.10
0.18 ± 0.01*
0.54 ± 0.05
0.82 ± 0.07
0.99 ± 0.21
1.00 ± 0.10
1.50 ± 0.17*
0.77 ± 0.07

Vmax
(pmol/mg/min)
MTX
261.5 ± 28.3
10.8 ± 1.06*
67.6 ± 12.2*
101.6 ± 7.7*
63.0 ± 10.1*
141.6 ± 20.0*#
276.8 ± 30.5#
68.0 ± 10.9*

Vmax/Kt

Ki (µM)

Ki (µM)

414.3 ± 80.1
60.8 ± 10.7*
122.8 ± 24.8
125.8 ± 15.3
73.6 ± 20.9*
150.2 ± 31.1
194.5 ± 30.1#
92.0 ± 20.0*

FA
0.59 ± 0.08
0.12 ± 0.03*
0.27 ± 0.07
0.46 ± 0.12
0.71 ± 0.16
0.47 ± 0.06
0.60 ± 0.12
0.55 ± 0.13

LCV
0.38 ± 0.08
0.13 ± 0.02
0.25 ± 0.06
0.46 ± 0.13
0.29 ± 0.06
0.72 ± 0.11#
0.53 ± 0.18
0.17 ± 0.06

wthPCFTHA and hPCFTHA mutants were transiently transfected into R1-11 cells, and 48 h later,
[3H]MTX uptake was assayed at pH 5.5 over 2 min at 37oC. To determine Kt and Vmax values,
cells were treated with [3H]MTX with concentrations between 0.33 µM and 5 µM, and results
were analyzed by Lineweaver-Burke plots. To determine Ki values, cells were incubated with 0.5
µM [3H]MTX with folic acid (FA) and LCV as competitors from 0.3 µM to 1.5 µM, with results
analyzed by Dixon plots. Data are presented as mean values ± standard errors from four
independent experiments. Values significantly different from those for wthPCFTHA (p < 0.05) are
marked with *. Values significantly different from tphPCFTHA (p < 0.05) are marked with # (only
tp-E247H and tp-E247R were compared to tphPCFT). Table previously published in Wilson et.
al. Biochem J. 2016.
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wt-, pt-, tp-, and tthPCFT proteins gave a composite RMSD value of 1.2 Å for 234 Cα atoms
from 10 transmembrane helices (TMDs 1-10), implying that the overall structures of these
various hPCFT forms were almost identical (Figure 4.6A). This suggests that the sequence
composition of the TMD6-7 loop has minimal impact on overall folding of the hPCFT protein.
We also considered isolated conformational changes involving the TMD6-7 loop domain that
may impact transport activity for the individual hPCFT insertion mutants compared to wild-type
PCFT. We explored the secondary structure changes in the hPCFT TMD6-7 loop domain for the
hPCFT-ThTr1 chimeric proteins, using the secondary structure prediction tool GOR4 (Garnier et
al., 1996). Whereas wild-type hPCFT showed significant α-helix (16.7%) for this region, this
was lost for the insertion mutants (tphPCFTHA, pthPCFTHA, and tthPCFTHA). This loss of αhelical structure for the TMD6-7 mutant proteins was accompanied by progressively increased
random coil structures, as reflected in major conformational changes (Figure 4.6B), from 60%
for wtPCFT to 70% for pthPCFT, 80% for tphPCFT and 87% for tthPCFT. Thus, there is an
inverse relationship between the extent of random coil for the TMD6-7 loop region and hPCFT
transport activity.
These results establish that the TMD6-7 loop is important for hPCFT transport activity.
However, this functional role likely depends on preservation of secondary structure rather than
particular sequence motifs.
4.3.5 Characterization of His247 Substitution and Deletion Mutants in Wild-Type hPCFT
and hPCFT-ThTr1 Chimera Transporters
While the above studies imply a relative independence of the TMD6-7 loop primary
sequence for transport activity, scanning alanine and cysteine mutagenesis (Figures 4.2 and 4.3)
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Figure 4.6 Protein modeling of PCFT/ThTr1 chimera mutants. Panels A and B, hPCFT
protein modeling using Robetta and SALIGN software, as described in Materials and Methods.
hPCFT TMDs 1-12 only, (including TMDs 1, 2, 4 5, 7, 8, 10, and 11, predicted to form the
transmembrane translocation pathway), as a composite structure from pphPCFTHA (green),
pthPCFTHA (pink), tphPCFTHA (cyan), and tthPCFTHA (yellow). In Panel B, the TMD6-7 loop is
highlighted and can be distinguished from TMDs1-12 (grey) including pphPCFTHA (green),
pthPCFTHA (pink), tphPCFTHA (cyan), and tthPCFTHA (yellow). Modeling done in collaboration
with Zhanjun Hou and Jun Ye. Figure previously published in Wilson et. al. Biochem J. 2016.
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nonetheless identified His247 as a residue for which its replacement consistently caused a
significant loss of transport activity. Unal et al. previously showed that amino acid substitutions
(Ala, Arg, Gln, Glu) at position 247 had various effects on hPCFT transport activity (Unal et al.,
2009a). All of these mutants were expressed (Figure 4.7B) and relative to wild-type hPCFT
(wthPCFTHA), activity ranged from ~5% for wt-H247R to ~13% for wt-H247A, and ~26% and
~28% for wt-H247E and wt-H247Q, respectively (Figure 4.7A).
Interestingly, the impact of position 247 replacements was much different for the hPCFTThTr1 chimeric transporters. For the partially active tphPCFTHA mutant with a glutamate at
position 247, substitution with alanine (tp-E247A) resulted in decreased transport (3% of
wthPCFT), while re-introduction of histidine (tp-E247H) or replacement with glutamine (tpE247Q) subtly increased transport over tphPCFTHA (~19% and ~22.4% of wthPCFT,
respectively) (Figure 4.7A). Arginine insertion at position 247 of tphPCFT restored transport
activity at ~50% of the wthPCFT level. These effects on activity for tp-E247H and tp-E247R
were accompanied by disproportionately elevated Vmax values compared to tphPCFT (Table 4.1),
even when normalized to surface expression levels on Western blots (Figure 4.5D). While the Ki
for LCV was increased for tp-E247H compared to tphPCFT, for both tp-E247H and tp-E247R,
there were minor differences in pH dependences for transport compared to tphPCFT (Figure
4.7F).
For pthPCFT, the effects of alanine, arginine, glutamine and glutamic acid substitutions
for His247 on transport activity (Figure 4.7A) and expression (Figure 4.7B) were nominal.
Histidine insertion at position 247 in tthPCFT resulted in a subtle but significant decrease in
activity (from 2% of wthPCFTHA for tthPCFT to 1% for tt-E247H) (p < 0.05) (Figure 4.7A).
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Figure 4.7 Analysis of 247/248 substitution and deletion mutants. Panels A and C, Amino
acid substitution and deletion mutants were generated from wthPCFTHA, pthPCFTHA ,
tphPCFTHA , and tthPCFTHA, as described in the text, and were transfected into R1-11 cells.
Transport activity was measured after 48 h with [3H]MTX (0.5 µM) over 2 min at pH 5.5 and at
37oC. Results are expressed as a percentage of wthPCFTHA activity and are reported as mean
values ± standard errors (error bars) from triplicate experiments. With the exception of tt-E247H,
all mutants were significantly more active than the non-transfected control, R1-11 (p<0.05) [*
indicates where transport activity is significantly different from parent wt-, pt-, tp-, or tthPCFTHA,
as appropriate; p < 0.05]. Panels B and D, Western blots are shown for membrane proteins (10
µg) from HA-tagged hPCFT 247/248 substitution and deletion mutants. Densitometry (as
relative percentages, noted below each lane) is representative of duplicate experiments and was
normalized to β-actin expression. Migrations of molecular mass standard proteins (in kDa) are
shown. Panel E, HA-tagged hPCFT surface membrane proteins (40 µg) were labeled with sulfoNHS-SS-biotin (0.25 mg/ml) and isolated on immobilized NeutrAvidinTM gel. Biotinylated
proteins were analyzed by SDS/PAGE and Western blotting. Relative densitometry (as relative
percentages, noted below each lane) is representative of duplicate experiments and results for
hPCFT were normalized to Na+/K+ ATPase expression. Migrations of molecular mass standard
proteins (in kDa) are shown. Panel F, R1-11 cells expressing hPCFT His247 mutant proteins
were tested for [3H]MTX transport activity as in panel A, using MES- and HEPES- buffered
saline, as appropriate, at various pHs. Uptake for each mutant at the individual pHs was
normalized to uptake at pH 5.5 (* indicates that mutant PCFT transport showed a greater
decrease from pH 5.5 to pH 6.0 than wthPCFT; p < 0.05). Figure previously published in Wilson
et. al. Biochem J. 2016.
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To further characterize the functional importance of His247 to hPCFT transport, we
deleted this residue entirely, using wthPCFTHA as a template, generating wt-ΔH247. Since
His247 in hPCFT is followed by His248 (thus, effectively replacing His247 in the wt-ΔH247
mutant), we also created three additional mutants in the wthPCFTHA background. These include
wt-H247A/H248A, in which both His247 and His248 are mutated to alanine, wt-ΔH247/ΔH248,
in which both histidines are deleted, and wt-ΔH247/H248A, in which His247 is deleted and
His248 is replaced by alanine. ΔH247 and ΔE247 deletion mutants were also prepared for
pthPCFTHA and tphPCFTHA, respectively.
All of the wild-type hPCFT His deletion mutants showed similar, albeit slightly
decreased, levels of PCFTHA protein from that for wthPCFTHA (Figure 4.7D). Interestingly, for
wt-ΔH247, wt-ΔH247/ΔH248 and wt-ΔH247/H248A, transport activity was significantly
increased over that for wt-H247A (p < 0.05) (Figure 4.7C); for wt-ΔH247 and wt-ΔH247/ΔH248
transport approximated ~46% and ~64%, respectively, of wthPCFTHA levels. Increased activity
for wt-ΔH247 and wt-ΔH247/ΔH248 compared to wt-H247A hPCFT was accompanied by
slightly increased surface protein (Figure 4.7E). When transport was normalized to surface
hPCFT levels, this gave ~75% and ~93% of that of wthPCFTHA for wt-ΔH247 and wtΔH247/ΔH248, respectively. While position 247 deletion in tphPCFT (tp-ΔE247) also increased
transport activity compared to tpE247A (23% of wthPCFT), position 247 deletion in pthPCFT
(pt-ΔH247) resulted in a subtle decrease in transport activity (14% of wthPCFTHA for pt-ΔH247
compared to 23% for pthPCFT) (p < 0.05) (Figure 4.7A).
We examined transport characteristics for the restored transport activity of the wt-ΔH247,
and wt-ΔH247/ΔH248 mutants compared to H247A and wthPCFTHA, including pH dependences
and transport kinetics. There were no differences in the pH profiles between mutant and wild-
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type PCFTs, as maximal transport activity was measured at pH 5.5 and decreased with increasing
pH (Figure 4.7F). By kinetic analysis, wt-H247A showed decreases in both Kt (4.2-fold) and
Vmax (26.7-fold) for MTX compared to wthPCFTHA (Table 4.1), similar to published results by
Unal et al (Unal et al., 2009a). Interestingly, for the deletion mutants (wt-ΔH247 and wtΔH247/ΔH248), the MTX Kts were restored to approximate the wild-type values, accompanying
increased Vmax values, compared to H247A (Table 4.1). The latter reflect increased surface
hPCFT, as noted above (Figure 4.7E). Analogous patterns were seen in the Kis for both folic acid
and LCV for the wt-H247A, wt-ΔH247, and wt-ΔH247/ΔH248 mutants, determined by Dixon
analysis from the inhibition of [3H]MTX uptake.
Overall, our results suggest that neither His247 nor His248 is absolutely essential for
hPCFT transport. Whereas wt-H247A resulted in increased affinity for transport substrates,
His247 deletion had no impact on substrate binding (as reflected in the Kt and Ki values for
various substrates). The decreased Vmax values for wt-H247A, wt-ΔH247, and wt-ΔH247/ΔH248
mutants were all accompanied by reduced surface hPCFT levels, suggesting decreased stability
(and intracellular trafficking) for these mutant transporters compared to wild-type hPCFT.
4.4 Discussion
hPCFT is predicted to be formed from distinct TMD1-6 and TMD7-12 segments, with
the longest of its 11 connecting loop domains linking TMDs 6 and 7 comprised of amino acids
236-265. In this chapter, we explored the structure and transport function of the TMD6-7
connecting loop using a range of complementary approaches.
(i) Ala and Cys substitutions mutagenesis across the TMD6-7 loop identified His247 as
the only amino acid residue in this stretch for which its replacement consistently and
substantially suppressed transport activity. However, deletion of His247 significantly restored
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transport activity compared to wt-H247A. This implies that His247 is not in itself essential to
high levels of transport. (ii) Further studies established that large (15 amino acid) segments of the
hPCFT TMD6-7 loop including His247 could be replaced with non-homologous sequence from
ThTr1 (in pthPCFTHA and tphPCFTHA), resulting in significant preservation of transport,
although complete deletion of the loop (in dlhPCFTHA) or its replacement with non-homologous
sequence from ThTr1 (in tthPCFTHA) abolished transport activity. These differences in transport
activity between the pthPCFTHA and tphPCFTHA compared to wthPCFTHA were independent of
substrate binding but were associated with a pronounced impact on transport Vmax, likely due to
impaired trafficking to the cell surface and loss of stability, resulting in decreased hPCFT protein
expression. (iii) While His247 replacements with Ala, Arg, Gln and Glu in wthPCFT replicated
previous findings of Unal et al. (Unal et al., 2009a), substitutions of Glu247 in tphPCFT
followed a distinctly different pattern. The same His247 replacements in pthPCFT showed no
obvious impact on transport activity. Analogous results were obtained for the His247 deletion
mutants (wt-ΔH247 and tp-ΔE247 versus pt-ΔH247). Thus, the impact of position 247 alterations
is context-dependent and varies with flanking sequence and secondary structure. Indeed, the role
of the TMD6-7 loop domain in hPCFT function appears to be largely unrelated to specific
primary sequence elements, as long as sufficient secondary structure is preserved and proper
spacing between the TMD1-6 and TMD7-12 segments is ensured to facilitate optimal membrane
transport. (iv) Consistent with the latter notion, hPCFT could be expressed as TMD1-6 and
TMD7-12 half-molecules to restore transport activity, albeit in low levels.
Collectively, our results demonstrate that the TMD6-7 loop structure is critical to
intracellular trafficking and protein stability essential to transport function. Our biochemical and
molecular modeling results further suggest that while absolute primary sequence elements of the
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TMD6-7 loop is not essential to transport function, as long as sufficient secondary structure is
preserved, the loop may nonetheless serve a unique functional role, even possibly restricting
substrate access to the folate binding site and membrane translocation pathway, as previously
suggested (Unal et al., 2009a). While our results imply that His247 can play a role in hPCFT
transport, this is subtle, as loss of His247 can be compensated by other primary sequence
elements as indicated by our results with pthPCFT His-replacement muttants. Characterization of
key structural features of hPCFT is important for understanding the transport mechanism,
including identifying critical determinants of substrate binding and membrane translocation.
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CHAPTER 5- TARGETING NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
VIA PCFT-MEDIATED UPTAKE OF 6-SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINE
THEINOYL ANTIFOLATES
5.1 Introduction
NSCLC is the leading cause of cancer-related deaths in the United States, accounting for
85% of all diagnosed lung cancers and resulting in over 100,000 deaths per year (American
Cancer Society, 2015). PMX is a 5-substituted pyrrolo[2,3-d]pyrimidine antifolate (Figure 1.2)
(Chattopadhyay et al., 2007) and is an important first-line and maintenance therapy in the
treatment of nonsquamous (NS)-NSCLC, although patient responses are variable (Esteban et al.,
2009; Genova et al., 2013; Gerber and Schiller, 2013; Tomasini et al., 2013). Cellular uptake of
folates and classic antifolates is primarily via the facilitative folate transporters, RFC and PCFT
(Matherly et al., 2014). FRα is expressed in some malignancies including NSCLC (Christoph et
al., 2013; Nunez et al., 2012; O'Shannessy et al., 2012) and is being exploited for targeted drug
delivery (Assaraf et al., 2014; Xia and Low, 2010). However, FRα levels in NS-NSCLC can be
variable (Christoph et al., 2013; Nunez et al., 2012; O'Shannessy et al., 2012), at least in part
reflecting epidermal growth factor receptor (EGFR) mutation status (Nunez et al., 2012) or stage
of disease (O'Shannessy et al., 2012), with the highest levels in a subset of specimens. RFC is a
ubiquitously expressed folate/anion antiporter, and is widely considered to be the major tissue
transporter of folate cofactors and antifolates such as MTX and PMX (Matherly et al., 2007).
PCFT was identified in 2006 as a folate/proton symporter with an acidic pH optimum and was
localized to the upper gastrointestinal tract where it transports dietary folates across the apical
brush border of the small intestine (Qiu et al., 2006). Although other tissues such as liver and
kidney also express PCFT (Desmoulin et al., 2012a), in these tissues its biologic role is less
certain since the neutral pH microenvironment is not conducive to high levels of PCFT transport
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(Zhao et al., 2009a). PCFT is commonly expressed in human tumor cells including NS-NSCLC
cell lines (Kugel Desmoulin et al., 2011), and likely facilitates PMX uptake and contributes to
antitumor efficacy with this disease since the acidic microenvironment of tumors greatly favors
transport by PCFT over RFC (Desmoulin et al., 2012a; Zhao and Goldman, 2007).
Once internalized, PMX is metabolized to polyglutamates by FPGS, resulting in drug
forms with enhanced cellular retention over nonpolyglutamyl PMX and increased binding
affinities for intracellular enzyme targets (Chattopadhyay et al., 2007). TS is the primary
intracellular enzyme target for PMX (Chattopadhyay et al., 2007) and TS levels have been
implicated in some studies as an important determinant of PMX clinical response, such that
tumors with highly elevated TS would be expected to show PMX resistance (Christoph et al.,
2013; Liu et al., 2013). At least some of the variable responses to PMX seen clinically may
reflect an impact of coadministering dexamethasone with PMX to alleviate possible side effects
since dexamethasone attenuates PMX cytotoxicity in NS-NSCLC cells by reversibly blocking
cell cycle progression, secondary to the presence of high levels of the glucocorticoid receptor a
(Patki et al., 2014). Interestingly, dexamethasone treatment of NS-NSCLC cells in vitro also
resulted in reduced expression of RFC and PCFT (Patki et al., 2014). PMX can inhibit folatedependent enzymes other than TS, including GARFTase and AICARFTase in de novo purine
nucleotide biosynthesis (Racanelli et al., 2009).
Given variable patient responses to PMX, another promising strategy is to develop
analogs with increased selectivity for membrane transport by PCFT over RFC, thus increasing
specificity toward tumors, while decreasing toxicity toward normal tissues (Desmoulin et al.,
2012a). Ideally, these agents would target intracellular enzymes other than TS, thus potentially
circumventing PMX resistance due to TS alterations.
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The synthesis and biologic activities of a novel series of 2’,4’ and 2’,5’ thienoyl 6substituted pyrrolo[2,3-d]pyrimidine antifolates, typified by AGF94 and AGF154 (Figure 1.2),
have been previously described (Cherian et al., 2013; Desmoulin et al., 2012b; Wang et al.,
2011; Wang et al., 2015). AGF94 and AGF154 exhibit transport specificity for PCFT over RFC
and deplete purine nucleotides due to inhibition of de novo biosynthesis at GARFTase, the first
folate-dependent step. Although GARFTase inhibitors have been previously described (i.e.,
LMX, AG2034) (Boritzki et al., 1996; Mendelsohn et al., 1999a) and have shown potent
antitumor effects, this was accompanied by unacceptable levels of toxicity in patients, possibly
reflecting significant RFC-driven transport of these compounds (Budman et al., 2001; Ray et al.,
1993). This problem may be overcome by combining GARFTase targeting and PCFT transport
selectivity, which characterizes antifolates such as AGF94 and AGF154. In this chapter, we
explore the therapeutic potential of these novel tumor-targeted 6-substituted pyrrolo[2,3d]pyrimidine antifolates with selective membrane transport by PCFT over RFC in NS-NSCLC.
The work described in this chapter was previously published in Molecular Pharmacology
(Wilson et al., 2016b).
5.2 Materials and Methods
5.2.1 Reagents
The 6-substituted pyrrolo[2,3-d]pyrimidine antifolates AGF94 [(S)-2-((5-[3-(2-amino-4oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)-propyl]-thiophene-2-carbonyl)-amino)pentanedioic acid] and AGF154 [(S)-2-((5-[3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)-propyl]-thiophene-3-carbonyl)-amino)-pentanedioic acid] were synthesized as
previously described (Wang et al., 2011; Wang et al., 2015). PMX [N-(4-[2-(2-amino-3,4dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl)-L-glutamic acid] (Alimta) was
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obtained from Eli Lilly and Co. (Indianapolis, IN). PT523 [Na-(4-amino-4-deoxypteroyl)-Ndhemiphthaloyl-L-ornithine) (Rosowsky et al., 1994) was a gift of Dr. A. Rosowsky (Boston,
MA). LCV was obtained from the Drug Development Branch, National Cancer Institute,
Bethesda, MD. [3H]PMX (87 Ci/mmol), [3H]AGF154 (12.3 Ci/mmol), and [14C(U)]glycine
(87mCi/mmol) were purchased from Moravek Biochemicals (Brea, CA). Other chemicals were
obtained from commercial sources in the highest available purity.
5.2.2 Real-Time Reverse-Transcription Polymerase Chain Reaction (RT-PCR) Analysis of
Folate-Related Transcripts
Patient cDNAs were purchased from Origene (Rockville, MD), including 26 NS-NSCLC
specimens (8, stage I; 5, stage II; 7, stage III; and 6, stage IV) and eight unmatched normal lung
specimens. RNAs were isolated from the NS-NSCLC cell lines using TRIzol reagent (Invitrogen,
Carlsbad, CA). cDNAs were synthesized with random hexamers and MuLV reverse transcriptase
(including RNase inhibitor) (Applied Biosystems, Waltham, MA) and were purified using a
QIAquick PCR Purification Kit (QIAGEN, Valen- cia, CA). Quantitative real-time RT-PCR was
performed using a Roche LightCycler 480 (Roche Diagnostics, Indianapolis, IN) with genespecific primers and FastStart DNA Master SYBR Green I Reaction Mix (Roche Diagnostics).
Primer sequences are available upon request. Transcript levels were normalized to transcript
levels of β-actin.
5.2.3 Immunohistochemistry (IHC)
The tissue microarray (BC041115b) and IHC services were purchased from US Biomax,
Inc. (Rockville, MD). The array included 61 NS-NSCLC specimens (25, stage I; 19, stage II; 16,
stage III; and 1, stage IV) and 10 unmatched normal lung tissues. The tissues were formalinfixed and paraffin-embedded. The tissue microarrays were deparafinized, rinsed, microwaved,
and incubated with polyclonal antibody to human PCFT raised in rabbits (Hou et al., 2012). The
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serum was purified using a peptide affinity column synthesized from Affi-Gel 10 (BioRad,
Richmond, CA). The slides were developed with ImmPRESS anti-Rabbit IgG (peroxidase)
(Vector Laboratories, Burlingam, CA) and peroxidase substrate 3,3’-diaminobenzidine
tetrahydrochloride, and then rinsed, counterstained with Hematoxylin QS (Vector Laboratories),
cleared, and mounted with permanent mounting medium (C0487; Sigma-Aldrich, St. Louis, MO).
The slides were manually scored by two independent pathologists with the intensities scored as
negative (0), weak (11), moderate (21), or strong (31), and then scanned by an Aperio Image
Scanner (Aperio Technologies, Inc., Vista, CA) for microarray image scanning. The total
positive cell numbers and intensity of antibody staining of each tissue core were computed.
5.2.4 Cell Culture Conditions
NS-NSCLC cell lines, including A549, H1437, H460, H1299, H1650, and H2030, were
obtained from the American Type Culture Collection (Manassas, VA). The identities of the NSNSCLC cell lines were verified by Genetica DNA Laboratories (Burlington, NC). HeLa cells
were gifts from Dr. I. David Goldman (Bronx, NY). Prior to experiments, all cell lines were
grown in folate-free RPMI 1640 supplemented with 10% dialyzed FBS (Sigma- Aldrich), 1%
penicillin/streptomycin, 2 mM L-glutamine, and 25 nM LCV for at least 2 weeks.
For growth inhibition assays, the NS-NSCLC cell lines were plated in 96-well culture
dishes (1500–4000 cells/well; 200 ml/well) in the aforementioned medium with drug
concentrations from 1 to 1000 nM PMX, AGF94, or AGF154. Cells were incubated from 96 to
120 hours (depending on the cell line) at 37° C in a CO2 incubator. Cell viabilities were
measured with a fluorescence-based viability assay (CellTiter Blue; Promega, Madison, WI) and
a fluorescence plate reader (emission at 590 nm; excitation at 560 nm) to determine drug
concentrations that inhibit growth by 50% (IC50). To confirm the targeted pathways and enzymes,
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proliferation assays were performed with H460 cells treated with PMX, AGF94, or AGF154 in
the presence of adenosine (60 mM), thymidine (10 mM), or AICA (320 mM) (Wang et al., 2011,
2015).
For colony-forming assays, H460 cells (100–150 cells) in log phase were plated into 60mm dishes in folate-free RPMI 1640 medium (pH 7.2), supplemented with 25 nM LCV, 10%
dialyzed fetal bovine serum, 1% penicillin/streptomycin, and 2 mM L-glutamine, and then
allowed to adhere for 24 hours. Cells were then treated with drugs in the aforementioned media
at pH 6.8 or 7.2. For treatments at pH 6.8, 25 mM 1,4-piperazinediethanesulfonic acid/25 mM
HEPES was added (Kugel Desmoulin et al., 2011). After 24 hours, cells were rinsed with PBS,
and then incubated in drug-free, folate-free RPMI 1640 medium (pH 7.2) plus dialyzed fetal
bovine serum and antibiotics, supplemented with 25 nM LCV. After 9 days, the dishes were
washed with PBS, 5% trichloroacetic acid, and then with borate buffer (10 mM, pH 8.8),
followed by 1% methylene blue (in borate buffer). Dishes were again rinsed with borate buffer,
and colonies were counted in order to calculate the percent colony formation relative to the
vehicle (e.g., dimethylsulfoxide) control.
5.2.5 Development of H460 PCFT Knockdown (KD) Cell Line
H460 cells were seeded at 2x105 cells per well in 24-well plates containing RPMI 1640
(pH 7.2), supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and 2 mM Lglutamine, with the addition of 4 mg/ml polybrene and 105 transducing units of MISSION
Lentiviral particles (Sigma-Aldrich) containing shRNA targeting PCFT or a nontargeted control
(NTC) shRNA sequence. After 24 hours, fresh medium including 2 mg/ml puromycin as a
selection marker was added. Confluent cultures were trypsinized and passaged 3 to 4 times in the
presence of 2 mg/ml puromycin, and then plated in 60-mm dishes in complete medium with 2
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mg/ml puromycin at a density of 100 cells/dish to isolate single clones. Clones were picked and
expanded and RNAs were isolated to determine the extent of PCFT knockdown by real-time RTPCR (described previously). Two PCFT KD clones were isolated, designated as KD-3 and KD- 4.
Altogether, five shRNAs were tested, of which only one (TRCN0000437092) gave .50%
knockdown for PCFT.
5.2.6 Gel Electrophoresis and Western Blotting
The NS-NSCLC cell lines were cultured, as described previously. The cells were
disrupted by sonication, cell debris was removed by centrifugation (1800 rpm, 5 minutes), and a
particulate membrane fraction was prepared by centrifugation at 37,000g. The membrane pellet
was solubilized with 1% SDS in 10 mM Tris-HCl (pH 7), containing protease inhibitors (Roche
Diagnostics). Membrane proteins (30 mg) were electrophoresed on 7.5% polyacrylamide gels
with SDS (Laemmli, 1970) and transferred to polyvinylidene difluoride membranes (Thermo
Fisher Scientific, Waltham, MA) (Matsudaira, 1987). To detect PCFT, human PCFT-specific
polyclonal antibody raised in rabbits to a carboxyl termini peptide (Hou et al., 2012) was used,
with IRDye800CW-conjugated goat anti-rabbit IgG secondary antibody (LICOR Biosciences,
Omaha, NE). Membranes were scanned and densitometry was performed with an Odyssey
infrared imaging system (LICOR Biosciences). Protein loading was normalized to levels of β actin using anti-β-actin mouse antibody (Sigma-Aldrich).
5.2.7 Antifolate Transport Assays
Transport assays were performed essentially as described previously (Desmoulin et al.,
2012b; Kugel Desmoulin et al., 2011; Kugel Desmoulin et al., 2010). For transport assays, the
NS-NSCLC cell lines were plated at 30%–40% confluence into 60-mm dishes containing
complete folate-free RPMI 1640 supplemented with 25 nM LCV. After 48 hours, cellular
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uptakes of [3H]PMX and [3H]AGF154 (both at 0.5 mM) were measured over 5 minutes (NSNSCLC cell lines) or 2 minutes (PCFT KD cell lines) at 37°C in 60-mm dishes in MES-buffered
saline (20 mM MES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, and 5 mM glucose; pH 5.5). The
dishes were washed three times with PBS and cells were solubilized in 0.5 N NaOH.
Intracellular radioactivity was calculated as pmol/mg of protein, based on measurements of
radioactivity and protein concentrations of the alkaline cell homogenates. To confirm PCFTmediated transport activity, 10 µM nonradioactive AGF94 was added to the transport incubations
to block uptake.
5.2.8 In Situ GARFTase Enzyme Inhibition Assay
Incorporation of [14C(U)]glycine into [14C]formyl glycinamide ribonucleotide, as an in
situ measure of intracellular GARFTase activity in folate-depleted H460 cells at pH 6.8, was
performed exactly as previously described (Kugel Desmoulin et al., 2010; Wang et al., 2011).
For these experiments, H460 cells were plated in folate-free RPMI 1640 plus 25 nM LCV, 10%
dFBS, 2 mM L-glutamine, and penicillin-streptomycin in 60 mm dishes at 20% confluency.
After 48 h, the media was replaced folate-free, L-glutamine-free RPMI 1640 plus
penicillin/streptomycin, 10% dFBS, 0.46 g/L NaHCO3 and 1.21 g/L NaCl medium, which had
been adjusted to pH 6.8, with antifolates at various concentrations (or DMSO). After 15h, cells
were washed twice with DPBS and the pH 6.8 media was replaced, containing antifolates and 4
µM azaserine and incubated for 30 min. Then, 2 mM L-glutamine and 0.1 mCi/L [14C]glycine
were added, followed by an 8h incubation at 37°C, after which cells were trypsinized and
washed twice with ice-cold DPBS. Cell pellets were treated with 2 ml of 5% trichloroacetic acid
at 0°C for 10 min. Cell debris was removed by centrifugation, and cell debris pellets were
solubilized in 0.5 N NaOH and protein concentrations were determined (Lowry et al., 1951). To
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remove trichloroacetic acid from supernatants, ice-cold ether was used to extract trichloroacetic
acid. The aqueous layer passed through a 1-cm column of AG1x8 (chloride form), 100 to 200
mesh (Bio-Rad Laboratories) washed twice with 0.5 N formic acid and then twice with 4 N
formic acid, and eluted as eight 1-mL fractions with 1 N HCl. Fractions were used to determine
radioactivity. Results were expressed as pmol/mg protein. Drug-treated samples were normalized
to untreated controls to calculate the IC50 values.
5.2.9 In Vivo Antitumor Efficacy of AGF94 Toward H460 Xenografts in SCID Mice
Cultured H460 cells were implanted subcutaneously (107 cells/flank) into female ICR
SCID mice (National Institutes of Health DCT/DTP Animal Production Program, Frederick,
MD) to develop a solid tumor xenograft model (passage 0). Mice were supplied water and food
ad libitum. Study mice were maintained on a folate-deficient diet (TD.00434; Harlan Teklad,
Madison, WI) starting 14 days prior to tumor implant to ensure that serum folate levels
approximated those of humans before the start of therapy (Cherian et al., 2013; Wang et al.,
2010; Wang et al., 2011). Serum folate assays (Varela-Moreiras and Selhub, 1992) were
performed just prior to tumor engraftment and were repeated at the conclusion of the drug
treatments. This design is analogous to those previously published (Alati et al., 1996; Gibbs et al.,
2005).
To test drug efficacy, experimental mice were pooled, divided into groups (five
mice/group), and bilaterally implanted subcutaneously with 30–60 mg H460 tumor fragments,
using a 12-gauge trocar (day 0). Chemotherapy began on day 1 after tumor implantation, when
the number of cells was between 107 and 108 cells (below the limit of palpation). Organic
solvent (ethanol, 5% v/v), carrier (Tween 80, 1% v/v), and sodium bicarbonate (0.5% v/v) were
used to effect solubilization of AGF94, while cisplatin and gemcitabine were dissolved in sterile
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saline. All drugs were administered intravenously using an injection volume of 0.2 ml. Mice
were weighed daily and tumor measurements were determined using a caliper two-to-three times
weekly. Mice were sacrificed when their individual tumor burdens reached 1500 mg
(asymptomatic). Mice were necropsied and tissue was harvested to evaluate potential organrelated toxicities (by H&E staining).
Methods for protocol design, drug treatments, toxicity evaluation, and data analysis were
previously described (Corbett et al., 1998; Corbett et al., 1997; Polin et al., 2011; Polin et al.,
1997). Experimental parameters as qualitative and quantitative end points to assess antitumor
activities include: T/C (as a percentage) and T–C (tumor growth delay) [where T is the median
time (days) required for the treatment group tumors to reach a predetermined size (e.g., 1000 mg)
and C is the median time (days) for the control tumors to reach the same size; tumor-free
survivors are excluded from these calculations]; and tumor cell kill [log10 cell kill total (gross) 5
(T–C)/(3.32)(Td), where (T–C) is the tumor growth delay, as described previously, and Td is the
tumor volume doubling time (days), estimated from the best-fit straight line from a log-linear
growth plot of control group tumors in exponential growth (100–800 mg)]. For comparisons of
antitumor activities with standard agents or between tumors, log10 kill values were converted to
an arbitrary activity rating (Corbett et al., 1997). With the exception of the H460 xenograft cell
line and the drugs used in treatment, these methods are identical to those described previously
(Cherian et al., 2013; Wang et al., 2010; Wang et al., 2011; Wang et al., 2015).
5.2.10 Statistical Analysis
Descriptive statistical tests (e.g., t tests) were conducted using GraphPad 6.0 software (La
Jolla, CA).
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5.3 Results
5.3.1 Expression Profiles for Folate Transport and Metabolism Genes in NS-NSCLC
Patient Specimens
To begin to identify key determinants of antitumor efficacy of the 2’,4’, and 2’,5’
thienoyl pyrrolo[2,3-d]pyrimidine antifolates AGF94 and AGF154 (Figure 1.2) toward NSNSCLC, we measured PCFT transcripts (by real-time RT-PCR) and proteins (by IHC) in NSNSCLC and unmatched (i.e., from different patients) normal lung specimens (Figure 5.1).
Clinical specimens were obtained from different commercial sources such that PCFT gene
expression and protein levels could not be directly compared for individual samples.
PCFT transcripts were similarly expressed (based on median values) in 26 NS-NSCLC
and 8 normal lung specimens, although the range was much broader in the former (16- versus 3fold, respectively) (Figure 5.1A). By IHC, PCFT proteins were substantially increased (3.8-fold)
in NS-NSCLC specimens (n = 61) over normal lung (n = 10) (P < 0.001) and again showed a
broad expression pattern (~150-fold for NS- NSCLC and ~4-fold for normal lung, respectively)
(Figure 5.1G-H). Representative IHC sections for NS-NSCLC specimens expressing low,
intermediate, and high PCFT levels are shown in Figure 5.2C. For both RT-PCR and IHC
analyses, there were no significant changes in PCFT levels with tumor stage.
Transcript levels for other genes relevant to antitumor efficacy of this series of
compounds were also measured in the clinical specimens, including folate transporters (RFC,
FRα) and metabolism enzymes (TS, GARFTase, and FPGS) (Figure 5.1B-F). Transcripts for all
these genes were detected. Transcript levels were increased in NS-NSCLC (n = 26) compared
with normal lung (n = 8) for TS (median 2.25-fold increased; P < 0.015) and GARFTase (median
~2-fold increased; P < 0.0001). Slightly decreased median RFC transcript levels (2.64-fold; P <
0.016) were measured in the NS-NSCLC specimens. Although median FRα and FPGS levels
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Figure 5.1 PCFT expression in primary NS-NSCLC and normal lung specimens. Panels AF, Results for quantitative real-time RT-PCR are shown for 26 NS-NSCLC and 8 normal lung
specimens (Origene). Gene transcript levels were normalized to transcript levels for β-actin. The
median value for the normal lung specimens was assigned a value of 1. Panels G and H, IHC
results are shown for 61 NS-NSCLC and 10 normal lung tissues from a tissue microarray (TMA)
(US Biomax, Inc.). The TMA was incubated with affinity-purified PCFT-specific antibody or
rabbit IgG, and the slides were developed, counterstained, and mounted, as described in
Materials and Methods. Representative images are shown in (Panel H) for IgG and for three NSNSCLC specimens with low-, intermediate-, and high-level staining (left to right). The slides
were scanned by an Aperio Image Scanner (Aperio Technologies, Inc.) for microarray image
scanning. The total positive cell numbers and intensity of antibody staining of each tissue core
were computed and are shown in Panel G. The median value for the normal lung specimens was
assigned a value of 1. Statistical significance between the groups was analyzed by the student’s t
test. An asterisk indicates a statistically significant difference between the median NS-NSCLC
value and the median value for the normal lung specimens (p < 0.001). Figure previously
published in Wilson et. al. Mol Pharmacol. 2016.
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Figure 5.2 PCFT expression and function in NS-NSCLC cell lines. Panels A-F, Results are
shown for gene transcript levels measured by real-time RT-PCR in NS- NSCLC cell lines (A549,
H1437, H460, H1299, H1650, and H2030). Gene transcript levels were normalized to transcript
levels for β-actin. The gene transcript level for the HeLa cell line was assigned a value of 1.
Results are shown as mean ± S.E. values from triplicate experiments. Panel G, Particulate
membrane fractions were prepared as described in Materials and Methods. Membrane proteins
(30 mg) from human tumor cell lines were electrophoresed on a 7.5% polyacrylamide gel and
immunoblotted with human PCFT polyclonal antibody. β-actin levels were used as loading
controls. Densitometry was performed using Odyssey software, and PCFT protein expression
was normalized to β-actin. Normalized densitometry results (as an average from three
experiments) are shown. Panels H and G, NS-NSCLC cells (in 60-mm dishes) were treated with
0.5 mM [3H]PMX or [3H]AGF154 at pH 5.5 and 37°C for 5 minutes (black bars).
Nonradioactive AGF94 (10 mM) was added to competitively block PCFT-mediated uptake as a
negative control for PCFT transport (white bars). Internalized pmol values of [3H]PMX or
[3H]AGF154 were normalized to total cell proteins and expressed as pmol/mg. Histograms show
mean 6 S.E. values from triplicate experiments. Figure previously published in Wilson et. al.
Mol Pharmacol. 2016.
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were unchanged between NS-NSCLC and normal lung specimens, the range was much broader
for the tumors (from 13-fold for FPGS and ~2000-fold for FRα, compared with 2- to 3-fold for
normal lung for both FPGS and FRα). Collectively, these results establish high-level expression
of PCFT in NS-NSCLC, along with appreciable expression of other folate-related genes.
Although FRα is expressed in NS-NSCLC, its levels were highly variable.
5.3.2 Expression Profiles for Folate Transport and Metabolism Genes in NS-NSCLC Cell
Lines
We extended our gene expression analysis to NS-NSCLC cell lines, including A549,
H1437, H460, H1299, H1650, and H2030. For these experiments, HeLa cells were used as a
positive control since HeLa cells express abundant RFC and PCFT accompanying low levels of
FRα (Kugel Desmoulin et al., 2011). PCFT was expressed in the six NS-NSCLC cell lines over a
~13-fold range, with the highest transcript levels in A549 cells and a very low level in H1299
cells (Figure 5.2A). Correlations between levels of PCFT transcripts by real-time RT-PCR and
PCFT proteins on western blots probed with PCFT antibody (Figure 5.2G) were inexact. For
H1299 cells, PCFT protein was undetectable. FRα was undetectable in five out of six of the NSNSCLC cell lines, the only exception being the H1437 cell line (expresses ~9% of the FRα levels
in HeLa cells) (Figure 5.3A). RFC, TS, GARFTase and FPGS transcripts were expressed at
similar levels among the various NS-NSCLC cell lines (Figure 5.2B-F).
5.3.3 PMX and AGF154 Transport by PCFT in NS-NSCLC Cell Lines
The 5-substituted pyrrolo[2,3-d]pyrimidine antifolate PMX is a transport substrate for
both RFC and PCFT (Matherly et al., 2014). Unlike PMX, the 6-pyrrolo[2,3-d] pyrimidine
thienoyl analogs AGF94 and AGF154 are highly selective transport substrates for PCFT over
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Figure 5.3 In vitro characterization of PMX, AGF94 and AGF154 of NS-NSCLC cell lines.
Panel A, NS-NSCLC cells were seeded in 96-well plates at 1500–4000 cells/ well in complete
folate-free RPMI 1640 (pH ~7.2), 10% dialyzed fetal bovine serum, and 25 nM LCV. Cells were
incubated with varying concentrations of PMX, AGF94, or AGF154 from 1 to 1000 nM for 4 to
5 days, depending on the cell line. Cell viabilities were determined with a fluorescence-based
assay (Cell Titer Blue). Mean IC50 6 S.E. values from triplicate experiments were determined
graphically for each drug. Asterisks designate statistically greater sensi- tivity for AGF94
compared with PMX (P , 0.01). Panels B-D, H460 cells were seeded in the presence of 0-1000
nM PMX, C1 or C2, with or without additions of 60 µM adenosine, 320 µM 5-aminoimidazole4-carboxamide (AICA), 10 µM thymidine, or adenosine plus thymidine. Cell viabilities were
determined with a fluorescence-based assay (Cell Titer BlueTM). Panel E, Incorporation of
[14C(U)]glycine into [14C]formyl glycinamide ribonucleotide (GAR) as an in situ measure of
endogenous GARFTase was determined. For the GARFTase assays, IC50 values were 78.9 nM
and 27.1 nM for C1 and C2, respectively. For PMX, the IC50 value was >1000 nM. Experimental
details are described in Materials and Methods. For Panels A-E, the plots show mean values ±
standard errors and represent triplicate experiments. Panels F and G, H460 cells (100–150 cells)
were plated in 60-mm dishes in complete folate-free RPMI 1640 (pH 7.2), 10% dialyzed fetal
bovine serum, and 25 nM LCV. After 24 hours, cells were then treated with PMX, AGF94, or
AGF154 at varying concentrations in complete folate-free RPMI 1640 (at pH 7.2 or 6.8)
supplemented with 25 nM LCV. After an additional 24 hours, cells were rinsed with PBS, and
then incubated in complete folate-free RPMI 1640 supplemented with 25 nM LCV (pH 7.2) for 9
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days. Colonies were stained with methylene blue and counted, and colony numbers were
normalized to the controls. Plots show mean ± S.E. values, representative of triplicate
experiments. Figure previously published in Wilson et. al. Mol Pharmacol. 2016.
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RFC, although both are also FRα substrates (Cherian et al., 2013; Desmoulin et al., 2012b; Wang
et al., 2011; Wang et al., 2015). To demonstrate that the PCFT proteins detected on western blots
in A549, H1437, H460, H1650, and H2030 NS-NSCLC cell lines could transport [3H] PMX and
[3H]AGF154, we measured cellular uptake of these compounds (both at 0.5 µM; 5 minutes;
37°C) at pH 5.5, the PCFT pH optimum. An excess (10 µM) of unlabeled AGF94 was added as a
competitive inhibitor of PCFT to confirm the PCFT- specific uptake component.
The NS-NSCLC cell lines accumulated [3H]PMX and [3H]AGF154 over 5 minutes to
generally similar extents (Figure 5.2H-I), but only partially reflected levels of PCFT proteins
(Figure 5.2G). For instance, PCFT proteins were generally proportional to transport of both
[3H]PMX and [3H]AGF154 for the H1437, H460, H1299, H1650, and H2030 cell lines; however,
transport was disproportionately low for A549 cells. For both [3H]PMX and [3H]AGF154,
uptake was blocked (~80%–95%) by nonradioactive AGF94. For PCFT-selective [3H]AGF154,
uptake for five of the NS-NSCLC cell lines far exceeded the low residual level measured in the
H1299 cells (P < 0.05).
5.3.4 Antiproliferative and Cytotoxic Activities of AGF94 and AGF154 Toward NS-NSCLC
Sublines Reflect Inhibition of GARFTase in De Novo Purine Nucleotide Biosynthesis
To evaluate the antiproliferative potencies of the 6-substituted pyrrolo[2,3-d]pyrimidine
thienoyl antifolates AGF94 and AGF154 compared with PMX toward the NS-NSCLC cell lines,
we performed cell outgrowth assays. Cells were treated in the presence of the drugs for 4 to 5
days and cell proliferation was assayed with a fluorescence-based assay (i.e., CellTiter Blue) to
calculate the IC50 values corresponding to drug concentrations that inhibit growth by 50%. Under
these conditions, the pH of the culture medium decreased to ~pH 6.7–6.8 (Kugel Desmoulin et
al., 2010). The NS-NSCLC cell lines were sensitive to AGF94 and AGF154 (Figure 5.3A), with
AGF94 IC50 values ranging from 45 nM (H1437) to 230 nM (H1299), and AGF154 IC50s
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ranging from 79 nM (H1437) to 288 nM (H1299). The PMX IC50 values ranged from 43 nM
(H1437) to 163 nM (H2030). Interestingly, the A549, H460, and H2030 cell lines were all more
sensitive to AGF94 than to PMX (p < 0.05). Resistance of the H1299 cell line to AGF94 and
AGF154 likely reflects the lack of detectable PCFT protein (Figure 5.2G) and limited PCFT
transport (Figure 5.2H-I). Although [3H]PMX uptake by PCFT was also low in H1299 cells
(Figure 5.2H), this was not manifested as PMX resistance (Figure 5.3A), likely reflecting RFC
transport of PMX (Matherly et al., 2014).
For additional experiments, we used H460 NS-NSCLC cells, reflecting their moderate
and proportional level of PCFT protein and transport (Figure 5.2G-I). In H460 cells, AGF94 and
AGF154 inhibited de novo purine nucleotide biosynthesis at the step catalyzed by GARFTase, as
reflected in protection from growth inhibition by adenosine (60 µM) and AICA (320 µM), but
not by thymidine (10 µM) (Figure 5.3C-D). GARFTase inhibition in H460 cells was confirmed
with a cell-based in situ assay that measures [14C(U)]glycine incorporation into the GARFTase
product, [14C]formyl glycinamide ribonucleotide (Figure 5.3E) (Kugel Desmoulin et al., 2010;
Wang et al., 2011; Wang et al., 2015). IC50 values for in situ GARFTase inhibition of 78.9 and
27.1 nM were measured for AGF94 and AGF154, respectively. AGF94 and AGF154 have been
previously described as GARFTase inhibitors in other tumor models (Wang et al., 2011; Wang et
al., 2015). By in vitro assays with isolated GARFTase, Ki values of 68 nM for AGF94 and 11
nM for AGF154 have been previously reported (Wang et al., 2015), paralleling IC50 values from
the in situ GARFTase assays in H460 cells.
We assessed cytotoxicity resulting from exposure of H460 cells to AGF94, AGF154, or
PMX, following treatment with drugs (0.1–10 µM) for 24 hours at pH 6.8 or 7.2 (approximating
the microenvironment pH of many solid tumors and normal tissues, respectively) (Gallagher et
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al., 2008; Gillies et al., 2002; Webb et al., 2011). Cells were then washed with PBS and
incubated in drug-free medium for 9 days (at neutral pH), at which time colonies were stained
with methylene blue and counted. Both AGF94 and AGF154 showed a steep concentrationdependent decrease in colony formation following drug treatments at pH 6.8, with a complete
loss of clonogenicity at 10 µM (Figure 5.3F). Conversely, while PMX was more active than
AGF94 or AGF154 at 0.1 µM, the dose-response relationship for PMX at pH 6.8 was shallow
and incomplete (~10%), even at 10 µM drug. However, following treatment at pH 7.2, PMX
showed a dramatically enhanced dose-responsive decrease in colony formation, whereas AGF94
and AGF154 showed progressively impaired responses (Figure 5.3G). These results demonstrate
selective antitumor efficacy of the novel 6-substituted pyrrolo [2,3-d]pyrimidine antifolates
AGF94 and AGF154 compared with PMX at a pH characterizing the tumor microenvironment
versus neutral pH typical of most normal tissues. Collectively, these studies establish that
AGF94 and AGF154 are cytotoxic toward H460 NS-NSCLC cells associated with inhibition of
GARFTase and de novo purine nucleotide biosynthesis.
5.3.5 Impact of Knockdown of PCFT on PMX and AGF154 Transport and Antitumor
Drug Efficacy
The results shown in Figure 5.2H and I demonstrate that both [3H]PMX and [3H]AGF154
are transported by PCFT into the NS-NSCLC cell lines. However, PMX (unlike AGF154) is also
transported by RFC (Matherly et al., 2014). To directly examine the impact of this apparent
transport redundancy by PCFT and RFC on PMX cellular uptake and antitumor efficacy
compared with AGF94 and AGF154, we tested five lentiviral shRNAs for knockdown of PCFT
in H460 NS-NSCLC cells. For the shRNA construct with the greatest knockdown, two clonal
PCFT KD cell lines, KD-3 and KD-4, were developed, both of which showed significant loss of
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PCFT gene expression (~2.7- and ~3.3-fold decreases, respectively), compared with NTC cells
or wild-type (i.e., nontransduced) H460 cells (Figure 5.4A). PCFT protein levels were also
reduced in KD-3 and KD-4 sublines (29% and 19% of the NTC level by densitometry) (Figure
5.4B). There were no significant differences in transcript levels for RFC, TS, GARFTase, and
FPGS between KD and NTC cells (data not shown), suggesting no significant off-target effects.
Furthermore, there were no significant differences in rates of cell proliferation between KD and
NTC cells (data not shown).
We also measured PCFT-specific transport activity for KD-3 and KD-4 cells with
[3H]PMX and [3H]AGF154 (both at 0.5 mM) over 2 minutes at 37°C and pH 5.5 in the presence
and absence of 10 mM nonradioactive AGF94 (Figure 5.4C and D, respectively). PCFTselective uptake for both substrates decreased in KD-3 and KD-4 cells compared with the NTC
(~70% and ~80% for [3H] AGF154 and [3H]PMX, respectively, calculated from the difference
with and without AGF94 competitor), paralleling changes in PCFT transcripts and proteins.
To extend these studies to analyses of drug sensitivities, we assessed in vitro antitumor
efficacies of PMX, AGF94, and AGF154 toward KD-3 and KD-4, compared with NTC and
wild-type H460 cells. Results were compared with those for PT523, a RFC-selective antifolate
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Figure 5.4 Characterization of H460 PCFT KD cells. Panel A, Real-time RT-PCR was used to
measure transcript levels for PCFT in H460 wild-type (WT), NTC, KD-3, and KD4 cells.
Transcript levels were normalized to β-actin and results are presented relative to those for WT
H460 cells (assigned a value of 1). Results are expressed as mean ± S.E. values and represent
triplicate experiments. The asterisks indicate a statistically significant difference between the
PCFT KD gene expression and that for the NTC cells (p < 0.05). Panel B, H460 particulate
membrane fractions were isolated as described in Materials and Methods. Membrane proteins
(30 mg) from WT, NTC, KD-3, and KD4 H460 cell lines were electrophoresed on a 7.5%
polyacrylamide gel and immunoblotted with PCFT antibody. β-actin protein levels were used as
loading controls. Densitometry was measured using Odyssey software, and PCFT protein
expression was normalized to β-actin. Normalized densitometry results (average from four
experiments) are noted below each lane. Panels C and D, WT, NTC, KD-3, and KD-4 H460
cells (in 60-mm dishes) were incubated with 0.5 mM [3H]PMX and [3H]AGF154 at pH 5.5 and
37°C, with or without 10 mM nonradioactive AGF94 for 2 minutes. Internalized [3H]PMX or
[3H]AGF154 was normalized to total cell protein and results calculated as pmol/mg. Uptake
results are presented as relative uptake with WT H460 cells assigned a value of 100%. Results
are expressed as mean ± S.E. values, representative of triplicate experiments. The asterisks
indicate a statistically significant difference between the PCFT transport activity in the KD (KD-
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3 and KD-4) cells and that of the NTC cells (p < 0.05). Panel E, The H460 sublines including
WT, NTC, KD-3, and KD-4 H460 cells were cultured in complete folate-free RPMI 1640 with
25 nM LCV in 96-well plates at 1500 cells/well with varying concentrations of PMX, AGF94,
AGF154 (left panel), or PT523 (right panel) for 4 days. Viable cells were measured by a
fluorescence-based assay (Cell Titer Blue) and IC50 values were determined graphically. Results
are expressed as mean IC50 ± S.E. values from triplicate experiments (the asterisk indicates
where IC50 values for PCFT KD cells are significantly greater than for NTC; p < 0.05). Figure
previously published in Wilson et. al. Mol Pharmacol. 2016.

126
with no PCFT transport activity (Rosowsky et al., 1994; Wang et al., 2010). Both KD and NTC
cells were highly sensitive to the growth inhibitory effects of PT523 (Figure 5.4E, right panel).
In contrast, the IC50 values in the KD cells were significantly increased for both AGF94 (2.7- and
3.0-fold increases for KD-3 and KC-4, respectively) and AGF154 (1.7- and 2.3-fold increases for
KD-3 and KC-4, respectively) (Figure 5.4, left panel). This further establishes the reliance on
PCFT membrane transport for AGF94 and AGF154 drug efficacy. For PMX, a similar, albeit
lesser, impact on drug sensitivity was observed for KD-3 and KD-4 cells (1.2- and 1.8-fold
decreases, respectively) (Figure 5.4E, left panel), suggesting a reduced dependence on PCFT
transport for PMX antitumor efficacy, likely reflecting its RFC substrate activity.
5.3.6 Effects of AGF94 on NS-NSCLC Tumor Growth In Vivo
To assess antitumor effects of AGF94 in the context of NS-NSCLC in vivo, we
performed antitumor efficacy studies with 8-week-old female ICR SCID mice implanted
subcutaneously with H460 tumor fragments. Mice were maintained ad libitum on a folatedeficient diet in order to decrease serum folates to levels approximating those seen in humans
(Alati et al., 1996; Wang et al., 2010; Wang et al., 2011; Wang et al., 2015). Control and drug
treatment groups were nonselectively randomized (five mice/group), and AGF94 (32 mg/kg),
gemcitabine (125 mg/kg), or cisplatin (2.4 mg/kg) was administered intravenously on days 1, 5,
9, and 13 after tumor implantation. Treatment regimens were based on the efficacious dose range
for each of the drugs (i.e., the highest nontoxic total dose range), as tolerated by SCID mice on
an every fourth day for four times schedule [the in-house highest nontoxic total dose ranges were
as follows: AGF94 (96–160 mg/kg); gemcitabine (450–750 mg/kg), and cisplatin (8–12 mg/kg)].
Mice were observed and weighed daily; tumors were measured two-to-three times per week.
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Figure 5.5 Analysis of in vivo efficacy of AGF94. An in vivo efficacy trial of AGF94 in H460
xenografts was performed. Female ICR SCID mice were maintained on a folate-deficient diet ad
libitum. Human H460 tumors were implanted bilaterally and subcutaneously, and mice were
nonselectively randomized into five mice per group. AGF94 [32 mg/kg injection, dissolved in
5% ethanol (v/v), 1% Tween 80 (v/v), and 0.5% NaHCO3], gemcitabine (125 mg/kg injection,
dissolved in 0.9% saline), and cisplatin (2.4 mg/kg injection, dissolved in 0.9% saline) were
administered on a schedule of every 4 days for four intravenous treatments on days 1, 5, 9, and
13 (indicated by arrows). Mice were observed and weighed daily; tumors were measured 2 to 3
times per week. On day 16, T/C values equaled 11%, 26%, and 28% for AGF94, gemcitabine,
and cisplatin, respectively. Antitumor activities were recorded for AGF94 (T–C = 9 days; 1.9
gross log10 kill), gemcitabine (T–C = 7 days; 1.5 gross log10 kill), and cisplatin (T–C = 8 days,
1.7 gross log10 kill). Data are shown for the median tumor burdens of each treatment group.
Figure previously published in Wilson et. al. Mol Pharmacol. 2016.
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AGF94 showed greater efficacy toward H460 xenografts (T/C 5 11%; T–C 5 9 days; 1.9
gross log10 kill) than either cisplatin (T/C 5 28%; T–C 5 8 days; 1.7 gross log10 kill) or
gemcitabine (T/C 5 26%; T–C 5 7 days; 1.5 gross log10 kill) (Figure 5.5). The drugs appeared to
be well tolerated and there was no drug-related lethality. Minimal adverse toxicities occurred and
there was no evidence of organ-related toxicities. The only dose-limiting symptom was weight
loss. For cisplatin and gemcitabine, mice sustained weight losses of 19.8% with a nadir on days
20–22, and 5.9% with a nadir on day 15, respectively. Full recovery did not occur prior to
sacrifice due to the mice reaching the tumor burden limit [94% weight recovery for cisplatin
within 4 days postnadir (day 26) and 99% weight recovery for gemcitabine 9 days postnadir (day
24)]. For AGF94, 14% maximal weight loss was measured on day 7 post-treatment, with full
weight recovery by day 16. These results demonstrate potent in vivo efficacy of AGF94 toward
H460 lung cancer xenografts.
5.4 Discussion
The potential utility of the 2’,4’, and 2’,5’ thienoyl pyrrolo [2,3-d]pyrimidine antifolates,
AGF94 and AGF154, for selective targeting of ovarian cancer and malignant mesothelioma via
FRα and/or PCFT over RFC, has been previously reported (Cherian et al., 2013; Wang et al.,
2011; Wang et al., 2015). In this chapter, we extended this work to NS-NSCLC, a disease for
which PMX is heavily used in both first-line and maintenance therapies (Genova et al., 2013;
Gerber and Schiller, 2013; Tomasini et al., 2013). However, only about one-third of patients with
NS-NSCLC respond to PMX, such that the median progression-free survival is only ~6 months
in the front-line setting, when combined with platinum, and ~4 months as a single agent in
patients with recurrent NS-NSCLC (Esteban et al., 2009).
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Our investigation of NS-NSCLC clinical specimens and cell lines established that PCFT
transcripts and proteins are significantly expressed in NS-NSCLC, along with RFC and FRα.
PCFT protein levels were increased in primary NS-NSCLC over normal lung specimens,
although there was no association of PCFT levels with tumor stage. In our analysis, FRα
transcripts were variably expressed in primary NS-NSCLC, and FRα was detected in only one of
the NS-NSCLC cell lines (H1437). A wide range of FRα expression in NSCLC has been
previously reported (Christoph et al., 2013; Nunez et al., 2012; O'Shannessy et al., 2012)
suggesting that a subset of these patients might be amenable to FR-targeted therapies (Assaraf et
al., 2014; Vergote and Leamon, 2015), whereas patients with lower FRα levels might be better
treated with other therapies.
We demonstrated high levels of PCFT transport in five out of six NS-NSCLC cell lines,
using radiolabeled PMX and AGF154 as surrogate substrates, accompanying detection of PCFT
transcripts and proteins. Correlations between levels of PCFT transcripts and proteins, or
between PCFT proteins and transport activity, were inconsistent for the NS-NSCLC cell lines,
suggesting involvement of post-transcriptional and post-translational regulatory mechanisms.
Similar results were previously reported for PCFT (Kugel Desmoulin et al., 2011) in a disparate
panel of human tumor cell lines, implying a post-translational regulation of PCFT. For H1299
NS-NSCLC cells, a lack of detectable PCFT protein was accompanied by very low levels of
transport activity. PCFT transport of PMX and AGF154 in H460 cells was further confirmed by
PCFT knockdowns. Although in vitro AGF94 and AGF154 antitumor efficacies were
significantly decreased in the PCFT KD cells, this effect was reduced for PMX, likely reflecting
transport promiscuity for PMX with both PCFT and RFC.
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PCFT transport of AGF94 and AGF154 into H460 cells was accompanied by inhibition
of cellular GARFTase in de novo purine nucleotide biosynthesis, and resulted in inhibition of
cell proliferation, even at comparatively neutral pH levels. Growth inhibition, as reflected in IC50
values, was generally on par with that for PMX, although increased sensitivity was measured for
AGF94 toward A549, H460, and H2030 NS-NSCLC cells. The basis for this is unclear. In vivo
AGF94 efficacy against an H460 tumor xenograft was also demonstrated, with T/C, T–C, and
log10 cell kill values modestly superior to those for cisplatin and gemcitabine. These results
provide proof-of-principle validation of our in vitro findings that antitumor effects of targeted
AGF94 may be equally potent, if not more potent, than standard chemotherapies used to treat
NS-NSCLC. Unfortunately, direct in vivo comparisons of AGF94 efficacy with PMX were not
possible due to elevated serum thymidine in mice, which circumvents antitumor efficacy of TS
inhibitors in the presence of thymidine kinase (van der Wilt et al., 2001).
The results of colony-forming assays with H460 cells treated with AGF94 and AGF154
at pH 6.8, conditions that approximate the pH of the tumor microenvironment (Gallagher et al.,
2008; Gillies et al., 2002; Webb et al., 2011)and favor PCFT over RFC transport, were of
particular interest. At pH 6.8, cytotoxicity for the 6-pyrrolo[2,3-d]pyrimidines AGF94 and
AGF154 was clearly evident, whereas for PMX cytotoxicity was modest and incomplete up to 10
mM drug. Conversely, PMX treatment at pH 7.2 potently inhibited clonogenicity, with
progressively reduced effects for AGF94, followed by AGF154. Thus, our results document
selective antitumor efficacies of the novel 6-substituted pyrrolo [2,3-d]pyrimidine antifolates
AGF94 and AGF154 compared with PMX at a pH characterizing the tumor microenvironment
versus a neutral pH characteristic of most normal tissues. Accordingly, transport specificities of
AGF94 and AGF154 for PCFT over RFC should confer selectivity for tumors including NS-
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NSCLC cells that express PCFT, which would be augmented by increased transport activity in
the acidic microenvironment typical of many tumors. By this reasoning, PMX might be expected
to show greater cytotoxicity than AGF94 or AGF154 toward normal tissues, where RFC
transport prevails over PCFT and neutral pH favors RFC transport. As previously noted, since a
subset of NS-NSCLC specimens also express significant FRα (Christoph et al., 2013; Nunez et
al., 2012; O'Shannessy et al., 2012), increased tumor targeting of AGF94 and AGF154 via FRα
in addition to PCFT (Wang et al., 2015; Webb et al., 2011) may also occur. The net effect of
these targeted therapies would be increased killing of tumors, while decreasing toxicity toward
normal tissues.
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CHAPTER 6- EFFECTS OF FLUORINATION ON ANTI-TUMOR EFFICACY OF
NOVEL 6-SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINE ANTIFOLATES
6.1 Introduction
In recent years, there has been in interest in treating ovarian cancer with folate receptortargeted agents (see Chapter 1.6.6) (Lorusso et al., 2012; Naumann et al., 2013; Siegel et al.,
2003). FRα has been shown to be overexpressed in ovarian cancers, with the expression level
correlating with histological grade (Buist et al., 1995; Garin-Chesa et al., 1993; Siu et al., 2012;
Toffoli et al., 1997; Veggian et al., 1989). Ovarian cancer is the most lethal of gynecological
cancers, with an estimated 22,280 new cases and 14,240 deaths resulting from ovarian cancer in
the United States in 2016 (Siegel et al., 2016). The 5-year survival rate is only 10-25% for
epithelial ovarian cancer patients, and this disease often recurs after initial treatment (Siegel et
al., 2016). Beyond platinum-based therapies, against which many tumors can develop resistance,
clinicians have few treatment options at their disposal (Temkin et al., 2016).
Recently, there has been an interest in the development of FRα-targeted therapies for the
treatment of ovarian cancer (see Chapter 1.6.6). FRα shows an increased expression in a subset
of ovarian cancer patients (Elnakat and Ratnam, 2004; Leamon et al., 2013; Toffoli et al., 1997;
Vergote et al., 2015). While FRα is only expressed on the apical membrane of normal ovarian
epithelial cells, in ovarian tumor cells FRα is exposed to the circulation, creating an opportunity
for tumor targeting via FRα uptake (Assaraf et al., 2014; Vergote et al., 2015). Additionally, our
laboratory recently described a substantial expression of PCFT protein in ovarian cancer patients
(Z. Hou and L. H. Matherly, manuscript submitted), suggesting a potential for PCFT-targeted
therapies for ovarian cancer.
Progress has been made in the development of tumor-targeted antifolate molecules based
on their selective transport by FRs and PCFT over RFC. Previously, we described the 6-
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substituted pyrrolo[2,3-d]pyrimidine benzoyl L-glutamate antifolates AGF17 and AGF23 (Figure
6.1) as GARFTase inhibitors which are transported by PCFT and FRα more favorably than RFC
(see Chapter 1.6.7) (Deng et al., 2008; Gangjee et al., 2005; Gangjee et al., 2004; Kugel
Desmoulin et al., 2010). Replacements of the side-chain benzoyl group with a thiophene resulted
in novel compounds AGF150 and AGF117, respectively (Figure 6.1) (Wang et al., 2012; Wang
et al., 2015), related to our lead compound AGF94 (see Chapter 5), while replacement of the
benzoyl moiety of AGF23 by a pyridine resulted in AGF107 (Figure 6.1) (C. George and L. H.
Matherly, unpublished). We previously described potent antitumor efficacy by our lead
compound AGF94 (see Chapter 5) toward ovarian cancer cell lines in vitro as well as in vivo
(Wang et al., 2011; Wang et al., 2015) (Z. Hou and L. H. Matherly, manuscript submitted).
AGF117, AGF150, and AGF107, like AGF17, AGF23, and AGF94 are all selective for PCFT
and FR cellular uptake over RFC.
In this chapter, we describe further modifications to these novel antifolate compounds
through the addition of fluorine to the side-chain benzoyl and thionyl groups. Fluorine
modifications of drugs have ample precedent and can improve potency and impact selectivity of
drugs by altering pKa, lipophilicity and hydrophobic interactions, modifying conformation, or
any combination of these possibilities (Gillis et al., 2015). Additionally, fluorine-labeled
antifolates have potential clinical applications as theranostic agents, as PET imaging using
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F-

labeled drugs can provide valuable tumor imaging data, as well as providing a measurement of
drug uptake for individual patients (Basu and Alavi, 2016). In this chapter, we describe five
novel antifolates containing fluorine ring substitutions and studies of their specificities for RFC,
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Figure 6.1 Structures of novel fluorinated antifolates. Structures are shown for both
previously established parent compounds (AGF17, AGF23, AGF107, AGF117 and AGF150)
and novel fluorinated compounds (AGF264, AGF270, AGF277, AGF278, AGF283). All
compounds were synthesized by Dr. Aleem Gangjee of Duquesne University in collaboration
with Dr. Larry Matherly.
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PCFT and FRα/β targeting compared to the corresponding parent compounds AGF17, AGF23,
AGF107, AGF117 and AGF150 (Figure 6.1). Among the new molecules, AGF278 emerged as
an antifolate with high potency and great specificity for PCFT and FRα activity over RFC. This
compound may prove to be an effective treatment for ovarian cancer patients, reflecting its
potency and dual targeting via FRα and PCFT.
6.2 Materials and Methods
6.2.1 Reagents
[3’,5’,7-3H]MTX (20 Ci/mmol) [3’, 5’, 7, 9-3H], folic acid (25 Ci/mmol), and [14C(U)]glycine (87 mCi/mmol) were purchased from Moravek Biochemicals (Brea, CA). Unlabeled
folic acid was purchased from Sigma-Aldrich (St. Louis, MO). LCV [(6R,S)5-formyl
tetrahydrofolate] was provided by the Drug Development Branch, National Cancer Institute
(Bethesda, MD). MTX was supplied by the Drug Development Branch, National Cancer
Institute.

PMX

[N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-

yl)ethyl]benzoyl]-L-glutamic acid] (Alimta) was provided by Eli Lilly and Co. (Indianapolis,
IN). PT523 [N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine] was a gift
from A. Rosowsky (Boston, MA). The 6-substituted pyrrolo[2,3-d]pyrimidine antifolates,
including AGF17, AGF23, AGF94, AGF107, AGF117, AGF150, AGF264, AGF270, AGF277,
AGF278 and AGF283, were all synthesized by Dr. Aleem Gangjee and colleagues at Duquesne
University (Pittsburgh, PA) (Figure 6.1). Other chemicals were obtained from commercial
sources in the highest available purities.
6.2.2 Cell Lines
The engineered CHO sublines including RFC-, PCFT- and FRα-null MTXRIIOuaR2-4
(R2), and RFC- (pC43-10), PCFT- (R2/PCFT4), or FRα- (RT16) and FRβ- (D4) expressing
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CHO sublines were previously described (Deng et al., 2008; Deng et al., 2009; Flintoff et al.,
1976; Flintoff and Nagainis, 1983; Wong et al., 1995). The CHO cells were grown in α-minimal
essential medium (MEM) supplemented with 10% bovine calf serum (Invitrogen, Carlsbad, CA),
L-glutamine (2 mM), penicillin (1000 U/ml), and streptomycin (1000 µg/ml) at 37° C with 5%
CO2. R2 transfected cells (PC43-10, RT16, R2/hPCFT4) were cultured in complete α-MEM
media plus G418 (1 mg/ml). Prior to the proliferation assays, RT16 and D4 cells were cultured in
complete folate-free RPMI 1640 (without added folate), plus 10% dialyzed fetal bovine serum
(FBS) (Sigma-Aldrich) and penicillin/streptomycin for 3 days. HeLa R1-11-FR2 and R1-11PCFT4 cells were derived from RFC- and PCFT-null R1-11 cells by stable transfection with
FRα-pcDNA3.1 and pZeoSV2(+)-PCFT constructs, respectively (Zhao et al., 2009b; Zhao et al.,
2008). These HeLa sublines, along with R1-11 cells, were gifts from Dr. I. David Goldman
(Albert Einstein School of Medicine, Bronx, NY). The R1-11-RFC2 cell line was developed in
our laboratory by transfection with the pZeoSV2-RFC vector and clonal selection, as previously
described (Wang et al., 2015). R1-11-RFC2, -PCFT4 and -FR2 sublines were routinely cultured
in folate-free RPMI 1640 medium, supplemented with 10% FBS (Sigma-Aldrich), L-glutamine,
penicillin-streptomycin solution, and 100 µg/ml Zeocin.
IGROV1 (Benard et al., 1985) and A2780 (Johnson et al., 1994) ovarian carcinoma cells
were a gift of Dr. Manohar Ratnam (Karmanos Cancer Institute) and Dr. Thomas Hamilton (Fox
Chase Cancer Center). SKOV3 (Morimoto et al., 1993) cells were purchased from the American
Type Culture Collection (Manassas, VA). IGROV1, SKOV3 and A2780 cells were routinely
cultured in folate-free RPMI 1640 medium, supplemented with 10% FBS (Sigma-Aldrich), Lglutamine, and penicillin-streptomycin solution. IGROV1 NTC and FRα knockdown cells (#4,
#10) were developed using MISSION® Lentiviral particles (Sigma-Aldrich) containing shRNA
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targeting FRα or a non-targeted control (NTC) shRNA sequence as previously described (Z. Hou
and L. H. Matherly, manuscript submitted).
6.2.3 Cell Proliferation Assays
For growth inhibition studies, cells (CHO, R1-11 and ovarian cancer cell lines) were
plated in 96 well dishes (~2000 cells/well, total volume of 200 µl) and treated with a range of
antifolate concentrations (0-1000 nM) in folate-free RPMI 1640 medium with 10% dialyzed
FBS, L-glutamine and penicillin/streptomycin, and supplemented with 2 nM (RT16, D4 CHO
cells) or 25 nM (all others) LCV, as previously described (Wang et al., 2015). To confirm FRmediated drug uptake, 200 nM folic acid was added to parallel incubations for RT16 and D4
cells. After 96 h, viable cells were assayed with Cell-Titer BlueTM reagent (Promega, Madison,
WI), with fluorescence measured with a fluorescence plate reader. Fluorescence measurements
were used for calculations of IC50s, corresponding to the drug concentrations at which cells
showed 50% loss of proliferation (Wang et al., 2011; Wang et al., 2015).
To confirm the targeted pathway/enzyme target, in vitro growth inhibition of IGROV1
tumor cells was measured in the presence of thymidine (10 µM) or adenosine (60 µM). For de
novo purine biosynthesis, additional protection experiments used AICA (320 µM) to distinguish
inhibitory effects at GARFTase from those at AICARFTase. Folic acid (200 nM) was used as an
inhibitor of FR-mediated anti-proliferative effects, as previously described (Deng et al., 2008;
Wang et al., 2011; Wang et al., 2015) (also see Chapter 5).
6.2.4 Folate Receptor Binding Assay
To determine antifolate relative binding affinities, RT16 and D4 CHO cells were plated
in 60 mm dishes at 7.5x105 cell/plate and grown for two days (~80% confluency) (Wang et al.,
2015). Cells were sequentially washed with Dulbecco’s phosphate-buffered saline (PBS) at 4° C
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(3x), followed by acidic buffer (10 mM sodium acetate, 150 mM NaCl, pH 3.5) (2x) to remove
FR-bound folates, and finally HEPES-buffered saline (20 mM HEPES, 140 mM NaCl, 5 mM
KCl, 2 mM MgCl2, 5 mM glucose, pH7.4) (HBS). Cells were treated with [3H]folic acid (50 nM,
specific activity, 0.5 Ci/mmol) in HBS in the presence and absence of unlabeled folic acid, MTX
(negative control), or the 6-substituted pyrrolo[2,3-d]pyrimidine antifolates (10 nM to 1000 nM)
for 15 min at 4° C. Dishes were washed with HBS at 4°C (3x), cells were solubilized with 0.5 N
NaOH (3 h, 37°C), and aliquots were measured for radioactivity and protein contents. Protein
concentrations were measured using Folin-phenol reagent (Lowry et al., 1951). FR-bound
[3H]folic acid was calculated as pmol/mg protein, and binding affinities were calculated as the
inverse molar ratios of unlabeled ligands required to inhibit [3H]folic acid binding by 50%. The
relative binding affinity of unlabeled folic acid was assigned a value of 1 (Deng et al., 2008;
Deng et al., 2009; Wang et al., 2012; Wang et al., 2010; Wang et al., 2011; Wang et al., 2015).
6.2.5 Transport Assays
R2 and R2/hPCFT4 CHO sublines and R1-11 and R1-11-RFC2 HeLa sublines were
grown in suspension as spinner cultures at densities of 2-5 x 105 cells/mL (Kugel Desmoulin et
al., 2010; Wang et al., 2015). Cells were isolated by centrifugation, washed with PBS (3x), and
the cell pellets (~1 x 107 cells) were suspended in transport buffer (2 ml) for cellular uptake
assays (Wang et al., 2015). PCFT-dependent uptake of 0.5 µM [3H]MTX was assayed in cell
suspension over 2 min at 37° C in MES-buffered saline (20 mM MES, 140 mM NaCl, 5 mM
KCl, 2 mM MgCl2, and 5 mM glucose) at pH 5.5 or in HBS at pH 6.8 in the presence or 1 or 10
µM inhibitor, while RFC-dependent uptake was measured over 2 min at 37° C in pH 7.2 HBS.
Transport was quenched with ice-cold PBS after 2 min and cells were washed three times with
ice-cold PBS. Cellular proteins were solubilized with 0.5 N NaOH (3 h, 37° C). Transport levels
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were expressed as pmol/mg protein, calculated using direct measurements of radioactivity and
protein contents of the cell homogenates. Protein concentrations were measured using Folinphenol reagent (Lowry et al., 1951). Transport levels were normalized to levels in untreated
(R2/PCFT4 or R1-11-RFC2) controls. To determine Ki values for 6-pyrrolo[2,3-d]pyrimidine
antifolates, transport was measured over 2 min with 0.5 µM [3H]MTX and 0.05-1 µM of
unlabeled antifolate (Kugel Desmoulin et al., 2010). Dixon plots were used to analyze data.
6.2.6 In Situ GARFTase Inhibition Assay
In situ measure of intracellular GARFTase activity, via incorporation of [14C(U)]glycine
into [14C]formyl glycinamide ribonucleotide, in IGROV1 cells at pH 6.8, was performed exactly
as previously described (Kugel Desmoulin et al., 2010; Wang et al., 2011) (also see Chapter 5).
Antifolates were used over a concentration range of 0.3 nM to 100 nM. Results were normalized
to cell proteins. To calculate the IC50 values, drug-treated samples were normalized to untreated
controls.
6.2.7 Statistical Analysis
Descriptive statistical tests (e.g., t tests) were conducted using GraphPad 6.0 software (La
Jolla, CA).
6.3 Results
6.3.1 Cytotoxic Activity in Engineered Models
In this chapter, our goal was to explore the antiproliferative effects of novel fluorinated 6substituted pyrrolo[2,3-d]pyrimidines (Figure 6.1) on tumor cells, and identify whether these
modifications to previously established antifolates may enhance potency or transporter
specificity. In order to determine the selectivity of each compound between RFC, PCFT, and
FRs, we utilized isogenic CHO sublines that were engineered to express RFC (PC43-10), PCFT
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(R2/hPCFT4), FRα (RT16), or FRβ (D4), all derived from the transporter-null CHO cell line
MTXRIIOuaR2-4 (R2) (Deng et al., 2008; Deng et al., 2009; Flintoff et al., 1976; Flintoff and
Nagainis, 1983; Wong et al., 1995). Cells were continuously treated with the novel 6-substituted
pyrrolo[2,3-d]pyrimidine antifolates for 4 days and proliferation measured with a fluorescencebased assay. IC50 values were determined for each drug in each cell line, and the novel
fluorinated antifolates were directly compared to their corresponding parent compounds.
AGF264 and AGF270 displayed an enhanced inhibition of proliferation toward R2/hPCFT4 cells
compared to parent compounds AGF23 and AGF17 (~3.5-fold and ~2.9-fold decrease in IC50,
respectively) (Table 6.1). Conversely, AGF277 had a decreased anti-proliferative effect on
R2/hPCFT4 cells relative to the parent AGF107 (~2.2-fold increase in IC50) (Table 6.1). AGF278,
in comparison to parent AGF117, had dramatically increased (~6.9-fold) in vitro efficacy in
RT16 cells (Table 6.1). AGF283, structurally homologous to AGF278 but with 3 rather than 4
bridge carbons, also displayed significantly enhanced in vitro efficacy in PC43, R2/hPCFT4 and
RT16 cells compared to its parent compound AGF150, although this increased activity was
accompanied by a dramatically increased non-specific activity in R2 cells (20.5 nM for AGF283
compared to 271 nM for AGF150). This suggests a high affinity for another transporter other
than RFC, PCFT or FRα/β. Collectively, these results suggest that fluorination of antifolate
compounds can have dramatic effects on anti-proliferative efficacy towards cells which express a
single folate uptake protein.
In order to extend the analysis from the CHO cell line models, we performed additional
ploriferation assays in engineered human cancer cells. We tested the drug efficacies toward
several HeLa sublines which were engineered from the RFC- PCFT- and FR-null R1-11 HeLa
cell line, including the R1-11-RFC2 (expresses RFC), R1-11-PCFT4 (PCFT) and R1-11-FR2
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Table 6.1
IC50 Values (nM) for Inhibition of CHO Sublines

PMX
AGF94
AGF23
AGF264
AGF17
AGF270
AGF107

R2
(null)
138(13)
249(25)
>1000
>1000
>1000
140(27)
>1000

PC43-10
(RFC)
26.2(5.5)
106(17)
>1000
>1000
424(116)
61.6(11.5)*
>1000

R2/hPCFT4
(PCFT)
8.3(2.7)
3.3(0.5)
83.1(20.1)
23.5(1.5)
10.9(1.9)
3.8(0.3)*
30.4(10.7)

RT16
(FRα)
42(9)
0.31(0.15)
0.84(0.07)
0.49(0.18)
0.68(0.22)
1.1(0.4)
1.3(0.1)

D4
(FRβ)
60(8)
0.16(0.02)
2.0(0.3)
1.6(0.44)
0.41(0.08)
3.9(0.1)*
0.52(0.09)

AGF277
AGF117
AGF278

>1000
>1000
>1000

467(142)
>1000
>1000

66.9(25.0)
32.0(11.6)
6.0(0.9)

0.69(0.39)
2.5(0.5)
0.36(0.12)*

0.44(0.13)
0.43(0.14)
0.75(0.42)

AGF150
AGF283

271(52)
20.5(1.6)*

157(36)
20.1(6.1)*

9.7(1.8)
1.5(0.4)*

0.71(0.20) 0.32(0.03)
0.14(0.03)* 0.19(0.02)*

Growth inhibition assays were performed using CHO sublines derived from RFC- PCFT-and
FR-null MTXRIIOuaR2-4 CHO cells (R2) and engineered to overexpress human RFC (PC4310), PCFT (R2/hPCFT4), FRα (RT16) or FRβ (D4). Results are shown as a mean of five
experiments (± standard error in parentheses) and are described as calculated IC50 values
representing the concentration at which growth of 50% of cells was inhibited relative to
untreated cells. Fluorinated compounds which displayed statistically different IC50 values from
parent compounds (directly above) within each cell line are marked with * (p < 0.05).
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Table 6.2
IC50 Values (nM) for Inhibition of HeLa R1-11 Sublines

PMX
AGF94
AGF23
AGF264
AGF17
AGF270
AGF107
AGF277
AGF117
AGF278
AGF150
AGF283

R1-11RFC2
23.8(1.5)
444(5)
>1000
>1000
>1000
507(76)
634(43.9)
>1000
>1000
213(9)
62.9(3.8)
66.2(6.2)

R1-11PCFT4
66.8(4.8)
53.1(15.5)
5.21(1.33)
21.6(17.1)
9.71(2.78)
5.54(3.35)
8.98(3.64)
37.6(16.3)
72.6(18.1)
5.01(2.12)*
40.0(9.8)
20.4(4.7)

R1-11FR2
863(81)
30.2(5.6)
11.6(2.7)
7.78(1.89)
12.2(4.4)
5.22(1.32)
6.54(1.29)
21.7(3.9)*
35.3(6.2)
2.84(0.67)*
7.57(1.16)
3.11(0.69)*

Growth inhibition assays were performed using HeLa sublines derived from R1-11 RFC- and
PCFT-null cells and engineered to overexpress human RFC (R1-11-RFC2), PCFT (R1-11PCFT4), or FRα (R1-11-FR2). Results are shown as a mean of five experiments (± standard error
in parentheses) and are described as calculated IC50 values representing the concentration at
which growth of 50% of cells was inhibited relative to untreated cells. Fluorinated compounds
which displayed statistically different IC50 values from parent compounds (directly above) within
each cell line are marked with * (p < 0.05).
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(FRα) cell lines (Wang et al., 2015; Zhao et al., 2009b; Zhao et al., 2008). Results generally
reflected growth inhibitions seen in the CHO cell lines (i.e., compare results in Table 6.1 with
those in Table 6.2). Notably, in this conext, AGF278 displayed a significantly enhanced efficacy
toward both R1-11-PCFT4 and R1-11-FR2 cells compared to AGF117, suggesting an increased
activity for both PCFT and FRα uptake (~14.5-fold and ~12.4-fold decrease in IC50, respectively)
(Table 6.2). AGF283 displayed an increased efficacy for R1-11-FR2 cells compared to AGF150
(~2.4-fold increase in IC50), as seen with RT16 CHO cells. However, unlike RT16 CHO cells,
AGF277 was significantly less potent than AGF107 in these cells (~3.3-fold decrease in IC50)
(Table 6.2). While AGF264 and AGF270 were selective toward PCFT4-expressing R1-11PCFT4 over the R1-11-RFC2 HeLa cells, this was not significantly enhanced compared to
respective parent compounds AGF23 and AGF17 (Table 6.2).
In order to more specifically describe the PCFT and FRα selectivies of these compounds,
RFC/PCFT and RFC/FR IC50 ratios were calculated (Table 6.3). For these selectivity ratios, a
larger number is indicative of increased selectivity for tumor specific (FR and/or PCFT)
transporters compared to ubiquitously expressed RFC. In this case, PMX, widely considered to
be an excellent substrate for both PCFT an RFC, displayed only a RFC/PCFT selectivity ratio of
only 0.36 (Table 6.3), a clear reflection of limited transporter selectivity. AGF94, considered to
be among the best PCFT substrates (Cherian et al., 2013; Desmoulin et al., 2012b; Wang et al.,
2011) (also see Chapter 5), showed an RFC2/PCFT4 IC50 ratio of 8.36 (~23.2-fold increase over
PMX) while also displaying an RFC2/FR2 IC50 ratio of 14.7 (~490-fold increase over PMX)
(Table 6.3). AGF283, as expected, did not display a high level of specificity for PCFT (3.25
RFC2/PCFT4 IC50 ratio), although there was substantial FRα selectivity (21.3 RFC2/FR2 IC50
ratio) (Table 6.3). We did observe over 90-fold specificity for PCFT (91.5 RFC2/PCFT4 IC50
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Table 6.3
Ratios of Transporter Selectivity over RFC
RFC2 IC50
PCFT4 IC50
PMX
0.36
AGF94
8.36
AGF270
91.5
AGF278
42.5
AGF283
3.25

RFC2 IC50
FR2 IC50
0.03
14.7
97.1
75
21.3

Selectivity ratios determined by IC50 values in R1-11-RFC2, R1-11-PCFT4 and R1-11-FR2 cell
lines (Table 6.2). By this metric, higher values represent an increased selectivity for PCFT or
FRα-mediated uptake compared to RFC. Compounds with >1000 nM IC50 values in the R1-11RFC2 cell line were excluded from comparison.
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ratio) and FRα (97.1 RFC2/FR2 IC50 ratio) for AGF270, somewhat greater than the specificity
seen for AGF278 with PCFT (42.5 RFC2/PCFT4 IC50 ratio) and FRα (75.0 RFC2/FR2 IC50
ratio) (Table 6.3). The levels of specificity for AGF270 and AGF278 are unprecedented, as these
selectivity ratios are much higher than that of our previous lead compound AGF94. Compared to
AGF94, AGF278 has a ~5-fold increase in selectivity for both PCFT and FRα over RFC, while
AGF270 had an ~11-fold increase for PCFT selectivity and a ~6-fold increase for FRα selectivity,
establishing AGF270 and AGF278 as the most selective PCFT- and FRα-targeted antifolates to
date (Table 6.3), establishing AGF270 and AGF278 as the most selective PCFT- and FRαtargeted antifolates to date (Table 6.3).
6.3.2 Transport Binding Specificity of 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates
for the Major Folate Transporters
In order to further examine the level of specificity for each compound in the context of
RFC and PCFT uptake, we determined the binding affinity for each compound as a competitor to
[3H]MTX. To determine the binding specificity of each antifolate for PCFT, we tested the
capability of each compound to inhibit 0.5 µM [3H]MTX uptake in PCFT-expressing R2/PCFT4
CHO cells at pH 5.5. All inhibitors were tested at 1 µM and 10 µM, and results were normalized
to those for the non-treated control R2/PCFT4 cells. PCFT-null R2 cells were used as a negative
control for membrane transport, while the RFC-specific antifolate PT523 was used as a negative
control for PCFT inhibition and PMX was used as a positive control for inhibition. All
compounds displayed some level of transport inhibition at both 1 µM and 10 µM. For AGF264,
inhibition was significantly greater than parent AGF23 at both 1 µM (80% compared to 66%
inhibition, respectively) and 10 µM (92% compared to 95%, respectively), suggesting an
enhanced PCFT selectivity (Figure 6.2A). AGF270 also displayed significantly greater inhibition
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Figure 6.2 PCFT and RFC transport inhibition by the fluorinated antifolates compared to
parent compounds. Panels A and B, Inhibition of PCFT [3H] MTX transport by unlabeled 6substituted pyrrolo[2,3-d]pyrimidine analogues in R2/PCFT4 CHO cells. Relative PCFT
inhibition for assorted antifolate substrates were measured at pH 5.5 (A) and pH 6.8 (B) over 2
min in the presence [3H] MTX (0.5 µM), with 1 or 10 µM of inhibitor. Results are presented as
mean values ± standard errors for three experiments. Results are normalized to transport in the
absence of any additions. Panel C, Inhibition of RFC [3H] MTX transport by unlabeled 6substituted pyrrolo[2,3-d]pyrimidine analogues in R1-11-RFC2 cells. Experiments were
performed as in A at pH 7.2. For all experiments, bars noted with asterisks were statistically
different from the corresponding parent compound (to the right) at the same concentration (p <
0.05) by paired t-test analysis.
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than parent AGF17 at 1 µM (74% compared to 61%, respectively), while AGF277 displayed
poorer inhibition than parent AGF107 at 1 µM (59% compared to 74%, respectively) (Figure
6.2A). These experiments were repeated at pH 6.8 and results were largely the same, albeit with
reduced transport inhibition (Figure 6.2B). While the results for AGF278 were similar at pH 5.5
and pH 6.8, at pH 6.8 with 10 µM AGF278, transport inhibition was significantly increased over
that for the parent AGF117 at 10 µM (51% compared to 66%, respectively). In order to
determine, Ki values, a quantititative measure of substrate binding affinities, for PCFT, we used
a range of inhibitor concentrations (0.05 µM to 1 µM) with a constant (1 µM) concentration of
[3H]MTX. Kis were calculated using Dixon analysis. Based on this parameter, all novel
fluorinated antifolates displayed differential PCFT specificities compared to parent antifolates
which were statistically significant. With the exception of AGF277, which had a higher Ki value
than parent AGF107 (~1.9-fold increase), all fluorinated antifolates had decreased Kis compared
to parent antifolates, suggesting an increased PCFT transport capability (Table 6.4). Notably,
AGF283 showed a ~4-fold decrease in Ki compared to parent AGF150.
Analogous experiments were performed to assess binding to RFC. For these experiments,
we measured [3H]MTX uptake (at 0.5 µM) in RFC-expressing R1-11-RFC2 HeLa cells at pH 7.2
in the presence of 1 µM and 10 µM inhibitor. Transporter-null R1-11 cells were used as a
negative control. Although some minor inhibition of RFC transport was observed at 10 µM
inhibitor, particularly for AGF150 and AGF283, these levels were modest and above 30%
inhibition (Figure 6.2C). In all cases, RFC inhibition by fluorinated antifolates was not
significantly different from the corresponding parent antifolate (Figure 6.2C). Together, these
data suggest that all 6-substituted pyrrolopyrimidines are potent PCFT inhibitors and poor RFC
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Table 6.4
Kinetic Inhibition Analysis of Antifolates Competing with MTX in R2/PCFT4 cells.
Ki
PMX
AGF94

0.12 (0.03)
0.14 (0.02)

AGF23
AGF264

0.46 (0.05)
0.17 (0.01)*

AGF17
AGF270

0.63 (0.13)
0.26 (0.01)*

AGF107
AGF277

0.24 (0.02)
0.46 (0.06)*

AGF117
AGF278

0.36 (0.03)
0.25 (0.01)*

AGF150
AGF283

0.28 (0.07)
0.07 (0.04)*

[3H]MTX uptake was assayed at using R2/PCFT4 cells at pH 5.5 over 2 min at 37oC. To
determine Ki values, cells were incubated with 0.5 µM [3H]MTX with antifolates as competitors
from 0.05 µM to 0.5 µM, with results analyzed by Dixon plots. Data are presented as mean
values ± standard errors from four independent experiments. For fluorinated antifolates, values
significantly different from those of parent antifolate (p < 0.05) are marked with *.
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inhibitors, paralleling inhibitions of proliferation (Table 6.2). Fluorination of compounds
appeared to enhance PCFT binding in several cases.
6.3.3 Folate Receptor Binding Affinity of 6-Substituted Pyrrolo[2,3-d]pyrimidine
Antifolates
As suggested by the antiproliferative effects in RT16, D4, and R1-11-FR2 cells, the
fluorinated 6-substituted pyrrolo[2,3-d]pyrimidine antifolates appeared to target FRs although
there were somewhat divergent specificities for FRα-expressing cells over FRβ-expressing cells.
As a direct metric for FR specificity, we measured the binding of each compound in competition
with 50 nM [3H]folic acid. A range of concentrations (10 nM to 1000 nM) was used to determine
IC50 values, corresponding to the concentration that inhibited [3H]folic acid binding. IC50 values
for the antifolate inhibitors were further normalized to that for non-radioactive folic acid, giving
a measure of relative binding affinities. Both RT16 (FRα) and D4 (FRβ) CHO cells were used in
order to test for relative affinity to both FR isoforms. Generally, results observed in D4 cells
were reflective of results in RT16, although binding affinities for FRβ tended to be lower,
suggesting an increased targeting for FRα over FRβ (assuming that the affinity for folic acid in
each isoform is equal). An exceptional difference was observed with AGF283, which appeared
to have a much stronger binding affinity for FRα (binding affinity 0.83) than for FRβ (binding
affinity 0.12), a ~7-fold difference in binding affinity. This difference was not observed between
RT16 and D4 anti-proliferative effects, likely due to the non-specific uptake of AGF283 (as
reflected by the low IC50 in R2 cells) (Table 6.1).
For both FRα and FRβ, the fluorinated antifolate AGF278 appeared to have an enhanced
specificity for FRs in comparison to its parent compound AGF117 (Figure 6.3A-B). Particularly
for FRα, AGF278 displayed a binding affinity approximating that of folic acid (1.0 binding
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Figure 6.3 FRα and FRβ binding affinities. Panels A and B, Binding of 6-substituted
pyrrolo[2,3-d]pyrimidine analogues to FRα (A) in RT16 cells and FRβ (B) in D4 relative to FA.
Relative binding affinities for assorted folate/antifolate substrates were determined over a range
of ligand concentrations from 10nM to 1000 nM and were calculated as the inverse molar ratios
of unlabeled compounds required to inhibit [3H] folic acid binding by 50% (the relative affinity
of folic acid being 1). Results are presented as mean values ± standard errors from three
experiments. The bars noted with asterisks were statistically different from the corresponding
parent compound (to the right) (p < 0.05) by paired t-test analysis.
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affinity for AGF278 compared to 0.42 for AGF117) (Figure 6.3A). While fluorinated analogs
AGF270 and AGF283 appeared to have no change in binding affinities compared to their
respective parent compounds AGF17 and AGF150, AGF264 and AGF277 showed lower binding
affinities than respective parent compounds AGF23 and AGF107, respectively. For AGF270, a
FRα binding affinity comparable to that for folic acid was measured, establishing potent FRα
binding. Thus, in general, fluorination of the targeted antifolates did not enhance antifolate
binding affinities to FR, as only AGF278 of the five novel fluorinated compounds displayed
significantly enhanced FR binding affinity compared to the parent compound AGF117.
6.3.4 Cytotoxicity of of 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates in Ovarian
Cancer Cell Lines
We extended our studies of these novel fluorinated pyrrolopyrimine antifolates to
clinically relevant ovarian cancer cells. We determined the antiproliferative efficacies toward
IGROV1, SKOV3, and A2780 cells. These three cell lines were previously shown to express
both PCFT and FRα transcripts, and while IGROV1 displayed the highest levels of FRα
transcripts and binding (~4-fold increase in binding over SKOV3, ~11-fold increase over A2780),
PCFT transcripts and binding were nearly identical between all three cell lines (<2-fold
difference) (Wang et al., 2015) (Z. Hou and L. H. Matherly, submitted). In two of three cell lines,
A2780 and IGROV1, we observed significant increases in in vitro efficacies for both AGF278
and AGF283 (from 2-fold to 29-fold increases), in comparison to respective parent compounds
AGF117 and AGF150 (Table 6.5). Furthermore, AGF278 and AGF283 were significantly more
potent than AGF94 toward both IGROV1 and A2780 cells (p < 0.02). These results suggest that
compounds with increased specificity for PCFT and FRα may also be more potent inhibitors of
proliferation in some ovarian cancer cell lines.
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Table 6.5
IC50 Values (nM) for Inhibition of Ovarian Cancer Cell Lines and FRα Knockdown Sublines

PMX
AGF94
AGF23
AGF264
AGF17
AGF270
AGF107
AGF277
AGF117
AGF278
AGF150
AGF283

SKOV3

A2780

24.1(2.1)
38.7(4.9)
868(32)
224(75)*
273(47)
27.9(2.5)*
90.5(16.4)
59.2(12.4)
114(34)
37.8(10.1)
25.1(2.6)
30.2(7.1)

39.4(9.2)
27.4(3.4)
14.2(3.6)
13.6(4.2)
2.72(0.53)
2.14(0.18)
5.42(1.39)
15.7(3.6)*
28.8(1.4)
3.11(0.14)*
21.7(1.5)
7.6(1.0)*

WT
104(11)
16.7(3.4)
4.37(0.95)
5.44(0.81)
2.01(0.14)
1.67(0.30)
1.87(0.19)
6.36(1.04)*
54.3(4.8)
1.90(0.15)*
12.1(1.6)
6.92(1.03)*

IGROV1
NTC
FR KD-4
71.0(8.5)
46.6(10.4)
10.1(1.5)
190(99)
5.21(1.59)
>1000
6.89(1.13)
>1000
1.97(0.69)
453(262)
1.14(0.25) 41.0(12.7)
1.55(0.18)
64.1(6.5)
5.17(1.34)*
>1000
40.7(5.8)
>1000
1.79(0.19)* 138(6.8)
12.8(1.4)
80.5(24.2)
5.61(1.20)* 85.6(3.9)

FR KD-10
22.2(6.6)
74.6(33.9)
>1000
>1000
190(48)
19.2(4.3)*
30.5(0.5)
>1000
>1000
66.9(28.3)
30.3(2.1)
42.2(11.2)

Growth inhibition assays were performed using ovarian cancer cell lines SKOV3, A780 and
IGROV1, as well as FRα-knockdown sublines (KD-4, KD-10) derived from IGROV1 as well as
non-targeted control (NTC) as previously described. Results are shown as a mean of five
experiments (± standard error in parentheses) and are described as calculated IC50 values
representing the concentration at which growth of 50% of cells was inhibited relative to
untreated cells. Fluorinated compounds which displayed statistically different IC50 values from
parent compounds (directly above) within each cell line are marked with * (p < 0.05).
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Interestingly, in the SKOV3 cells, we observed a significant increase in efficacy for
AGF264 (224 nM IC50) in comparison to AGF23 (868 nM IC50), and an increased efficacy for
AGF270 (27.9 nM IC50) compared to AGF17 (273 nM IC50). Differences between AGF278 (37.8
nM IC50) and AGF117 (114 nM IC50) also suggested an increased efficacy, although this
difference was not statistically significant (Table 6.5). However, contradictory to the enhanced
efficacy observed in IGROV1 and A2780, AGF278 and AGF283 did not have IC50 values in
SKOV3 which were significantly lower than AGF94 (p > 0.05). Because SKOV3 has roughly
equivalent PCFT expression to both IGROV1 and A2780, with FRα expression higher than
A2780 but lower than IGROV1 (Hou and Matherly, manuscript submitted), the differential
effects observed in the SKOV3 cell line are likely due to factors other than antifolate uptake.
Additionally, we tested the antiproliferative effects of the novel compounds in IGROV1
FRα knockdowns (KD-4, KD-10) and non-targeted control (NTC) (Hou and Matherly,
manuscript submitted). These knockdown cell lines each display >90% knockdown of FRα, as
reflected in gene expression (measured by real-time RT-PCFT) and levels of FRα protein
(measured by direct binding of [3H]folic acid). Knockdown of FRα was accompanied by modest
decreases in PCFT gene and protein expression (decreases of 28% for KD-4 and 40% for KD-10
compared to NTC) and PCFT membrane transport. Under these conditions, PMX efficacy was
increased ~2-fold by FRα knockdown, suggesting that decreased FR-driven LCV uptake (and a
reduction of folate pools) had a greater impact on PMX efficacy than on the decreased FR-driven
PMX uptake, as FRα-mediated uptake of PMX into solid tumor cell lines has been shown to be
of minor importance (Chattopadhyay et al., 2004). However, for other 6-substituted pyrollo[2,3d]pyrimidine antifolates, FR knockdown in IGROV1 cells greatly reduced drug efficacy. The
fold change in efficacy with FR knockdown varied between drugs. For instance, for some
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Figure 6.4 Cytotoxicity via colony formation assay. IGROV1 cells (400 cells) were plated in
6-well plates in complete folate-free RPMI 1640 (pH 7.2), 10% dialyzed fetal bovine serum, and
25 nM LCV. After 24 hours, cells were then treated with PMX, AGF17, AGF270, AGF117 or
AGF278 at varying concentrations (0.1 to 10 µM) in complete folate-free RPMI 1640 adjusted to
pH 6.8 and supplemented with 25 nM LCV. After an additional 24 hours, cells were rinsed with
PBS, and then incubated in complete folate-free RPMI 1640 supplemented with 25 nM LCV (pH
7.2) for 9 days. Colonies were stained with methylene blue and counted, and colony numbers
were normalized to the controls. Plots show mean ± S.E. values, representative of triplicate
experiments. IC50 (mean and S.E.) values (µM) were as follows PMX: 7.4 (1.0); AGF17: 1.7
(0.5); AGF270: 0.7 (0.1); AGF117: >10 (0); AGF278: 0.5 (0.1).
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compounds, including AGF283, we saw a subtle increase in IC50 (~11-fold,) compared to NTC,
while other drugs, such as AGF278, we saw a dramatic increase in drug efficacy (~57-fold
increase in IC50), likely reflecting differences in the specificities for PCFT and FRα over RFC
(Table 6.3). Some drugs, such as AGF264 and AGF277, were completely ineffective in
IGROV1 FR knockdowns, possibly reflecting the decreased PCFT expression in these cells in
conjunction with FR knockdown.
As an additional method to evaluate antitumor efficacy in vitro using IGROV1 cells, we
used a colony formation assay to measure cytotoxicity under conditions more representative of
those characterizing the tumor microenvironment (i.e., pH 6.8) (see Chapter 5). Cells were
seeded in 6-well plates at a density of 400 cells/well, and one day later were treated with drugs
for 24 hours in pH 6.8 media, followed by nine days of growth in the absence of drug. Here, we
observed that AGF17, AGF270 and AGF278 were all significantly more potent than PMX (IC50
values of 1.7, 0.7, 0.5 and 7.4 µM, respectively) (Figure 6.4), paralleling the PCFT-specificity
observed in engineered models (Tables 6.1-6.3, Figure 6.2). Interestingly, AGF117 was
completely ineffective in clonogenic assays, and the potency of AGF278 far exceeded that for
AGF117 at 1 µM and above (p < 0.05) (Figure 6.4). These experiments establish that these drugs
are cytotoxic rather than simply cytostatic.
6.3.5 Metabolic Activity of of 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates
We next determined the metabolic target for each compound. It has been well established
that AGF17, AGF23, AGF117 and AGF150 are all potent inhibitors of GARFTase, the first
folate dependent reaction in de novo purine nucleotide biosynthesis (Figure 1.6), with little to no
activity towards TS, DHFR, or AICARFTase (Deng et al., 2008; Deng et al., 2009; Wang et al.,
2012; Wang et al., 2015) (also see Chapter 5). By testing growth inhibition in the presence of
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Figure 6.5 Protection assay in IGROV1 cells. Growth inhibition of IGROV1 cells and
protection by excess folic acid, nucleosides, AICA. IGROV1 cells were plated (2000 cells/well)
in folate-free RPMI 1640 medium with 10% FBS, antibiotics, L-glutamine, and 25 nM LCV with
a range of concentrations antifolates in the presence of folic acid (200 nM), adenosine (60 µM),
and/or thymidine (10 µM) or AICA (320 µM). Cell proliferation was assayed with Cell Titer
Blue using a fluorescence plate reader. Data are representative of at least triplicate experiments.
Error bars represent standard error for each replicate. IC50 values for IGROV1 cells without
additions are detailed in Table 6.4.
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Figure 6.6 In situ GARFTase activity by the fluorinated antifolates compared to parent
compounds. Incorporation of [14C(U)]glycine into [14C]formyl glycinamide ribonucleotide
(GAR) as an in situ measure of endogenous GARFTase activity in IGROV1 cells. Cells were
treated with a range of concentrations of antifolates in media which was adjusted to pH 6.8 IC50
values (nM) are listed with S.E. values. Data are representative of triplicate experiments. IC50
values for fluorinated antifolates which are statistically different from parent antifolates are
marked with * (p < 0.05).
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thymidine (10 nM), adenosine (60 nM) or AICA (320 nM) in IGROV1 cells, we determined that
antiproliferative activities of these compounds were completely protected by the addition of
either adenosine or AICA, suggesting de novo purine nucleotide biosynthesis as the targeted
pathway with inhibition of GARFTase as the principal cellular target (Figure 6.5). Compounds
were also tested in the presence of 200 nM folic acid, and we observed that some compounds
displayed incomplete protection under this condition, particularly AGF278, AGF150 and
AGF283, suggesting an alternative uptake mechanism to folate receptor, most likely PCFT,
consistant with the results observed in the PCFT-expressing CHO and HeLa sublines (Tables
6.1-6.3).
In order to determine the potency of GARFTase inhibition, we utilized an in situ
GARFTase assay to measure the accumulation of [14C]formyl GAR (the GARFTase product in
de novo purine biosynthesis) in IGROV1 cells. Cells were treated with [14C]glycine, which
allowed for incorporation of [14C] into formyl GAR, and azaserine, which allowed for formylGAR accumulation, in the presence of absence of the targeted antifolates. PMX was included as
a negative control, as it displays weak GARFTase activity (Racanelli et al., 2009), while AGF94,
an established potent GARFTase inhibitor, was included as a positive control (Wang et al., 2011).
In this case, we observed that all the 6-substituted pyrrolo[2,3-d]pyrimidine compounds were
potent GARFTase inhibitors, with nearly all IC50 values below 3 nM (Figure 6.6), a paralleling
the range at which these compounds inhibit IGROV1 cell proliferation (Table 6.5). However, in
most cases, GARFTase activity of the fluorinated antifolates was not significantly different than
for parent antifolates (Figure 6.6). The exception to this is AGF270, which displayed a
significantly lower IC50 value than AGF17 (1.0 nM compared to 2.5 nM, respectively),
suggesting an increased GARFTase inhibition (p < 0.05) (Figure 6.5).
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6.4 Discussion
Our previous studies have demonstrated the potential therapeutic utility of novel 6substituted pyrollo[2,3-d]pyrimidine antifolates for the targeted treatment of ovarian cancer, lung
cancer, and malignant mesothelioma (Cherian et al., 2013; Wang et al., 2012; Wang et al., 2015)
(Z. Hou and L. H. Matherly, manuscript submitted) (also see Chapter 5). In this chapter, we
expanded our studies to include several novel fluorinated antifolate molecules (Figure 6.1)
derived from previously studied PCFT- and FR-targeted inhibitors with established patterns of
transporter specificity and limited transport by the ubiquitous RFC (Wang et al., 2012; Wang et
al., 2010; Wang et al., 2011; Wang et al., 2015). Fluorination of drugs is a common strategy to
enhance efficacy and specificity of small molecule therapeutics (Gillis et al., 2015). In this case,
fluorination of antifolates played a substantial albeit variable role in drug efficacy via changes to
transporter specificity.
We observed that AGF278 in particular displayed enhanced PCFT transport, as well as
increased FR-binding, which led to increased efficacy toward PCFT- and FR- expressing CHO
and HeLa cells, in comparison to parent drug AGF117. In engineered CHO cells, AGF278
displayed inhibition toward transporter-null (R2) and RFC-expressing cells (PC43-10) up to
1000 nM, while showing very potent in PCFT- (R2/PCFT4) and FR-expressing (RT16/D4) cells
(Table 6.1). In engineered HeLa cells, AGF278 also displayed a high level of PCFT and FRα
specificity (Table 6.3). Similarly, AGF278 showed an increased potency toward ovarian cancer
cell lines with both high (IGROV1) and low (A2780) FRα expression, accompanied by similar
levels of PCFT, and this potency was dramatically reduced by FR knockdown in IGROV1 cells
(Table 6.4). AGF278 was specifically targeted to both PCFT and FRα (Table 6.3) and showed
enhanced potency toward certain ovarian cancer cells lines (Table 6.4) than the previous lead
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compound AGF94 (Wang et al., 2011). Finally, AGF278 was a highly effective inhibitor of
IGROV1 colony formation, while parent compound AGF117 failed to inhibit colony formation
in conditions representing the acidic tumor microenvironment (Figure 6.4).

These results

establish that AGF278 is cytotoxic rather than cytostatic.
The notion of PCFT- and FRα-targeted treatments for cancer is not unprescedented. PMX,
an excellent PCFT substrate, is used for the treatment of several cancer types (e.g., non-small
cell lung cancer, malignant pleural mesothelioma), while several novel therapeutics have been
developed to target ovarian cancer using FRα as the primary mechanism of delivery. Here, we
describe compounds which display high affinities for both FRs and PCFT, with minimal offtarget (RFC) uptake, typified by AGF278. Additionally, these compounds may have an
additional therapeutic applications, as the addition of fluorine could allow these molecules to be
used as PET imaging agents. As a theranostic tool,
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F-labeled antifolates could used to detect

tumors and to measure drug uptake in patients to directly determine tumor targeting. Certainly,
these novel antifolates will be the subject of future studies.
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CHAPTER 7- CONCLUSIONS
The goal of this dissertation work was to characterize key domains of PCFT protein
structure, as well as to characterize novel PCFT-targeted antifolate compounds. Using SCAM, a
reentrant loop structure was identified in the TMD2-3 loop domain via accessibility of singlecysteine mutants in this region to the membrane-impermeable MTSEA-biotin (Chapter 2). The
interface for PCFT oligomerization was characterized using cysteine-scanning and MTS-6-MTS
crosslinking (Chapter 3). Through the development of PCFT half molecules and PCFT/ThTr1
chimera proteins, the functional significance of the TMD6-7 loop region of PCFT was
determined (Chapter 4). In a continuation of the ongoing effort to identify novel PCFT-targeted
antifolate drugs, AGF94 and AGF154 were characterized in the context of NS-NSCLC and their
increased

specificity

under

conditions

approximinating

those

in

the

acidic

tumor

microenvironment was demonstrated (Chapter 5). Previously established PCFT- and FRαtargeted antifolates were modified through fluorine substitution, resulting in very targeted
compounds including AGF278 (Chapter 6).
Structural information about PCFT will contribute to our understanding of both nutrition
and HFM, given the important role that PCFT plays in the uptake of dietary folates. These
studies will provide insights into future crystal structures of PCFT when they become available.
Additionally, the work presented here is significant in its contribution toward the development of
novel cancer therapies. As protein modeling technologies become increasingly advanced, PCFT
structural information will become increasingly important in the development of PCFT-targeted
antifolates. Likewise, the continued characterization of antifolate molecules will lead to the
development of structure/activity relationships for PCFT, allowing for comprehensive data
analysis of each antifolate compound and its relationship to PCFT structural elements.
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The development of PCFT-targeted antifolates will provide a useful tool for clinicians in
a wide variety of tumor types, reflecting broad expression of PCFT in tumors and high level
activity under conditions approximating those in the tumor microenvironment. As previously
described (see Chapter 1), classical antifolate molecules are used to treat a wide variety of tumor
types, despite off-target effects. PCFT-targeted antifolates may provide a method by which
chemotherapy can become more targeted. As tumor profiling becomes cheaper and more
universal, PCFT may be a useful biomarker for clinicians to use to identify proper treatments for
patients. Accordingly, PCFT-targeted antifolate molecules may become an increasingly valuable
tool to clinicians as the field of oncology moves away from conventional chemotherapy in favor
of more targeted treatments.
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APPENDIX- Copyrights
Wilson et. al. 2016 reprinted with permission of the American Society for
Pharmacology and Experimental Therapeutics. All rights reserved. Copyright © 2016 by
The American Society for Pharmacology and Experimental Therapeutics.
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Folate is a B9 vitamin essential to DNA synthesis. The proton-coupled folate transporter
(PCFT) is a newly discovered proton/folate symporter with an acidic pH optimum and broad
expression across a variety of solid tumor types, with limited expression in normal tissues.
Several antifolate molecules have been developed as cancer therapeutics, although these classical
antifolates display numerous off-target effects due to transport by the ubiquitous reduced folate
carrier (RFC). In this dissertation, we determine the roles of multiple PCFT structure/function
domains, and develop PCFT-specific antifolates to target solid tumors. We utilize substituted
cysteine accessibility methods (SCAM) to identify a novel reentrant loop structure between the
second and third transmembrane domains (TMDs), which is critical to PCFT function, using
membrane-impermeable thiol-reactive reagent MTSEA-biotin. We also utilize SCAM to identify
and characterize the PCFT oligomerization interface at TMDs 3 and 6 via crosslinking reagent
MTS-6-MTS. By the development of PCFT and ThTr1 chimera molecules, creation of PCFT
half molecules, and cysteine- and alanine-scanning mutagenesis, we determined the purely
structural role of the TMD6-7 connecting loop region. We studied novel 6-substituted
pyrrolo[2,3-d]pyrimidine thienoyl regioisomers related to pemetrexed (PMX), a standard NS-
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NSCLC treatment. [AGF94 (2’,5’) and AGF154 (2’,4’)], which showed potencies comparable to
PMX toward six NS-NSCLC cell lines. Uptake of [3H]AGF154 was comparable to that of
[3H]PMX at acidic pH. De novo purine biosynthesis inhibition by AGF94/154 was confirmed by
an in situ assay which measures incorporation of [14C]glycine into formyl GAR. In vivo efficacy
of AGF94 was seen toward H460 tumor xenografts in severe-combined immunodeficient mice.
Additonal antifolates were synthesized through the addition of fluorine to existing molecules and
studied for their transport specifiticies correlating with anti-proliferative effects. In particular,
AGF278 displayed increased specificity to PCFT, while also being very potent toward ovarian
cancer cell lines. In conclusion, we established the role of three key structural domains of PCFT
while also developing several novel PCFT-targeted antifolates for use as cancer therapeutics for
NS-NSCLC and ovarian cancer. These novel antifolates are targeted to the acidic tumor
microenvironment via selective transport by PCFT.
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